


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update October 19 - October 25, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 43 2020 1032 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[Retracted papers](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

Mainstream Media

New York Times - Corona update

Hospitals Are Reeling Under a 46 Percent Spike in Covid-19 Patients

U.S. reports more than 500,000 cases in a week, a record, as the Trump administration says it ended the pandemic.

Why You Shouldn't Worry About Studies Showing Waning Coronavirus Antibodies

Pfizer C.E.O. All but Rules Out Vaccine Before Election Day.

Some Covid Survivors Have Antibodies That Attack the Body, not Virus

How Trump and Bolsonaro broke Latin-America 's defenses

Why False Positives Merit Concern, Too

Nurses Are at High Risk for Covid Among Health Workers, C.D.C. Says

Two Companies Restart Virus Trials in U.S. After Safety Pauses

Coronavirus Vaccine Tracker

Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

'I witnessed first-hand the manipulation of things'

U.S. coronavirus infections hit record levels

Some Americans refuse to wear masks even as their hometowns become hot spots

Here are the Trump administration's four most profound failures in the pandemic

With proper measures flying can be safer than eating at a restaurant

A brief, intense shutdown would give the U.S. a second chance against the virus

The biggest problem isn't when a vaccine is ready. It's how to distribute it

Guardian - Corona update

Statistical illiteracy isn't a niche problem. During a pandemic, it can be fatal

Germany sees record infections as Russia and Ukraine report record deaths

calls grow for UK-wide lockdown as death toll rises

Oxford Covid vaccine works in all ages, trials suggest

Race is clearly a factor in Covid deaths, but the UK government is in denial

Key Articles

1. **Statin Use and In-Hospital Mortality in Diabetics with COVID-19.** J Am Heart Assoc 2020:e018475 Saeed O, Castagna F, Agalliu I *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092446>

This retrospective single-center study in an NYC hospital. (March 1st – May 2nd, 2020). Included were 4 252 confirmed COVID-19 patients grouped by statin use. Diabetics + statin (N=983), these were older patients (69 ±11 years vs. 67 ±14 years); they had lower inflammatory markers (CRP: 10.2, IQR: 4.5-18.4 vs. 12.9, IQR: 5.9-21.4 mg/dl, p<0.01). Cumulative in-hospital mortality (24% vs. 39%, p<0.01) compared with diabetic not using statins (N=1283). Propensity score matching; HR:0.88 (0.83-0.94, p<0.01) and IPTW, HR:0.88 (0.84-0.92, p<0.01) Mortality in non-diabetics that used or did no use statins (20% vs 21%, P=0.82) were the same.

2. Routine use of statins and increased mortality related to COVID-19 in in patients with type 2 diabetes: Results from the CORONADO study.

Biochim Biophys Acta Mol Cell Biol Lipids 2020; 1866:158839 Pimentel LL, Rodríguez-Alcalá LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080357> Retrospective nation-wide study in France (March 10th – April 10th, 2020) 2 449 confirmed COVID-19 patients grouped by statin use. Diabetics + statin use (N=1192). these were older patients (71.1 years vs. 70.2 years). Mortality in statin users at 7 days compared with diabetics not using statins 12.8% vs. 9.8%; at 28 days 23.9% vs. 18.2%. IPTW-7 days, OR:1.74 (1.13-2.65,) 2IPTW-28 days OR:1.46 (1.08–1.95).

Both studies were quite comparable but with stark different outcomes and conclusions.

3. Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada. Infection 2020; Hoffmann C, Wolf E.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098532>

Case fatality rate (CFR of COVID-19), the ratio of deaths to known cases, is an important metric in addressing the impact of this pandemic. Using data collected in 20 European countries, USA and Canada country-specific CFR's were calculated. Age weighs heavily on this number, between 80-96%, and marked differences were observed in the percentage of elderly patients in different countries, ranging from 4.9% - 40.4%. For each 5% increase in patients >70 years, CFR increased by 2.5% (1.9-3.5%). The authors urge for detailed demographic data and standardized data collection to ensure accurate CFR estimates.

4. Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study.

Diabetes Metab. 2020; Cariou B, Goronflot T, Rimbert A *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091555>

5. Immunity and Coagulation/Fibrinolytic Processes may Reduce the Risk of Severe Illness in Pregnant Women with COVID-19. Am J Obstet Gynecol

2020; Zhong Y, Cao Y, Zhong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098813>

6. Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China. BMC Med 2020; 18:330 Yang R, Mei H, Zheng T *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33070775>

7. The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis. Clin Infect Dis 2020;

Xu J, Teng Y, Shang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079200>

8. The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19

Patients: A Systematic Review and Meta-analysis. *J Med Virol* 2020; Wang Y, Chen B, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095513>

9. **Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar.** *J Am Coll Cardiol* 2020; 76:1999-2010 Pinney SP, Giustino G, Halperin JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092736>
10. **Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.** *J Am Coll Cardiol* 2020; 76:2024-2035 Mechanick JI, Rosenson RS, Pinney SP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092738>
11. **Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP).** *Virol J* 2020; 17:160 Mautner L, Baillie CK, Herold HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087160>
12. **Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers.** *Vaccines (Basel)* 2020; 8 Martínez-Baz I, Trobajo-Sanmartín C, Arregui I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076405>
13. **Reliability of induced sputum test is greater than that of throat swab test for detecting SARS-CoV-2 in patients with COVID-19: A multi-center cross-sectional study.** *Virulence* 2020; 11:1394-1401 Lai T, Xiang F, Zeng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073676>
14. **Monoclonal antibodies for anti-infective therapy.** *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz* 2020; Klug B, Schnierle B, Trebesch I.
15. **The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.** *Vaccines (Basel)* 2020; 8 Gopalaswamy R, Ganesan N, Velmurugan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081331>

Basic Science (53 articles) Grundlagenforschung

1. **A How-to Guide to Building a Robust SARS-CoV-2 Testing Program at a University-Based Health System.** *Acad Pathol* 2020; 7:2374289520958200 Nimer SD, Chapman J, Reidy L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088910>
2. **ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart.** *Arterioscler. Thromb. Vasc. Biol.* 2020:Atvbaha120315229 Sakamoto A, Kawakami R, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086866>

3. **Nano-sized formazan analogues: Synthesis, structure elucidation, antimicrobial activity and docking study for COVID-19.** Bioorg. Chem. 2020; 105:104354 Mahmoud HK, Asghar BH, Harras MF, Farghaly TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091672>
4. **A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).** Biosens. Bioelectron. 2020; 171:112715 Lee JH, Choi M, Jung Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099241>
5. **Findings from an OMFS journal club: is COVID-19 the catalyst we have needed to embrace technology?** Br. J. Oral Maxillofac. Surg. 2020; Aulakh GS, Duggal S, Sutton D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071050>
6. **MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.** Brief. Bioinform. 2020; Feng Z, Chen M, Xue Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078827>
7. **Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.** Cell. Mol. Bioeng. 2020:1-9 Alagumuthu M, Rajpoot S, Baig MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072222>
8. **Single-cell analysis identified lung progenitor cells in COVID-19 patients.** Cell Prolif. 2020:e12931 Zhao Z, Zhao Y, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094537>
9. **Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.** Cell Rep. 2020:108322 Zhou T, Teng IT, Olia AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091382>
10. **Why does the novel Coronavirus Spike Protein interact so strongly with the human ACE2? A thermodynamic answer.** Chembiochem 2020; de Andrade J, Bruno Gonçalves PF, Netz PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084150>
11. **Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis.** Clin. Hemorheol. Microcirc. 2020; Nugroho J, Wardhana A, Mulia EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074221>
12. **Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity.** Clin Transl Immunology 2020; 9:e1189 Graham NR, Whitaker AN, Strother CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072323>
13. **Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.** Comput. Biol. Med. 2020; 126:104054 Skariyachan S, Gopal D, Chakrabarti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074111>
14. **Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.** Curr. Drug Targets 2020; Vieira C, Nery L, Martins L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081670>
15. **Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19.** Cytokine Growth Factor Rev. 2020; Gabriele L, Fragale A, Romagnoli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071044>

16. **CD147 as a novel receptor in the pathogenesis of SARS-CoV-2: Is there any correlation with risk of COVID-19 in dermatological diseases?** Dermatol Ther 2020:e14443Pourani MR, Abdollahimajd F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089902>
17. **Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia.** EMBO Mol Med 2020:e13001Gibellini L, De Biasi S, Paolini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078545>
18. **Susceptibility of Raccoon Dogs for Experimental SARS-CoV-2 Infection.** Emerg Infect Dis 2020; 26Freuling CM, Breithaupt A, Müller T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089771>
19. **Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection.** Emerg Microbes Infect 2020:1-19Rathnasinghe R, Strohmeier S, Amanat F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073694>
20. **Epigenetic modifications of RNA and their implications in antiviral immunity.** Epigenomics 2020; Paramasivam A, Priyadharsini JV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078621>
21. **Translating bioactive peptides for COVID-19 therapy.** Eur. J. Pharmacol. 2020:173661Bhullar KS, Drews SJ, Wu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098835>
22. **Immunopathology of galectin-3: an increasingly promising target in COVID-19.** F1000Res 2020; 9:1078Caniglia JL, Asuthkar S, Tsung AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082935>
23. **Heme oxygenase-1 modulation: a potential therapeutic target for COVID-19 and associated complications.** Free Radic. Biol. Med. 2020; Singh D, Wasan H, Reeta KH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091573>
24. **Bibliometric and Visualization Analysis of Human Coronaviruses: Prospects and Implications for COVID-19 Research.** Front Cell Infect Microbiol 2020; 10:581404Deng Z, Chen J, Wang T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072630>
25. **Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.** Front. Immunol. 2020; 11:552925Beeraka NM, Sadhu SP, Madhunapantula SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072093>
26. **The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.** Front Med (Lausanne) 2020; 7:552991Canevelli M, Remoli G, Trentin F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072781>
27. **Translation-Associated Mutational U-Pressure in the First ORF of SARS-CoV-2 and Other Coronaviruses.** Front. Microbiol. 2020; 11:559165Khrustalev VV, Giri R, Khrustaleva TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072018>
28. **Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.** Front. Pharmacol. 2020; 11:574703Rubsamen R, Burkholz S, Massey C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071786>
29. **Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment.** Heliyon 2020; 6:e05278Shehroz M, Zaheer T, Hussain T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083627>
30. **Understand variability of COVID-19 through population and tissue variations in expression of SARS-CoV-2 host genes.** Inform Med Unlocked 2020; 21:100443Chen L, Zheng S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072849>

31. **Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19.** Inform Med Unlocked 2020; 21:100438Oladipo EK, Ajayi AF, Ariyo OE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33043110>
32. **Methylene blue inhibits the replication of SARS-Cov-2 in vitro.** Int J Antimicrob Agents 2020:106202Gendrot M, Andreani J, Duflot I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075512>
33. **Higher binding affinity of Furin to SARS-CoV-2 spike (S) protein D614G could be associated with higher SARS-CoV-2 infectivity.** Int J Infect Dis 2020; Mohammad A, Alshawaf E, Marafie SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075532>
34. **Prevention of SARS-CoV-2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2.** J Biomol Struct Dyn 2020:1-25Gyebi GA, Adegunloye AP, Ibrahim IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089728>
35. **Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.** J. Chem. Neuroanat. 2020:101874Singh N, Rai S, Singh V, Singh MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091590>
36. **Reissuing the sigma receptors for SARS-CoV-2.** J. Clin. Neurosci. 2020; 80:72-73Yesilkaya UH, Balcioglu YH, Sahin S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099370>
37. **SARS-CoV-2 specific virulence factors in COVID-19.** J Med Virol 2020; Kumar A, Prasoon P, Kumari C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085084>
38. **Evolutionary dynamics of SARS-CoV-2 nucleocapsid (N) protein and its consequences.** J Med Virol 2020; Shaminur Rahman M, Rafiul Islam M, Rubayet UI Alam ASM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095454>
39. **Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect.** J. Mol. Struct. 2020:129459Altalhi TA, Alswat K, Alsanie WF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082599>
40. **Cardiorenal tissues express SARS-CoV-2 entry genes and basigin (BSG/CD147) increases with age in endothelial cells.** JACC Basic Transl Sci 2020; Ahmetaj-Shala B, Vaja R, Atanur SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073064>
41. **In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor.** Microorganisms 2020; 8Mohammadi S, Heidarizadeh M, Entesari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080900>
42. **Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.** Microorganisms 2020; 8Sada M, Saraya T, Ishii H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092045>
43. **Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach.** Nat Prod Bioprospect 2020; Dahab MA, Hegazy MM, Abbass HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090359>
44. **Development of a novel platform of virus-like particle (VLP) based vaccine against coronavirus 2019 (SARS-CoV-2) by exposing of epitopes: an immunoinformatics approach.** New Microbes New Infect 2020:100786Ghorbani A, Zare F, Sazegari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072338>

45. **Changes from COVID-19. A perspective from internal pediatric medicine.** An Pediatr (Engl Ed) 2020; Alcalá Minagorre PJ, Villalobos Pinto E, Ramos Fernández JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072818>
46. **Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function.** PeerJ 2020; 8:e10234 Berrio A, Gartner V, Wray GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088633>
47. **Transcriptional and proteomic insights into the host response in fatal COVID-19 cases.** Proc Natl Acad Sci U S A 2020; Wu M, Chen Y, Xia H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082228>
48. **An Overview of the Crystallized Structures of the SARS-CoV-2.** Protein J 2020; Ionescu MI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098476>
49. **High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.** SLAS Discov 2020:2472555220963667 Smith E, Davis-Gardner ME, Garcia-Ordóñez RD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33043784>
50. **Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein.** Stem Cell Rev Rep 2020; Ropa J, Cooper S, Capitano ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089452>
51. **Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.** Vaccine 2020; Safavi A, Kefayat A, Mahdevar E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082015>
52. **Expression Pattern of the SARS-CoV-2 Entry Genes ACE2 and TMPRSS2 in the Respiratory Tract.** Viruses 2020; 12 Liu Y, Qu HQ, Qu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081421>
53. **Are Viral Vectors Any Good for RNAi Antiviral Therapy?** Viruses 2020; 12 Lundstrom K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092124>

Biomarkers - Genetics (117 articles)

1. **Multivariate analysis of CT imaging, laboratory, and demographical features for prediction of acute kidney injury in COVID-19 patients: a Bi-centric analysis.** Abdom Radiol (NY) 2020; Hectors SJ, Riyahi S, Dev H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098478>
2. **Rapid, Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip.** ACS Nano 2020; Alafeef M, Dighe K, Moitra P, Pan D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079516>
3. **Added value of anti-SARS-CoV-2 antibody testing in a Flemish nursing home during an acute COVID-19 outbreak in April 2020.** Acta Clin. Belg. 2020:1-6 Buntinx F, Claes P, Gulikers M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070766>
4. **[SARS-CoV-2 and the Importance of Dialogue Between Clinicians and the Laboratory].** Acta Med Port 2020; Franco-Leandro P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079058>
5. **An improved multivariate model that distinguishes COVID-19 from seasonal flu and other respiratory diseases.** Aging (Albany NY) 2020; 12 Guo X, Li Y, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085645>

6. **Serological Survey following SARS-CoV-2 Outbreaks at Long Term Care Facilities in Metro Vancouver, British Columbia: Implications for Outbreak Management and Infection Control Policies.** Am. J. Infect. Control 2020; Vijn R, Ghafari C, Hayden A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086096>
7. **SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations.** Anal. Bioanal. Chem. 2020;1-23Jayamohan H, Lambert CJ, Sant HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073312>
8. **Characteristics of coagulation alteration in patients with COVID-19.** Ann. Hematol. 2020;1-8Luo HC, You CY, Lu SW, Fu YQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079220>
9. **Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.** Ann. Natl. Acad. Med. Sci. 2020; 56:112-115Shekhar S, Copacino CE, Barrera FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082620>
10. **Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2.** Ann Oncol 2020; Marra A, Generali D, Zagami P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098994>
11. **Identification of novel mutations in the methyltransferase complex (Nsp10-Nsp16) of SARS-CoV-2.** Biochem Biophys Rep 2020; 24:100833Azad GK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072893>
12. **Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG.** Biochem. Med. (Zagreb) 2020; 30:030901Gambino CM, Lo Sasso B, Colomba C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071558>
13. **Easing diagnosis and pushing the detection limits of SARS-CoV-2.** Biol Methods Protoc 2020; 5:bpaa017Kiran U, Gokulan CG, Kuncha SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072873>
14. **A Biomarker Based Severity Progression Indicator for COVID-19: The Kuwait Prognosis Indicator Score.** Biomarkers 2020;1-21Jamal MH, Doi SA, AlYouha S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090050>
15. **A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).** Biosens. Bioelectron. 2020; 171:112715Lee JH, Choi M, Jung Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099241>
16. **Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features.** BMC Infect. Dis. 2020; 20:775De Angelis G, Posteraro B, Biscetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076874>
17. **Continuous thrombocytopenia after SARS-CoV-2 nucleic acid negative in a non-severe COVID-19 patient for several months.** BMC Infect. Dis. 2020; 20:774Wu X, Luo D, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076856>
18. **Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.** BMC Med 2020; 18:332Russell TW, Golding N, Hellewell J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087179>
19. **A model based on CT radiomic features for predicting RT-PCR becoming negative in coronavirus disease 2019 (COVID-19) patients.** BMC Med. Imaging 2020; 20:118Cai Q, Du SY, Gao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081700>

20. **Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients.** Cell Prolif. 2020:e12923Chen L, Zhao J, Peng J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073910>
21. **Large-Scale Multi-omic Analysis of COVID-19 Severity.** Cell Syst 2020; Overmyer KA, Shishkova E, Miller IJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096026>
22. **Analyzing the impact of the media campaign and rapid testing for COVID-19 as an optimal control problem in East Java, Indonesia.** Chaos Solitons Fractals 2020:110364Aldila D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082625>
23. **Rapid and extraction-free detection of SARS-CoV-2 from saliva by colorimetric reverse-transcription loop-mediated isothermal amplification.** Clin Chem 2020; Lalli MA, Langmade SJ, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098427>
24. **Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2.** Clin Chem 2020; Suhandynata RT, Hoffman MA, Huang D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33084854>
25. **Development, evaluation, and validation of machine learning models for COVID-19 detection based on routine blood tests.** Clin Chem Lab Med 2020; Cabitza F, Campagner A, Ferrari D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079698>
26. **Complete blood counts and cell population data from Sysmex XN analyser in the detection of SARS-CoV-2 infection.** Clin Chem Lab Med 2020; Urrechaga E, Aguirre U, España PP, García de Guadiana L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33079699>
27. **Positive control synthesis method for COVID-19 diagnosis by one-step real-time RT-PCR.** Clin Chim Acta 2020; 511:149-153Cho H, Jung YH, Cho HB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33058837>
28. **Evaluation of the clinical performance of single-, dual-, and triple-target SARS-CoV-2 RT-qPCR methods.** Clin Chim Acta 2020; 511:143-148Hu X, Zhu L, Luo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33058839>
29. **The N gene of SARS-CoV-2 was the main positive component in repositive samples from a cohort of COVID-19 patients in Wuhan, China.** Clin Chim Acta 2020; Zhang X, Li M, Zhang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096033>
30. **Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis.** Clin. Hemorheol. Microcirc. 2020; Nugroho J, Wardhana A, Mulia EP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074221>
31. **SARS CoV-2 Surveillance and Exposure in the Perioperative Setting with Universal testing and Personal Protective Equipment (PPE) Policies.** Clin Infect Dis 2020; Aslam A, Singh J, Robilotti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090210>
32. **Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination.** Clin Infect Dis 2020; Oldoni E, van Gool A, García Bermejo L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091118>
33. **Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.** Clin Infect Dis 2020; Yang B, Fulcher JA, Ahn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079180>

34. **Lymphocyte count and partial pressure of oxygen can be used as a screening test for COVID-19 in secondary care.** Clin Infect Pract 2020:100045Chan TY, Van Der Valk RA, Danso-Bamfo S, Ogunko AGR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083784>
35. **Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.** Curr. Drug Targets 2020; Vieira C, Nery L, Martins L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081670>
36. **Diabetes, D-dimer and COVID-19: The possible role of glucose control.** Diabetes Metab Syndr 2020; 14:1987Ceriello A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080539>
37. **The role of androgens in COVID-19.** Diabetes Metab Syndr 2020; 14:2003-2006Moradi F, Enjezab B, Ghadiri-Anari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091758>
38. **Dacron swab and PBS are acceptable alternatives to flocced swab and viral transport media for SARS-CoV-2.** Diagn. Microbiol. Infect. Dis. 2020; 99:115209Kline A, Putnam NE, Youn JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080426>
39. **A perspective on re-detectable positive SARS-CoV-2 nucleic acid results in recovered COVID-19 patients.** Disaster Med Public Health Prep 2020:1-19He Y, Dong YC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087207>
40. **SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review.** Ecancermedicalsecience 2020; 14:1100Haradaa G, Antonacio FF, Gongora AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082850>
41. **Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiotensin-2, heat shock protein-27 and epithelial mesenchymal transition.** Ecancermedicalsecience 2020; 14:1099Saha A, Anirvan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082849>
42. **Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia.** EMBO Mol Med 2020:e13001Gibellini L, De Biasi S, Paolini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078545>
43. **Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020.** Emerg Infect Dis 2020; 26Chan PKS, Lui G, Hachim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089772>
44. **The duration of SARS-CoV-2 shedding in patients recovering from COVID-19.** Epidemiol. Mikrobiol. Immunol. 2020; 69:148-151Cimrman Š, Macková L, Král V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086857>
45. **Epigenetic modifications of RNA and their implications in antiviral immunity.** Epigenomics 2020; Paramasivam A, Priyadharsini JV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078621>
46. **Evaluation of three immunochromatographic tests in COVID-19 serologic diagnosis and their clinical usefulness.** Eur J Clin Microbiol Infect Dis 2020:1-4Pegoraro M, Militello V, Salvagno GL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078222>
47. **Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to six months post disease onset.** Eur. J. Immunol. 2020; Figueiredo-Campos P, Blankenhaus B, Mota C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084029>

48. **Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 patients.** *Eur. J. Immunol.* 2020; Oja AE, Saris A, Ghandour CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073359>
49. **SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.** *Euro Surveill* 2020; 25:Lumley SF, Eyre DW, McNaughton AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094717>
50. **Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients.** *Febs j.* 2020; Zeng HL, Di C, Yan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098359>
51. **The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection.** *Front Cell Infect Microbiol* 2020; 10:550571 Branco A, Sato MN, Alberca RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072624>
52. **Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology.** *Front. Immunol.* 2020; 11:560381 Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072099>
53. **The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.** *Front Med (Lausanne)* 2020; 7:552991 Canevelli M, Remoli G, Trentin F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072781>
54. **Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future?** *Front. Microbiol.* 2020; 11:571553 Bhattacharyya P, Biswas SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072032>
55. **Geographical Distribution of Genetic Variants and Lineages of SARS-CoV-2 in Chile.** *Front Public Health* 2020; 8:562615 Castillo AE, Parra B, Tapia P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072699>
56. **Epidemiological and Genomic Analysis of SARS-CoV-2 in 10 Patients From a Mid-Sized City Outside of Hubei, China in the Early Phase of the COVID-19 Outbreak.** *Front Public Health* 2020; 8:567621 Chen J, Hilt EE, Li F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072702>
57. **Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany.** *Front Public Health* 2020; 8:570543 Solbach W, Schiffner J, Backhaus I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072707>
58. **MiR-146a rs2910164 G > C polymorphism modulates Notch-1/IL-6 signaling during infection: a possible risk factor for Crohn's disease.** *Gut Pathog.* 2020; 12:48 Keewan E, Naser SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072191>
59. **Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity.** *Hum Genomics* 2020; 14:40 Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092637>
60. **Proposed clinical indicators for efficient screening and testing for COVID-19 infection using Classification and Regression Trees (CART) analysis.** *Hum Vaccin Immunother* 2020; 1-4 Zimmerman RK, Nowalk MP, Bear T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079625>
61. **Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing2.** *Infect. Agent. Cancer* 2020; 15:61 Ajenifuja KO, Belinson J, Goldstein A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072179>

62. **A Viewpoint On Potential Biomarkers For Infectious COVID-19 severity: An Updated Literature Survey.** *Infect Disord Drug Targets* 2020; Mali SN, Mohajer F, Ziarani GM, Pratap AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076812>
63. **Understand variability of COVID-19 through population and tissue variations in expression of SARS-CoV-2 host genes.** *Inform Med Unlocked* 2020; 21:100443Chen L, Zheng S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072849>
64. **Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: an Egyptian pilot model in a university with 12 public hospitals and medical centers.** *Int J Epidemiol* 2020; Mostafa A, Kandil S, El-Sayed MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094320>
65. **Immune system changes during COVID-19 recovery play key role in determining disease severity.** *Int. J. Immunopathol. Pharmacol.* 2020; 34:2058738420966497Fathi F, Sami R, Mozafarpour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076729>
66. **A Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital.** *Int J Infect Dis* 2020; Herzberg J, Vollmer T, Fischer B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075538>
67. **SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic.** *Int J Infect Dis* 2020; Venugopal U, Jilani N, Rabah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075539>
68. **Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19.** *Int. J. Lab. Hematol.* 2020; Liu L, Zheng Y, Cai L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099889>
69. **Reducing False Negative PCR Test for COVID-19.** *Int J MCH AIDS* 2020; 9:408-410Bahreini F, Najafi R, Amini R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072432>
70. **Objective evaluation of the nasal mucosal secretion in COVID-19 patients with anosmia.** *Ir. J. Med. Sci.* 2020; Islamoglu Y, Gemcioglu E, Ates I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074449>
71. **Nitric oxide's physiologic effects and potential as a therapeutic agent against Covid-19.** *J Breath Res* 2020; Ricciardolo FLM, Bertolini F, Carriero V, Högman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080582>
72. **Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** *J. Clin. Lab. Anal.* 2020:e23618Cheng L, Li H, Li L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078400>
73. **SARS-CoV-2 Viral Load, IFN λ Polymorphisms and the Course of COVID-19: An Observational Study.** *J Clin Med* 2020; 9Amodio E, Pipitone RM, Grimaudo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076493>
74. **Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World.** *J Clin Med* 2020; 9Augustine R, Das S, Hasan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096742>
75. **Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.** *J. Diabetes Sci. Technol.* 2020:1932296820965203Jankovic I, Basina M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084380>
76. **Implementation of Drive-Through Testing for COVID-19 Using an External Emergency Department Triage.** *J. Emerg. Med.* 2020; Bradley K, Constantine T,

- Morel B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092971>
77. **Prolonged SARS-CoV-2 replication in an immunocompromised patient.** J Infect Dis 2020; Baang JH, Smith C, Mirabelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089317>
 78. **Multiplex rt-Real Time PCR assays for diagnostic testing of SARS-CoV-2 and seasonal influenza viruses. A challenge of the phase 3 pandemic setting.** J Infect Dis 2020; Mancini F, Barbanti F, Scaturro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080031>
 79. **Associations between genetically predicted protein levels and COVID-19 severity.** J Infect Dis 2020; Zhu J, Wu C, Wu L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083826>
 80. **A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality.** J Infect Public Health 2020; Serin I, Sari ND, Dogu MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071210>
 81. **Can urine be a potential biohazard in times of SARS-CoV-2 pandemic?** J Med Virol 2020; Mattos EC, Matsuda EM, Colpas DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085089>
 82. **Intricacies in characterizing positivity in pooled sample testing for SARS-CoV-2.** J Med Virol 2020; Mohanty S, Ravindra A, Gupta K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085120>
 83. **Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19.** J Med Virol 2020; Yang P, Wang N, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073361>
 84. **Implementation of a nurse practitioner led drive through COVID-19 testing site.** J. Nurse Pract. 2020; Dippel KS, Kelly EK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071679>
 85. **Systematic screening for SARS-CoV-2 in pregnant women admitted for delivery in a Portuguese maternity.** J. Perinat. Med. 2020; Figueiredo R, Tavares S, Moucho M, Ramalho C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085639>
 86. **Usefulness of COVID-19 screen-and-test approach in pregnant women: an experience from a country with low COVID-19 burden.** J. Perinat. Med. 2020; Šterbenc A, Premru Sršen T, Lučovnik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090969>
 87. **Perspective on Proteomics for Virus Detection in Clinical Samples.** J. Proteome Res. 2020; Grossegasse M, Hartkopf F, Nitsche A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090795>
 88. **The role of Interleukin-4 in COVID-19 associated male infertility - A hypothesis.** J Reprod Immunol 2020; 142:103213 Renu K, Subramaniam MD, Chakraborty R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080435>
 89. **Use of Continuous Glucose Monitoring to Assess TPN-induced Hyperglycemia in an Adult Patient with Severe COVID-19.** JPEN J. Parenter. Enteral Nutr. 2020; Chow KW, Kelly DJ, Gupta R, Miller JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085780>
 90. **SARS-CoV-2 presence in the saliva, tears and cerumen of COVID-19 patients.** Laryngoscope 2020; Hanege FM, Kocoglu E, Kalcioğlu MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094833>
 91. **Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes.** Mar. Drugs 2020; 18 Mazzotta S,

- Carullo G, Schiano Moriello A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081023>
92. **Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein.** *mBio* 2020; 11:Wang X, Lam JY, Wong WM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082264>
 93. **The potential use of ABO blood group system for risk stratification of COVID-19.** *Med. Hypotheses* 2020; 145:110343AbdelMassih AF, Mahrous R, Taha A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086161>
 94. **The utilization of rapid serological tests in COVID-19 diagnostics - a high risk of false-negative results in outpatient care, with particular emphasis on dental treatment.** *Med. Pr.* 2020; Tysiąc-Miśta M, Bulanda S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095209>
 95. **High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19.** *Mol. Immunol.* 2020; 128:64-68Guirao JJ, Cabrera CM, Jiménez N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075636>
 96. **Incidence of Health Care-Associated COVID-19 During Universal Testing of Medical and Surgical Admissions in a Large US Health System.** *Open Forum Infect Dis* 2020; 7:ofaa435Long DR, O'Reilly-Shah V, Rustagi AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088847>
 97. **Clinical Ordering Practices of the SARS-CoV-2 Antibody Test at a Large Academic Medical Center.** *Open Forum Infect Dis* 2020; 7:ofaa406Wienczek JR, Head CL, Sifri CD, Parsons AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072813>
 98. **Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.** *Pathog Immun* 2020; 5:327-341Fomina DS, Lysenko MA, Beloglazova IP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089038>
 99. **Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults.** *Pathog Immun* 2020; 5:312-326Hornick A, Tashtish N, Osnard M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089037>
 100. **Comparative analysis of three laboratory based serological assays for SARS-CoV-2 in an Australian cohort.** *Pathology* 2020; Davidson N, Evans J, Giammichele D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070955>
 101. **Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.** *Pathology* 2020; Tan SS, Saw S, Chew KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092816>
 102. **Risk factors for redetectable positivity in recovered COVID-19 children.** *Pediatr Pulmonol* 2020; Peng D, Zhang J, Ji Y, Pan D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33049115>
 103. **COVID-19: molecular and serological detection methods.** *PeerJ* 2020; 8:e10180Dhamad AE, Abdal Rhida MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083156>
 104. **Mutations of SARS-CoV-2 nsp14 exhibit strong association with increased genome-wide mutation load.** *PeerJ* 2020; 8:e10181Eskier D, Suner A, Oktay Y, Karakulah G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083157>
 105. **Transcriptional and proteomic insights into the host response in fatal COVID-19 cases.** *Proc Natl Acad Sci U S A* 2020; Wu M, Chen Y, Xia H *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082228>
106. **Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study.** Respir Res 2020; 21:276Sonnweber T, Boehm A, Sahanic S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087116>
 107. **SARS-CoV-2 Detection on Bronchoalveolar Lavage: An Italian Multicenter experience.** Respiration 2020;1-9Patrucco F, Albera C, Bellocchia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075793>
 108. **Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings.** Rev. Esp. Quimioter. 2020; Candel FJ, Barreiro P, San Román J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070578>
 109. **Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review.** Rev Med Virol 2020; Comber L, Walsh KA, Jordan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091200>
 110. **Three-tier stratification for CNS COVID-19 to help decide which patients should undergo lumbar puncture with CSF analysis: A case report and literature review.** Rom. J. Intern. Med. 2020; Ramakrishna JM, Libertin CR, Siegel J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098636>
 111. **Functionalized TiO(2) Nanotube-Based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2.** Sensors (Basel) 2020; 20Vadlamani BS, Uppal T, Verma SC, Misra M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080785>
 112. **Admission Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a Pooled Analysis and Meta-summary of Literature.** SN Compr Clin Med 2020;1-6Sachdeva S, Desai R, Gupta U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073173>
 113. **Serum pooling for rapid expansion of anti-SARS-CoV-2 antibody testing capacity.** Transfus. Clin. Biol. 2020; Allen JWL, Verkerke H, Owens J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096207>
 114. **Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP).** Virol J 2020; 17:160Mautner L, Baillie CK, Herold HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087160>
 115. **Reliability of induced sputum test is greater than that of throat swab test for detecting SARS-CoV-2 in patients with COVID-19: A multi-center cross-sectional study.** Virulence 2020; 11:1394-1401Lai T, Xiang F, Zeng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073676>
 116. **Coronavirus testing in women attending antenatal care.** Women Birth 2020; Rolnik DL, Korman TM, Rindt A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092997>
 117. **Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients.** World J Clin Cases 2020; 8:4370-4379Wang L, He WB, Yu XM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083396>

Children (40 articles)

1. **Diarrhea as a Presenting Symptom of Coronavirus Disease 2019 in Children.** Adv Biomed Res 2020; 9:35Moradveisi B, Ataee P, Ghaffarieh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072647>

2. **Higher Executive Control Network Coherence Buffers Against Puberty-Related Increases in Internalizing Symptoms During the COVID-19 Pandemic.** Biol Psychiatry Cogn Neurosci Neuroimaging 2020; Chahal R, Kirshenbaum JS, Miller JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097469>
3. **The immediate effect of COVID-19 pandemic on children and adolescents with obsessive compulsive disorder.** BMC Psychiatry 2020; 20:511 Nissen JB, Højgaard D, Thomsen PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081741>
4. **ATRIAL FIBRILLATION IN A PEDIATRIC PATIENT WITH COVID-19 INFECTION.** Cardiol. Young 2020;1-9 Santi AD, Aquino P, Dorfman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070790>
5. **'When will I be free': Lessons from COVID-19 for Child Protection in South Africa.** Child Abuse Negl. 2020;104715 Haffejee S, Levine DT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071025>
6. **Invisible children and non-essential workers: Child protection during COVID-19 in Israel according to policy documents and media coverage.** Child Abuse Negl. 2020;104770 Katz C, Cohen N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071026>
7. **Family violence against children in the wake of COVID-19 pandemic: a review of current perspectives and risk factors.** Child Adolesc Psychiatry Ment Health 2020; 14:40 Pereda N, Díaz-Faes DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088340>
8. **Implications of COVID-19-induced nationwide lockdown on children's behaviour in Punjab, India.** Child Care Health Dev. 2020; Sama BK, Kaur P, Thind PS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33047842>
9. **The Effect of the Coronavirus (Covid-19) Pandemic on Health-Related Quality of Life in Children.** Child Youth Serv Rev 2020; 119:105595 Adibelli D, Sümen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071408>
10. **The effect of the coronavirus (COVID-19) pandemic on health-related quality of life in children.** Child Youth Serv Rev 2020; 119:105595 Adibelli D, Sümen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071408>
11. **A child's right to protection during the COVID-19 crisis: An exploratory study of the Child Protective Services of Estonia.** Child Youth Serv Rev 2020; 119:105568 Toros K, Falch-Eriksen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071404>
12. **High Levels of Stress Due to the SARS-CoV-2 Pandemic among Parents of Children with and without Chronic Conditions across the USA.** Children (Basel) 2020; 7M ALvT, Edlynn E, Maddaloni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096787>
13. **Considerations for nutrition support in critically ill children with COVID-19 and paediatric inflammatory multisystem syndrome temporally associated with COVID-19.** Clin. Nutr. 2020; Marino LV, Valla FV, Tume LN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097307>
14. **Death due to COVID-19 in an Infant with Combined Immunodeficiencies.** Endocr. Metab. Immune Disord. Drug Targets 2020; Ahanchian H, Moazzen N, Joghatayi SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087035>
15. **Kawasaki-like Syndrome as an Emerging Complication of SARS-CoV-2 Infection in Young Adults.** Eur J Case Rep Intern Med 2020; 7:001886 Burgi Vieira C, Ferreira AT, Botelho Cardoso F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083367>

16. **Decrease in Hospitalizations and Increase in Deaths during the Covid-19 Epidemic in a Pediatric Hospital, Yaounde-Cameroon and Prediction for the Coming Months.** Fetal Pediatr Pathol 2020;1-14 Chelo D, Mekone Nkwelle I, Nguefack F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078968>
17. **Effect of Population Lockdown on Pediatric Emergency Room Demands in the Era of COVID-19.** Front Pediatr 2020; 8:521 Valitutti F, Zenzeri L, Mauro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072657>
18. **A Child with Acute Lymphoblastic Leukemia in Institutional Isolation during the COVID Pandemic: A Multifaceted Responsibility.** Indian J. Palliat. Care 2020; 26:S170-s172 Rathore P, Kumar S, Shweta *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088114>
19. **Child in Institutional Quarantine - A Unique Challenge.** Indian J. Palliat. Care 2020; 26:S142-s144 Singh N, Haokip N, Rathore P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088104>
20. **Association between Physical Activity and Mood States of Children and Adolescents in Social Isolation during the COVID-19 Epidemic.** Int J Environ Res Public Health 2020; 17 Zhang X, Zhu W, Kang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096659>
21. **Mental Health and the COVID-19 Crisis: The Hopes and Concerns for Children as Schools Re-open.** Interchange (Tor : 1984) 2020:1-16 Fontenelle-Tereshchuk D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071449>
22. **The future of telemedicine visits after COVID-19: perceptions of primary care pediatricians.** Isr J Health Policy Res 2020; 9:53 Grossman Z, Chodick G, Reingold SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081834>
23. **Mental health and its correlates among children and adolescents during COVID-19 school closure: The importance of parent-child discussion.** J. Affect. Disord. 2020; 279:353-360 Tang S, Xiang M, Cheung T, Xiang YT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099049>
24. **COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C): a novel disease that mimics Toxic Shock Syndrome. The superantigen hypothesis.** J Allergy Clin Immunol 2020; Rivas MN, Porritt RA, Cheng MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075409>
25. **Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children: A Call to Action.** J Am Coll Cardiol 2020; 76:1962-1964 Friedman KG, Harrild DM, Newburger JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092731>
26. **Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic.** J Clin Transl Endocrinol 2020:100238 Fung A, Irvine M, Ayub A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072519>
27. **Low impact of SARS-CoV-2 infection among paediatric acute respiratory disease hospitalizations.** J Infect 2020; Melé M, Henares D, Pino R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098956>
28. **Visitor Restriction Policy on Pediatric Wards during Novel Coronavirus (COVID-19) Outbreak: A Survey Study across North America.** J Pediatric Infect Dis Soc 2020; Kitano T, Piché-Renaud PP, Groves HE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090211>
29. **Pancreatitis in Pediatric Patients with COVID-19.** J Pediatric Infect Dis Soc 2020; Samies NL, Yarbrough A, Boppana S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075134>

30. **Reversible Myocardial Injury Associated with SARS-CoV-2 in an Infant.** JACC Case Rep 2020; Sharma M, Gorstein S, Aldrich ML *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073245>
31. **COVID-19, children and schools: overlooked and at risk.** Med. J. Aust. 2020; Hyde Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099775>
32. **Is Covid-19 lockdown related to an increase of accesses for seizures in the emergency department? An observational analysis of a paediatric cohort in the Southern Italy.** Neurol Sci 2020; Palladino F, Merolla E, Solimeno M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33095368>
33. **Changes from COVID-19. A perspective from internal pediatric medicine.** An Pediatr (Engl Ed) 2020; Alcalá Minagorre PJ, Villalobos Pinto E, Ramos Fernández JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072818>
34. **Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection.** An Pediatr (Engl Ed) 2020; Storch-de-Gracia P, Leoz-Gordillo I, Andina D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083499>
35. **Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients.** Pediatr Blood Cancer 2020; 67:e28737Al-Ghafry M, Aygun B, Appiah-Kubi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098753>
36. **Suspected COVID-19-related reticulated purpura of the soles in an infant.** Pediatr. Dermatol. 2020; Andina D, Colmenero I, Santonja C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085141>
37. **Overview of chest involvement at computed tomography in children with coronavirus disease 2019 (COVID-19).** Pediatr Radiol 2020;1-9Peng X, Guo Y, Xiao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084963>
38. **Impact of COVID-19 outbreak on mental health and perceived strain among caregivers tending children with special needs.** Res. Dev. Disabil. 2020; 107:103790Dhiman S, Sahu PK, Reed WR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091712>
39. **Where have the children with epilepsy gone? An observational study of seizure-related accesses to emergency department at the time of COVID-19.** Seizure 2020; 83:38-40Davico C, Marcotulli D, Lux C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080483>
40. **[Features of neurological manifestations of the COVID-19 in children and adults].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2020; 120:114-120Kholin AA, Zavadenko NN, Nesterovskiy YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081456>

Clinical Features (40 articles)

1. **Multivariate analysis of CT imaging, laboratory, and demographical features for prediction of acute kidney injury in COVID-19 patients: a Bi-centric analysis.** Abdom Radiol (NY) 2020; Hectors SJ, Riyahi S, Dev H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098478>
2. **Diarrhea as a Presenting Symptom of Coronavirus Disease 2019 in Children.** Adv Biomed Res 2020; 9:35Moradveisi B, Ataee P, Ghaffarieh A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072647>

3. **An improved multivariate model that distinguishes COVID-19 from seasonal flu and other respiratory diseases.** Aging (Albany NY) 2020; 12Guo X, Li Y, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085645>
4. **Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).** Ann. Hepatol. 2020; Lopez-Mendez I, Aquino-Matus J, Gall SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099028>
5. **Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features.** BMC Infect. Dis. 2020; 20:775De Angelis G, Posteraro B, Biscetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076874>
6. **The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study.** BMC Infect. Dis. 2020; 20:777Omrani AS, Almaslamani MA, Daghfal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076848>
7. **Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study.** BMC Infect. Dis. 2020; 20:787Xiong S, Liu L, Lin F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092539>
8. **Haemoptysis as the first presentation of COVID-19: a case report.** BMC Pulm. Med. 2020; 20:275Peys E, Stevens D, Weygaerde YV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092563>
9. **The Natural History of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Composite But Incomplete Picture.** Clin Infect Dis 2020; Sachithanandham J, Thio CL, Balagopal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090197>
10. **Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.** Clin Infect Dis 2020; Yang B, Fulcher JA, Ahn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079180>
11. **Behavioral Changes Without Respiratory Symptoms as a Presenting Sign of COVID-19 Encephalitis.** Cureus 2020; 12:e10469Rebeiz T, Lim-Hing K, Khazanehdari S, Rebeiz K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083172>
12. **Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).** EClinicalMedicine 2020;100591Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078138>
13. **Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results.** Eur Arch Otorhinolaryngol 2020; Viola P, Ralli M, Pisani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095432>
14. **Urinary Retention and Severe Hyponatremia: An Unusual Presentation of COVID-19.** Eur J Case Rep Intern Med 2020; 7:001905Saleh AO, Al-Shokri SD, Ahmed AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083368>
15. **Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China.** Expert Rev. Respir. Med. 2020; Yang R, Gui X, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074039>
16. **COVID-19: In the Eye of the Cytokine Storm.** Front. Immunol. 2020; 11:558898de la Rica R, Borges M, Gonzalez-Freire M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074039>

term=33072097

17. **Proposed clinical indicators for efficient screening and testing for COVID-19 infection using Classification and Regression Trees (CART) analysis.** Hum Vaccin Immunother 2020;1-4 Zimmerman RK, Nowalk MP, Bear T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33079625>
18. **Testing Olfactory and Gustatory Dysfunctions among Quarantine COVID-19 Suspects.** Indian J Otolaryngol Head Neck Surg 2020;1-6 Bidkar V, Mishra M, Selvaraj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078124>
19. **Otolaryngologic Manifestation and Long-Term Outcome in Mild COVID-19: Experience from a Tertiary Care Centre in India.** Indian J Otolaryngol Head Neck Surg 2020;1-6 Panda S, Mohamed A, Sikka K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078125>
20. **Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.** Int Immunopharmacol 2020; 89:107093 Nili A, Zarei E, Ghamari A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091817>
21. **COVID-19 and late-onset hypertension with hyporeninaemic hypoaldosteronism.** Int J Clin Pract 2020:e13773 Manda AKJ, Kho J, Metaxa S, Missouriis CG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078526>
22. **Two cases of skin manifestations prior to the onset of COVID-19 respiratory symptoms.** Int. J. Dermatol. 2020; Altayeb A, Cordaro A, Caesar J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33084036>
23. **Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.** Int J Environ Res Public Health 2020; 17 Faes C, Abrams S, Beckhoven DV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080869>
24. **Clinical characteristics of COVID-19 in pregnant women: A retrospective descriptive single-center study from a tertiary hospital in Muscat, Oman.** Int J Gynaecol Obstet 2020; Santhosh J, Al Salmani M, Khamis F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075146>
25. **Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State, Nigeria.** Int J Infect Dis 2020; Abayomi A, Odukoya O, Osibogun A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075534>
26. **COVID toes: where do we stand with the current evidence?** Int J Infect Dis 2020; Baek M, Herman A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075530>
27. **Periungual desquamation in a Japanese Adult recovering from severe COVID-19.** Int J Infect Dis 2020; Nakamoto T, Ishikane M, Sasaki R, Ohmagari N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075533>
28. **COVID-19 Wounds: Unusual Lower Extremity Bullae.** Int. J. Low. Extrem. Wounds 2020;1534734620964284 Zinder R, Andrews C, Cristallo J, Flattau A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33076733>
29. **COVID-19 Pneumonia Resembling an Acute Exacerbation of Interstitial Pneumonia.** Intern Med 2020; Kitayama T, Kitamura H, Hagiwara E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087668>
30. **Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study.** J Epidemiol Glob Health 2020; Alharthy A, Aletreby W, Faqihi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095982>

31. **Self-perceived general and ear-nose-throat symptoms related to the COVID-19 outbreak: a survey study during quarantine in Italy.** J. Int. Med. Res. 2020; 48:300060520961276Micarelli A, Granito I, Carlino P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081538>
32. **Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China.** J Med Virol 2020; Chen Y, Ke Y, Liu X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085103>
33. **Early Clinical Factors Predicting the Development of Critical Disease in Japanese Patients with COVID-19: A Single-Center, Retrospective, Observational Study.** J Med Virol 2020; Higuchi T, Nishida T, Iwahashi H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090527>
34. **Covid-19 in pandemic flu season: Are we able to distinguish by clinical appearance?** MMW-Fortschritte der Medizin 2020; 162:48-53Oette M.
35. **COVID-19-associated myositis may be dermatomyositis.** Muscle Nerve 2020; Tanboon J, Nishino I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095493>
36. **Diaphragmatic myoclonus due to SARS-CoV-2 infection.** Neurol Sci 2020; Borroni B, Gazzina S, Dono F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090303>
37. **Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.** Pathog Immun 2020; 5:327-341Fomina DS, Lysenko MA, Beloglazova IP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089038>
38. **Suspected COVID-19-related reticulated purpura of the soles in an infant.** Pediatr. Dermatol. 2020; Andina D, Colmenero I, Santonja C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085141>
39. **Critically Ill Patients with COVID-19: A Narrative Review on Prone Position.** Pulm Ther 2020:1-14Qadri SK, Ng P, Toh TSW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085052>
40. **Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort.** Rev. Med. Interne 2020; Jourdes A, Lafaurie M, Martin-Blondel G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077266>

CNS (33 articles)

1. **Objective evaluation of odor loss in COVID-19 and other suspected cases.** Am. J. Otolaryngol. 2020; 42:102761Seden N, Yiğit E, Yiğit Ö, Kaygısız İ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080550>
2. **Neuroinvasive potential of SARS-CoV2 with neuroradiological and neuropathological findings: is the brain a target or a victim?** APMIS 2020; Franca RA, Ugga L, Guadagno E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098147>
3. **The cognitive consequences of the COVID-19 epidemic: collateral damage?** Brain Commun 2020; 2:fcaa069Ritchie K, Chan D, Watermeyer T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074266>
4. **Neurological manifestations in COVID-19: a systematic review and meta-analysis.** Brain Inj. 2020:1-20Chua TH, Xu Z, King NKK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074036>
5. **Behavioral Changes Without Respiratory Symptoms as a Presenting Sign of COVID-19 Encephalitis.** Cureus 2020; 12:e10469Rebeiz T, Lim-Hing K,

- Khazanehdari S, Rebeiz K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083172>
6. **Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results.** Eur Arch Otorhinolaryngol 2020; Viola P, Ralli M, Pisani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095432>
 7. **Urinary Retention and Severe Hyponatremia: An Unusual Presentation of COVID-19.** Eur J Case Rep Intern Med 2020; 7:001905Saleh AO, Al-Shokri SD, Ahmed AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083368>
 8. **Meningitis as an Initial Presentation of COVID-19: A Case Report.** Front Public Health 2020; 8:474Naz S, Hanif M, Haider MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072684>
 9. **COVID-19 Pandemic and Neurological Disease: A Critical Review of the Existing Literature.** Hosp Pract Res 2020; 5:81-86Assari S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094214>
 10. **Testing Olfactory and Gustatory Dysfunctions among Quarantine COVID-19 Suspects.** Indian J Otolaryngol Head Neck Surg 2020;1-6Bidkar V, Mishra M, Selvaraj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078124>
 11. **Objective evaluation of the nasal mucosal secretion in COVID-19 patients with anosmia.** Ir. J. Med. Sci. 2020; Islamoglu Y, Gemcioglu E, Ates I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074449>
 12. **Antivirals Against SARS-CoV2: Relevance to the Treatment of Alzheimer's Disease.** J. Alzheimers Dis. 2020; Itzhaki RF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074241>
 13. **Acute myelitis and SARS-CoV-2 infection. A new etiology of myelitis?** J. Clin. Neurosci. 2020; 80:280-281Águila-Gordo D, Manuel Flores-Barragán J, Ferragut-Lloret F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099361>
 14. **How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy.** J. Clin. Neurosci. 2020; 79:231-236Armocida D, Palmieri M, Frati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070902>
 15. **Locked-In with COVID-19.** J. Clin. Neurosci. 2020; 79:80-83Avula A, Gill A, Nassar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070924>
 16. **Mild encephalopathy with reversible splenium lesion (MERS) in a patient with COVID-19.** J. Clin. Neurosci. 2020; 79:272-274Kakadia B, Ahmed J, Siegal T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070911>
 17. **Arterial and venous strokes in the setting of COVID-19.** J. Clin. Neurosci. 2020; 79:60-66Kaneh MF, Thomas T, Sharma K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070919>
 18. **Letter to the editor. Concerning the article entitled "Guillain Barre syndrome associated with COVID-19 infection: A case report".** J. Clin. Neurosci. 2020; 79:257-258Karimi N, Sedaghat Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070907>
 19. **Approach to critical illness myopathy and polyneuropathy in the older SARS-CoV-2 patients.** J. Clin. Neurosci. 2020; 79:241-245McClafferty B, Umer I, Fye G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070904>
 20. **Cerebral nervous system vasculitis in a Covid-19 patient with pneumonia.** J. Clin. Neurosci. 2020; 79:71-73Vaschetto R, Cena T, Sainaghi PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070922>
 21. **Ototoxicity prevention during the SARS-CoV-2 (Covid-19) emergency.** J Glob Antimicrob Resist 2020; Ciorba A, Skarżyński PH, Pelucchi S, Hatzopoulos S.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075521>
22. **COVID-19 in Parkinson's disease: what holds the key?** J. Neurol. 2020; Sainz-Amo R, Baena-Álvarez B, Pareés I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098468>
 23. **Why Does COVID-19 Affect Patients with Spinal Cord Injury Milder? A Case-Control Study: Results from Two Observational Cohorts.** J Pers Med 2020; 10Calvo E, Corbacho-Alonso N, Sastre-Oliva T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096722>
 24. **Seizure And COVID-19: Association and Review of Potential Mechanism.** Neurol Psychiatry Brain Res 2020; Joseph R, Narula N, Daouk A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071468>
 25. **Seizure and COVID-19: Association and review of potential mechanism.** Neurol Psychiatry Brain Res 2020; 38:49-53Narula N, Joseph R, Katyal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071468>
 26. **Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions.** Neurol Sci 2020; Favas TT, Dev P, Chaurasia RN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089477>
 27. **Neurotropism of SARS-CoV-2 and its neuropathological alterations: similarities with other coronaviruses.** Neurosci. Biobehav. Rev. 2020; Hu J, Jolkkonen J, Zhao C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091416>
 28. **Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience.** Parkinsonism Relat. Disord. 2020; Tan EK, Albanese A, Chaudhuri K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071183>
 29. **Potential Neurological Manifestations of COVID-19: A Narrative Review.** Postgrad. Med. 2020; Pergolizzi JV, Jr., Raffa RB, Varrassi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089707>
 30. **Three-tier stratification for CNS COVID-19 to help decide which patients should undergo lumbar puncture with CSF analysis: A case report and literature review.** Rom. J. Intern. Med. 2020; Ramakrishna JM, Libertin CR, Siegel J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098636>
 31. **Neurological Complications of SARS-CoV, MERS-CoV, and COVID-19.** SN Compr Clin Med 2020;1-11Alshebri MS, Alshouimi RA, Alhumidi HA, Alshaya AI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083695>
 32. **[Features of neurological manifestations of the COVID-19 in children and adults].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2020; 120:114-120Kholin AA, Zavadenko NN, Nesterovskiy YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081456>
 33. **[Clinical and pathogenetic aspects of nervous system impairments in COVID-19].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2020; 120:130-136Kutlubaev MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081458>

Coagulation (26 articles)

1. **Immunity and Coagulation/Fibrinolytic Processes may Reduce the Risk of Severe Illness in Pregnant Women with COVID-19.** Am J Obstet Gynecol 2020; Zhong Y, Cao Y, Zhong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098813>
2. **COVID-19, Hypercoagulability and Cautiousness with Convalescent Plasma.** Am J Respir Crit Care Med 2020; Sanfilippo F, La Rosa V, Oliveri F, Astuto M.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085908>
3. **[COVID-19 and venous thromboembolism].** Ann. Cardiol. Angeiol. (Paris) 2020; Trimaille A, Bonnet G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081917>
 4. **Characteristics of coagulation alteration in patients with COVID-19.** Ann. Hematol. 2020;1-8Luo HC, You CY, Lu SW, Fu YQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079220>
 5. **Continuous thrombocytopenia after SARS-CoV-2 nucleic acid negative in a non-severe COVID-19 patient for several months.** BMC Infect. Dis. 2020; 20:774Wu X, Luo D, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076856>
 6. **COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature.** Cardiorenal Med. 2020;1-8Mahajan P, Dass B, Radhakrishnan N, McCullough PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091905>
 7. **Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment.** Cardiovasc. Drugs Ther. 2020;1-15Gasecka A, Borovac JA, Guerreiro RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074525>
 8. **Prevalence and Risk Factors of Thromboembolism among Patients With Coronavirus Disease-19: A Systematic Review and Meta-Analysis.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620967083Kefale B, Tegegne GT, Degu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074717>
 9. **The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620960797Wijaya I, Andhika R, Huang I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079569>
 10. **Enteral feeding and non-invasive ventilation during the COVID-19 crisis: A new snorkeling mask specially-fit to provide both concomitantly.** Clin. Nutr. 2020; Lemyze M, Mascot M, Orfi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071011>
 11. **Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19.** Cureus 2020; 12:e10447Daid SS, Toribio AD, Lakshmanan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072456>
 12. **Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications.** Dermatol Ther 2020; Szolnoky G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078864>
 13. **Vaccines for adults: An update.** Deutsche Medizinische Wochenschrift 2020; 145:1464-1468Seybold U.
 14. **Right atrial thrombus in a patient with COVID-19 pneumonia: a case report.** Eur Heart J Case Rep 2020; 4:1-4Shamsah MA, Bitar ZI, Alfoudri H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089061>
 15. **Mondor's Disease in SARS-CoV-2 Infection: A Case of Superficial Vein Thrombosis in the Era of COVID-19.** Eur J Case Rep Intern Med 2020; 7:001803Lessiani G, Bocatonda A, D'Ardes D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083359>
 16. **Case Series: Evidence of Borderzone Ischemia in Critically-Ill COVID-19 Patients Who "Do Not Wake Up".** Front. Neurol. 2020; 11:964Pirau L, Ottenhoff L, Williamson CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071927>

17. **Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review.** Int. J. Surg. Case Rep. 2020; 76:409-414Rodriguez-Nakamura RM, Gonzalez-Calatayud M, Martinez Martinez AR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083204>
18. **Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report.** J. Clin. Neurosci. 2020; 79:30-32Sugiyama Y, Tsuchiya T, Tanaka R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33070913>
19. **The clinical spectrum of pulmonary thromboembolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A European case series.** J Crit Care 2020; 61:39-44Sakr Y, Giovini M, Leone M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075608>
20. **Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series.** J Neurol Sci 2020; 419:117183Mowla A, Shakibajahromi B, Shahjouei S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075595>
21. **Preventing the development of severe CoVID 19 by modifying immunothrombosis.** Life Sci 2020:118617Morris G, Bortolasci CC, Puri BK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33096114>
22. **Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients.** Pediatr Blood Cancer 2020; 67:e28737Al-Ghafry M, Aygun B, Appiah-Kubi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098753>
23. **Covid-19 and in situ pulmonary artery thrombosis.** Respir. Med. 2020:106176Mandal AKJ, Kho J, Ioannou A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092932>
24. **Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis.** Respir Med Case Rep 2020; 31:101263Salam S, Mallat J, Elkambergy H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083223>
25. **Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg.** Thromb Res 2020; 194:216-219Pizzolo F, Rigoni AM, De Marchi S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074107>
26. **Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients.** World J Clin Cases 2020; 8:4370-4379Wang L, He WB, Yu XM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083396>

Complications (72 articles)

1. **Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS.** Am J Emerg Med 2020; Lentz S, Roginski MA, Montrieff T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071092>
2. **Effect of PEEP and Proning on Ventilation and Perfusion in COVID-19 ARDS.** Am J Respir Crit Care Med 2020; Perier F, Tuffet S, Maraffi T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075235>
3. **[COVID-19 and mechanical circulatory support].** Ann. Cardiol. Angeiol. (Paris) 2020; Hekimian G, Frere C, Collet JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092785>
4. **Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.** Ann. Natl. Acad. Med. Sci. 2020; 56:112-115Shekhar S, Copacino CE,

- Barrera FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082620>
5. **New HIV diagnoses in patients with COVID-19: two case reports and a brief literature review.** *BMC Infect. Dis.* 2020; 20:771 Zhang JC, Yu XH, Ding XH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076830>
 6. **COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature.** *Cardiorenal Med.* 2020:1-8 Mahajan P, Dass B, Radhakrishnan N, McCullough PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091905>
 7. **Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment.** *Cardiovasc. Drugs Ther.* 2020:1-15 Gąsecka A, Borovac JA, Guerreiro RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074525>
 8. **Prevalence and Risk Factors of Thromboembolism among Patients With Coronavirus Disease-19: A Systematic Review and Meta-Analysis.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620967083 Kefale B, Tegegne GT, Degu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074717>
 9. **Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study.** *Clin Infect Dis* 2020; Geretti AM, Stockdale AJ, Kelly SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095853>
 10. **Clinical Predictors of COVID-19 Disease Progression and Death: Analysis of 214 Hospitalized Patients from Wuhan, China.** *Clin. Respir. J.* 2020; Liu J, Liu Z, Jiang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090710>
 11. **A Novel Case of Severe Respiratory Symptoms and Persistent Pulmonary Hypertension in a Saudi Neonate With SARS-CoV-2 Infection.** *Cureus* 2020; 12:e10472 Algadeeb KB, AlMousa HH, AlKadhem SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083174>
 12. **Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19.** *Cureus* 2020; 12:e10447 Daid SS, Toribio AD, Lakshmanan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072456>
 13. **Post-Extubation Stridor Complicating COVID-19-Associated Acute Respiratory Distress Syndrome: A Case Series.** *Cureus* 2020; 12:e10492 Moran JV, Godil SA, Goldner B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083191>
 14. **Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications.** *Dermatol Ther* 2020; Szolnoky G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078864>
 15. **The impact of metabolic syndrome on morbidity and mortality among intensive care unit admitted COVID-19 patients.** *Diabetes Metab Syndr* 2020; 14:1979-1986 Alamdari NM, Rahimi FS, Afaghi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080538>
 16. **Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).** *EClinicalMedicine* 2020:100591 Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078138>
 17. **Aspergillosis Complicating Severe Coronavirus Disease.** *Emerg Infect Dis* 2020; 27 Marr KA, Platt A, Tornheim JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084566>

18. **Death due to COVID-19 in an Infant with Combined Immunodeficiencies.** Endocr. Metab. Immune Disord. Drug Targets 2020; Ahanchian H, Moazzen N, Joghatayi SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087035>
19. **Atherosclerotic spontaneous coronary artery dissection (A-SCAD) in a patient with COVID-19: case report and possible mechanisms.** Eur Heart J Case Rep 2020; 4:1-6Albiero R, Seresini G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089040>
20. **Case report: high-grade atrioventricular block in suspected COVID-19 myocarditis.** Eur Heart J Case Rep 2020; 4:1-6Ashok V, Loke WI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089060>
21. **A case report of unusually long episodes of asystole in a severe COVID-19 patient treated with a leadless pacemaker.** Eur Heart J Case Rep 2020; 4:1-6Cakulev I, Sahadevan J, Osman MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089056>
22. **Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report.** Eur Heart J Case Rep 2020; 4:1-6Chitturi KR, Thacker S, Al-Saadi MA, Kassi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089052>
23. **Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer.** Eur. J. Cancer 2020; 140:140-146Caffo O, Gasparro D, Di Lorenzo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091718>
24. **COVID-19 and Cytomegalovirus Co-infection: A Challenging Case of a Critically Ill Patient with Gastrointestinal Symptoms.** Eur J Case Rep Intern Med 2020; 7:001911Amaral PH, Ferreira BM, Roll S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083369>
25. **Kawasaki-like Syndrome as an Emerging Complication of SARS-CoV-2 Infection in Young Adults.** Eur J Case Rep Intern Med 2020; 7:001886Burgi Vieira C, Ferreira AT, Botelho Cardoso F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083367>
26. **Mondor's Disease in SARS-CoV-2 Infection: A Case of Superficial Vein Thrombosis in the Era of COVID-19.** Eur J Case Rep Intern Med 2020; 7:001803Lessiani G, Boccatonda A, D'Ardes D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083359>
27. **Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy.** Eur J Intern Med 2020; Benfaremo D, Perini L, Marconi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092952>
28. **Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China.** Front. Endocrinol. (Lausanne) 2020; 11:571037Zhang N, Wang C, Zhu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071977>
29. **Familial Mediterranean Fever and COVID-19: Friends or Foes?** Front. Immunol. 2020; 11:574593Stella A, Lamkanfi M, Portincasa P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072117>
30. **Systemic mycoses: a potential alert for complications in COVID-19 patients.** Future Microbiol. 2020; 15:1405-1413Segrelles-Calvo G, de SAGR, Frases S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085538>

31. **Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.** Int J Environ Res Public Health 2020; 17:Faes C, Abrams S, Beckhoven DV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080869>
32. **Co-infection of malaria and dengue in pregnant women with SARS-CoV-2.** Int J Gynaecol Obstet 2020; Mahajan NN, Kesarwani SN, Shinde SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090458>
33. **Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).** Int J Occup Environ Med 2020; 11:157-178Maveddat A, Mallah H, Rao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098401>
34. **Case report of sequential bilateral spontaneous pneumothorax in a never-ventilated, lung-healthy COVID-19-patient.** Int. J. Surg. Case Rep. 2020; 75:441-445Caviezel C, Weiss L, Haessig G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076191>
35. **Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review.** Int. J. Surg. Case Rep. 2020; 76:409-414Rodriguez-Nakamura RM, Gonzalez-Calatayud M, Martinez Martinez AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083204>
36. **How to ventilate obese patients in the ICU.** Intensive Care Med 2020; De Jong A, Wrigge H, Hedenstierna G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095284>
37. **Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study.** J Allergy Clin Immunol 2020; Mahil SK, Dand N, Mason KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075408>
38. **COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C): a novel disease that mimics Toxic Shock Syndrome. The superantigen hypothesis.** J Allergy Clin Immunol 2020; Rivas MN, Porritt RA, Cheng MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075409>
39. **Nitric Oxide Ventilation Improves Recirculation and Right Ventricular Function During Venovenous Extracorporeal Membrane Oxygenation in a COVID-19 Patient.** J Cardiothorac Vasc Anesth 2020; Heuts S, Ubben JF, Banks-Gonzales V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077329>
40. **SARS-CoV-2 Viral Load, IFN λ Polymorphisms and the Course of COVID-19: An Observational Study.** J Clin Med 2020; 9:Amodio E, Pipitone RM, Grimaudo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076493>
41. **Acute myelitis and SARS-CoV-2 infection. A new etiology of myelitis?** J. Clin. Neurosci. 2020; 80:280-281Águila-Gordo D, Manuel Flores-Barragán J, Ferragut-Lloret F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099361>
42. **Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report.** J. Clin. Neurosci. 2020; 79:30-32Sugiyama Y, Tsuchiya T, Tanaka R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070913>
43. **Awake prone positioning for COVID-19 hypoxemic respiratory failure: A rapid review.** J Crit Care 2020; 61:63-70Weatherald J, Solverson K, Zuege DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096347>
44. **Factors associated with the poor outcomes in diabetic patients with COVID-19.** J Diabetes Metab Disord 2020:1-10Rastad H, Ejtahed HS, Mahdavi-Ghorabi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072634>

45. **Prolonged SARS-CoV-2 replication in an immunocompromised patient.** J Infect Dis 2020; Baang JH, Smith C, Mirabelli C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089317>
46. **Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series.** J Neurol Sci 2020; 419:117183Mowla A, Shakibajahromi B, Shahjouei S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075595>
47. **The role of Interleukin-4 in COVID-19 associated male infertility - A hypothesis.** J Reprod Immunol 2020; 142:103213Renu K, Subramaniam MD, Chakraborty R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080435>
48. **Use of Continuous Glucose Monitoring to Assess TPN-induced Hyperglycemia in an Adult Patient with Severe COVID-19.** JPEN J. Parenter. Enteral Nutr. 2020; Chow KW, Kelly DJ, Gupta R, Miller JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085780>
49. **The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals.** Med. Hypotheses 2020; 145:110345Cañas CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080459>
50. **Co-infections - COVID-19 plus HIV: Risks for severe disease.** MMW-Fortschritte der Medizin 2020; 162:19Starostzik C.
51. **High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19.** Mol. Immunol. 2020; 128:64-68Guirao JJ, Cabrera CM, Jiménez N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075636>
52. **COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema.** New Microbes New Infect 2020:100785Zayet S, Klopfenstein T, Mezher C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072337>
53. **Spontaneous Pneumothorax in an Elderly Patient With Coronavirus Disease (COVID-19) Pneumonia.** Ochsner J 2020; 20:343-345Rehman T, Josephson G, Sunbuli M, Chadaga AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071674>
54. **Sepsis, Phages, and COVID-19.** Pathogens 2020; 9Górski A, Borysowski J, Międzybrodzki R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076482>
55. **Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection.** An Pediatr (Engl Ed) 2020; Storch-de-Gracia P, Leoz-Gordillo I, Andina D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083499>
56. **Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients.** Pediatr Blood Cancer 2020; 67:e28737Al-Ghafry M, Aygun B, Appiah-Kubi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098753>
57. **Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID-19.** Pharmacotherapy 2020; Adams CD, Altshuler J, Barlow BL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33068459>
58. **SARS-CoV-2 in pleural fluid in a kidney transplant patient.** Postgrad. Med. 2020; Bennett D, Franchi F, De Vita E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070680>
59. **Critically Ill Patients with COVID-19: A Narrative Review on Prone Position.** Pulm Ther 2020:1-14Qadri SK, Ng P, Toh TSW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085052>

60. **Covid-19 and in situ pulmonary artery thrombosis.** Respir. Med. 2020;106:176Mandal AKJ, Kho J, Ioannou A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092932>
61. **COVID-19 in a patient with a flare of systemic lupus erythematosus: a rare case-report.** Respir Med Case Rep 2020;101:252Alharthy A, Faqihi F, Nasim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078093>
62. **Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis.** Respir Med Case Rep 2020; 31:101263Salam S, Mallat J, Elkambergy H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083223>
63. **Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity.** Respir Med X 2020; 2:100023Wigén J, Löfdahl A, Bjermer L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083782>
64. **Cardiovascular system and COVID-19: manifestations and therapeutics.** Rev Cardiovasc Med 2020; 21:399-409Mahenthiran AK, Mahenthiran AK, Mahenthiran J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070544>
65. **Critical complications of COVID-19: A descriptive meta-analysis study.** Rev Cardiovasc Med 2020; 21:433-442Vakili K, Fathi M, Pezeshgi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070547>
66. **Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.** Rev Cardiovasc Med 2020; 21:339-344Zhang J, McCullough PA, Tecson KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070539>
67. **Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy.** Rev Cardiovasc Med 2020; 21:315-319Zhang J, Tecson KM, McCullough PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070537>
68. **Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort.** Rev. Med. Interne 2020; Jourdes A, Lafaurie M, Martin-Blondel G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077266>
69. **Neurological Complications of SARS-CoV, MERS-CoV, and COVID-19.** SN Compr Clin Med 2020;1-11Alshebri MS, Alshouimi RA, Alhumidi HA, Alshaya AI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083695>
70. **Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study.** Ther. Adv. Respir. Dis. 2020; 14:1753466620963016Procopio G, Cancelliere A, Trecarichi EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070706>
71. **The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison.** Thromb Res 2020; 196:486-490Brüggemann RAG, Spaetgens B, Gietema HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091701>
72. **Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg.** Thromb Res 2020; 194:216-219Pizzolo F, Rigoni AM, De Marchi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074107>

Cured – Recovered (6 articles)

1. **The N gene of SARS-CoV-2 was the main positive component in repositive samples from a cohort of COVID-19 patients in Wuhan, China.** Clin Chim Acta

- 2020; Zhang X, Li M, Zhang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096033>
2. **Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiotensin-2, heat shock protein-27 and epithelial mesenchymal transition.** Ecanermedalscience 2020; 14:1099 Saha A, Anirvan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082849>
 3. **Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020.** Emerg Infect Dis 2020; 26 Chan PKS, Lui G, Hachim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089772>
 4. **Periungual desquamation in a Japanese Adult recovering from severe COVID-19.** Int J Infect Dis 2020; Nakamoto T, Ishikane M, Sasaki R, Ohmagari N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075533>
 5. **The effect of COVID-19 lockdown on acute type A aortic dissection: insights from Bologna.** JTCVS Tech 2020; Murana G, Folesani G, Botta L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073253>
 6. **Risk factors for redetectable positivity in recovered COVID-19 children.** Pediatr Pulmonol 2020; Peng D, Zhang J, Ji Y, Pan D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33049115>

Cardiovascular disease (97 articles)

1. **Myocarditis Associated With COVID-19.** Am J Med Case Rep 2020; 8:498-502 Oleszak F, Maryniak A, Botti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088905>
2. **New-Onset myocardial injury in COVID-19 Pregnant Patients: A Case Series of 15 Patients.** Am J Obstet Gynecol 2020; Mercedes BR, Serwat A, Naffaa L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098814>
3. **Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?** Am J Respir Crit Care Med 2020; Caviades I, Soto R, Torres A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085901>
4. **Pulmonary Vasculature: A Target for COVID-19.** Am J Respir Crit Care Med 2020; Chen L, Tang R, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085902>
5. **COVID-19, Hypercoagulability and Cautiousness with Convalescent Plasma.** Am J Respir Crit Care Med 2020; Sanfilippo F, La Rosa V, Oliveri F, Astuto M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085908>
6. **[Impact of the COVID-19 pandemic on the activities of the cardiology department of the Ignace Deen National Hospital at the Conakry University Hospital].** Ann. Cardiol. Angeiol. (Paris) 2020; Barry IS, Baldé EY, Béavogui M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071020>
7. **[COVID-19 and arrhythmias].** Ann. Cardiol. Angeiol. (Paris) 2020; Fiorina L, Younsi S, Horvilleur J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081916>
8. **[Out-of-hospital sudden cardiac arrest and COVID-19 pandemic].** Ann. Cardiol. Angeiol. (Paris) 2020; Pechmajou L, Marijon E, Perrot D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071022>
9. **[COVID-19 and venous thromboembolism].** Ann. Cardiol. Angeiol. (Paris) 2020; Trimaille A, Bonnet G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081917>
10. **Exploring the Role of Endothelial Cell Resilience in Cardiovascular Health and Disease.** Arterioscler. Thromb. Vasc. Biol. 2020:Atvbaha120314346 Gao Y, Galis ZS.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33086867>

11. **ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart.** *Arterioscler. Thromb. Vasc. Biol.* 2020;Atvbaha120315229Sakamoto A, Kawakami R, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086866>
12. **Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease.** *Biochim Biophys Acta Mol Cell Biol Lipids* 2020; 1866:158839Pimentel LL, Rodríguez-Alcalá LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080357>
13. **Cardiology on the cutting edge: updates from the European Society of Cardiology (ESC) Congress 2020.** *BMC Cardiovasc. Disord.* 2020; 20:448Gallego-Colon E, Bonaventura A, Vecchié A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070781>
14. **ATRIAL FIBRILLATION IN A PEDIATRIC PATIENT WITH COVID-19 INFECTION.** *Cardiol. Young* 2020;1-9Santi AD, Aquino P, Dorfman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070790>
15. **COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature.** *Cardiorenal Med.* 2020;1-8Mahajan P, Dass B, Radhakrishnan N, McCullough PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091905>
16. **Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment.** *Cardiovasc. Drugs Ther.* 2020;1-15Gasecka A, Borovac JA, Guerreiro RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074525>
17. **Double Trouble: Combined Cardiovascular Effects of Particulate Matter Exposure and COVID-19.** *Cardiovasc Res* 2020; Tanwar V, Adelstein JM, Wold LE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084879>
18. **System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.** *Chem. Biol. Interact.* 2020;109299Khan AA, Khan Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098839>
19. **QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry.** *Clin Infect Dis* 2020; Santoro F, Monitillo F, Raimondo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098645>
20. **The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis.** *Clin Infect Dis* 2020; Xu J, Teng Y, Shang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079200>
21. **Bowel Ischemia in a Patient With SARS CoV-2-Like Illness and Negative Real-Time Reverse Transcription Polymerase Chain Reaction Test Results During the Peak of the Pandemic.** *Cureus* 2020; 12:e10442Almafrefji I, Ranganath S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072452>
22. **Incomplete Trifascicular Block and Mobitz Type II Atrioventricular Block in COVID-19.** *Cureus* 2020; 12:e10461Gubitosa JC, Xu P, Ahmed A, Pergament K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083164>
23. **Acute ST-Elevation Myocardial Infarction Before and During the COVID-19 Pandemic: What is the Clinically Significant Difference?** *Cureus* 2020;

- 12:e10523Mengal N, Saghir T, Hassan Rizvi SN *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094064>
24. **Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications.** *Dermatol Ther* 2020; Szolnoky G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078864>
 25. **BRACE-CORONA trial - COVID-19: No severe course in patients undergoing RAS inhibition.** *Deutsches Arzteblatt International* 2020; 117:A1816Eckert N.
 26. **COVID-19 after heart transplant: Risk of severe progressions and mortality are probably significantly increased.** *Deutsches Arzteblatt International* 2020; 117:A1814-A1815Siegmund-Schultze N.
 27. **Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study.** *Diabetes Metab.* 2020; Cariou B, Goronflot T, Rimbert A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091555>
 28. **Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study.** *ESC Heart Fail* 2020; Lassen MCH, Skaarup KG, Lind JN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089972>
 29. **Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak.** *ESC Heart Fail* 2020; Severino P, D'Amato A, Saglietto A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094929>
 30. **Protecting the most vulnerable during COVID-19 and beyond: a case report on the remote management of heart failure patients with cardiac implantable electronic devices.** *Eur Heart J Case Rep* 2020; 4:1-6Ahmed FZ, Crosbie C, Kahn M, Motwani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089059>
 31. **Atherosclerotic spontaneous coronary artery dissection (A-SCAD) in a patient with COVID-19: case report and possible mechanisms.** *Eur Heart J Case Rep* 2020; 4:1-6Albiero R, Seresini G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089040>
 32. **Case report: high-grade atrioventricular block in suspected COVID-19 myocarditis.** *Eur Heart J Case Rep* 2020; 4:1-6Ashok V, Loke WI.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089060>
 33. **COVID-19 fulminant myocarditis: a case report.** *Eur Heart J Case Rep* 2020; 4:1-6Bernal-Torres W, Herrera-Escandón Á, Hurtado-Rivera M, Plata-Mosquera CA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089053>
 34. **A case report of unusually long episodes of asystole in a severe COVID-19 patient treated with a leadless pacemaker.** *Eur Heart J Case Rep* 2020; 4:1-6Cakulev I, Sahadevan J, Osman MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089056>
 35. **Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report.** *Eur Heart J Case Rep* 2020; 4:1-6Chitturi KR, Thacker S, Al-Saadi MA, Kassi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089052>
 36. **Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report.** *Eur Heart J Case Rep* 2020; 4:1-6Li A, Garcia-Bengochea Y, Stechel R, Azari BM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089055>
 37. **Ventricular tachycardia storm management in a COVID-19 patient: a case report.** *Eur Heart J Case Rep* 2020; 4:1-6Mitacchione G, Schiavone M, Gasperetti A, Forleo GB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089046>

38. **Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series.** Eur Heart J Case Rep 2020; 4:1-6Peigh G, Leya MV, Baman JR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089039>
39. **Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report.** Eur Heart J Case Rep 2020; 4:1-6Schnaubelt S, Breyer MK, Siller-Matula J, Domanovits H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089045>
40. **Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.** Eur Heart J Case Rep 2020; 4:1-5Semedo E, Kapel GF, van Opstal J, van Dessel P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089050>
41. **Right atrial thrombus in a patient with COVID-19 pneumonia: a case report.** Eur Heart J Case Rep 2020; 4:1-4Shamsah MA, Bitar ZI, Alfoudri H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089061>
42. **COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.** Eur Heart J Case Rep 2020; 4:1-6Wang LY, Ng GYP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089048>
43. **Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality.** Eur Heart J Qual Care Clin Outcomes 2020; Mohamed MO, Banerjee A, Clarke S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079204>
44. **Kawasaki-like Syndrome as an Emerging Complication of SARS-CoV-2 Infection in Young Adults.** Eur J Case Rep Intern Med 2020; 7:001886Burgi Vieira C, Ferreira AT, Botelho Cardoso F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083367>
45. **Transient ST Segment Elevation in a Patient with COVID-19 and a Normal Transthoracic Echocardiogram.** Eur J Case Rep Intern Med 2020; 7:001913Tuaima T, Kinsara AJ, Alrajawi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083370>
46. **Renin angiotensin system at the interface of COVID-19 infection.** Eur. J. Pharmacol. 2020;173656Gul R, Uh-Hyun K, Alfadda AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086029>
47. **Maintaining stroke care in Europe during the COVID-19 pandemic: Results from an international survey of stroke professionals and practice recommendations from the European Stroke Organisation.** Eur Stroke J 2020; 5:230-236Aguiar de Sousa D, van der Worp HB, Caso V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072876>
48. **Stroke care in Italy: An overview of strategies to manage acute stroke in COVID-19 time.** Eur Stroke J 2020; 5:222-229Zedde M, Pezzella FR, Paciaroni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072875>
49. **Arrhythmogenic syncope leading to cardiac rhythm management procedures during COVID-19 lockdown.** Expert Rev. Med. Devices 2020; Russo V, Pafundi PC, Rapacciuolo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090884>
50. **Atrial fibrillation in COVID-19: A review of possible mechanisms.** Faseb.j 2020; 34:11347-11354Stone E, Kiat H, McLachlan CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078484>
51. **Negative Impact of the COVID-19 Pandemic on Admissions for Intracranial Hemorrhage.** Front. Neurol. 2020; 11:584522Abdulazim A, Ebert A, Etminan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071955>
52. **Case Series: Evidence of Borderzone Ischemia in Critically-Ill COVID-19 Patients Who "Do Not Wake Up".** Front. Neurol. 2020; 11:964Pirau L, Ottenhoff L,

- Williamson CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071927>
53. **Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19.** *Front. Physiol.* 2020; 11:555039Al Heialy S, Hachim MY, Senok A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071815>
 54. **Cardiogenic shock following cardiac tamponade and Takotsubo in COVID-19.** *Future Cardiol* 2020; Torabi AJ, Villegas-Galaviz J, Guglin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078963>
 55. **Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.** *Int. J. Biol. Macromol.* 2020; Liu P, Xie X, Gao L, Jin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080267>
 56. **Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.** *Int J Cardiol* 2020; Audrey F, Delphine V, Serena R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075384>
 57. **Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic.** *Int J Cardiol Heart Vasc* 2020; 31:100659Lauridsen MD, Butt JH, Østergaard L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072848>
 58. **COVID-19 and late-onset hypertension with hyporeninaemic hypoaldosteronism.** *Int J Clin Pract* 2020:e13773Manda AKJ, Kho J, Metaxa S, Missouriis CG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078526>
 59. **Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review.** *Int. J. Surg. Case Rep.* 2020; 76:409-414Rodriguez-Nakamura RM, Gonzalez-Calatayud M, Martinez Martinez AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083204>
 60. **Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.** *Intern Emerg Med* 2020:1-11Yahyavi A, Hemmati N, Derakhshan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085063>
 61. **Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children: A Call to Action.** *J Am Coll Cardiol* 2020; 76:1962-1964Friedman KG, Harrild DM, Newburger JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092731>
 62. **Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar.** *J Am Coll Cardiol* 2020; 76:2011-2023Giustino G, Pinney SP, Lala A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092737>
 63. **Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:1965-1977Kim J, Volodarskiy A, Sultana R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092732>
 64. **Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.** *J Am Coll Cardiol* 2020; 76:2024-2035Mechanick JI, Rosenson RS, Pinney SP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092738>
 65. **The Right Ventricle: A Target in COVID-19 Cardiac Insult.** *J Am Coll Cardiol* 2020; 76:1978-1981Pellikka PA, Naqvi TZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092733>
 66. **Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar.** *J Am Coll Cardiol* 2020; 76:1999-2010Pinney SP, Giustino G, Halperin JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092736>

67. **Statin Use and In-Hospital Mortality in Diabetics with COVID-19.** J Am Heart Assoc 2020:e018475 Saeed O, Castagna F, Agalliu I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092446>
68. **Feasibility and Consistency of Results with Deployment of an In-Line Filter for Exercise-Based Evaluations of Heart Failure Patients During the COVID-19 Pandemic.** J. Card. Fail. 2020; Bhat RR, Schoenike MW, Kowal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098974>
69. **Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19.** J. Cardiovasc. Pharmacol. Ther. 2020:1074248420967792 Salah HM, Mehta JL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078623>
70. **Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?** J. Cell. Physiol. 2020; Patil M, Singh S, Henderson J, Krishnamurthy P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078408>
71. **Vasculitis-related stroke in young as a presenting feature of novel coronavirus disease (COVID19) - Case report.** J. Clin. Neurosci. 2020; 79:169-171 de Sousa GC, de Sousa TC, Sakiyama MAK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070890>
72. **Arterial and venous strokes in the setting of COVID-19.** J. Clin. Neurosci. 2020; 79:60-66 Kananeh MF, Thomas T, Sharma K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33070919>
73. **Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report.** J. Clin. Neurosci. 2020; 79:30-32 Sugiyama Y, Tsuchiya T, Tanaka R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33070913>
74. **Olfactory gyrus intracerebral hemorrhage in a patient with COVID-19 infection.** J. Clin. Neurosci. 2020; 79:275-276 Thu SS, Matin N, Levine SR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33070912>
75. **Microcirculation alterations in severe COVID-19 pneumonia.** J Crit Care 2020; 61:73-75 Kanoore Edul VS, Caminos Eguillor JF, Ferrara G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33096349>
76. **The clinical spectrum of pulmonary thromboembolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A European case series.** J Crit Care 2020; 61:39-44 Sakr Y, Giovini M, Leone M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075608>
77. **Cardiac Manifestations of Coronavirus Disease 2019 (COVID-19): a Multicenter Cohort Study.** J Korean Med Sci 2020; 35:e366 Kim M, Nam JH, Son JW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075857>
78. **The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis.** J Med Virol 2020; Wang Y, Chen B, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095513>
79. **Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series.** J Neurol Sci 2020; 419:117183 Mowla A, Shakibajahromi B, Shahjouei S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075595>
80. **Impact of COVID-19 on Stroke Caseload in a Major Hyperacute Stroke Unit.** J. Stroke Cerebrovasc. Dis. 2020; 29:105383 Mag Uidhir F, Bathula R, Sivagnanaratnam A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099122>
81. **Mitigating the effects of COVID-19 pandemic on controlling vascular risk factors among participants in a carotid stenosis trial.** J. Stroke Cerebrovasc.

- Dis. 2020;105362Turan TN, Meschia JF, Chimowitz MI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071206>
82. **Acute aorto-iliac occlusion in patient with COVID-19.** J. Vasc. Surg. 2020; Naudin I, Long A, Michel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075454>
 83. **Cardiorenal tissues express SARS-CoV-2 entry genes and basigin (BSG/CD147) increases with age in endothelial cells.** JACC Basic Transl Sci 2020; Ahmetaj-Shala B, Vaja R, Atanur SS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073064>
 84. **Reversible Myocardial Injury Associated with SARS-CoV-2 in an Infant.** JACC Case Rep 2020; Sharma M, Gorstein S, Aldrich ML *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073245>
 85. **ECG: essential in care of patients with COVID-19.** Med. J. Aust. 2020; Lam K, McClelland S, Dallo MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098111>
 86. **Supra and infratentorial massive strokes in previously healthy young patients with SARS-CoV-2. The role of neurosurgery.** Neurocirugia (Astur.) 2020; Rascón-Ramírez FJ, Carrascosa-Granada Á M, Vargas-Jiménez AC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33097419>
 87. **Update on cerebrovascular manifestations of COVID-19.** Neurol Sci 2020;1-13Naeimi R, Ghasemi-Kasman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083934>
 88. **Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients.** Pediatr Blood Cancer 2020; 67:e28737Al-Ghafry M, Aygun B, Appiah-Kubi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098753>
 89. **A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?** Pharmacol Res Perspect 2020; 8:e00666Kurdi A, Abutheraa N, Akil L, Godman B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084232>
 90. **Covid-19 and in situ pulmonary artery thrombosis.** Respir. Med. 2020;106176Mandal AKJ, Kho J, Ioannou A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092932>
 91. **Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis.** Respir Med Case Rep 2020; 31:101263Salam S, Mallat J, Elkambergy H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083223>
 92. **Cardiovascular system and COVID-19: manifestations and therapeutics.** Rev Cardiovasc Med 2020; 21:399-409Mahenthiran AK, Mahenthiran AK, Mahenthiran J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070544>
 93. **Usefulness of machine learning in COVID-19 for the detection and prognosis of cardiovascular complications.** Rev Cardiovasc Med 2020; 21:345-352Zimmerman A, Kalra D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070540>
 94. **[Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience].** Rev. Esp. Cardiol. 2020; Rodríguez-Leor O, Cid-Álvarez B, de Prado AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071427>
 95. **EEG findings and clinical prognostic factors associated with mortality in a prospective cohort of inpatients with COVID-19.** Seizure 2020; 83:1-4Skorin I, Carrillo R, Perez CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075670>

96. **The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison.** Thromb Res 2020; 196:486-490Brüggemann RAG, Spaetgens B, Gietema HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091701>
97. **Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg.** Thromb Res 2020; 194:216-219Pizzolo F, Rigoni AM, De Marchi S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074107>

Diagnosis (8 articles)

1. **An improved multivariate model that distinguishes COVID-19 from seasonal flu and other respiratory diseases.** Aging (Albany NY) 2020; 12Guo X, Li Y, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085645>
2. **MH-COVIDNet: Diagnosis of COVID-19 using deep neural networks and meta-heuristic-based feature selection on X-ray images.** Biomed. Signal Process. Control 2021; 64:102257Canayaz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33042210>
3. **Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features.** BMC Infect. Dis. 2020; 20:775De Angelis G, Posteraro B, Biscetti F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33076874>
4. **A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality.** J Infect Public Health 2020; Serin I, Sari ND, Dogu MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071210>
5. **Advanced Machine Learning-Based Analytics on COVID-19 Data Using Generative Adversarial Networks.** Mater Today Proc 2020; Vijay Kumar J, Harshavardhan A, Bhukya H, Krishna Prasad AV.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078094>
6. **Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein.** mBio 2020; 11Wang X, Lam JY, Wong WM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082264>
7. **Differential diagnosis of COVID-19 in symptomatic patients at the University Hospital Center Mohammed VI, Marrakesh.** Pan Afr. Med. J. 2020; 36:269Krati K, Rizkou J, Errami AA, Essaadouni L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088398>
8. **Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.** Pathology 2020; Tan SS, Saw S, Chew KL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092816>

DM-MS-Obesity (25 articles)

1. **Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.** Ann. Natl. Acad. Med. Sci. 2020; 56:112-115Shekhar S, Copacino CE, Barrera FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082620>
2. **COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region.** Curr.

- Diabetes Rev. 2020; Al Dawish MA, Robert AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087031>
3. **Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study.** Diabetes Metab. 2020; Cariou B, Goronflot T, Rimbert A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091555>
 4. **Effects of COVID-19 pandemic lockdown on gestational diabetes mellitus: A retrospective study.** Diabetes Metab. 2020; Ghesquière L, Garabedian C, Drumez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33069845>
 5. **The impact of metabolic syndrome on morbidity and mortality among intensive care unit admitted COVID-19 patients.** Diabetes Metab Syndr 2020; 14:1979-1986Alamdari NM, Rahimi FS, Afaghi S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080538>
 6. **Diabetes, D-dimer and COVID-19: The possible role of glucose control.** Diabetes Metab Syndr 2020; 14:1987Ceriello A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080539>
 7. **Decentralized COVID-19 measures in Brazil were ineffective to protect people with diabetes.** Diabetes Metab Syndr 2020; 14:1973-1978Ugliara Barone MT, Harnik SB, Chaluppe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075740>
 8. **Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy.** Diabetes Res Clin Pract 2020;108513Barchetta I, Agata Cimini F, Bertocchini L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075424>
 9. **Impact of obesity, fasting plasma glucose level, blood pressure, and renal function on the severity of COVID-19: a matter of sexual dimorphism?** Diabetes Res Clin Pract 2020;108515Huh K, Lee R, Ji W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33096185>
 10. **Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China.** Front. Endocrinol. (Lausanne) 2020; 11:571037Zhang N, Wang C, Zhu F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071977>
 11. **Management of gestational diabetes in women with a concurrent Sars-Cov-2 infection, experience of a single center in Northern Italy.** Int J Gynaecol Obstet 2020; D'Ambrosi F, Rossi G, Soldavini CM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33099770>
 12. **How to ventilate obese patients in the ICU.** Intensive Care Med 2020; De Jong A, Wrigge H, Hedenstierna G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095284>
 13. **Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.** J Am Coll Cardiol 2020; 76:2024-2035Mechanick JI, Rosenson RS, Pinney SP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092738>
 14. **Statin Use and In-Hospital Mortality in Diabetics with COVID-19.** J Am Heart Assoc 2020:e018475Saeed O, Castagna F, Agalliu I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092446>
 15. **The Value of Telemedicine for the Follow-up of Patients with New Onset Type 1 Diabetes Mellitus During COVID-19 Pandemic in Turkey: A Report of Eight Cases.** J. Clin. Res. Pediatr. Endocrinol. 2020; Evin F, Er E, Ata A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33084289>

16. **Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic.** J Clin Transl Endocrinol 2020:100238Fung A, Irvine M, Ayub A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072519>
17. **Young people with type 1 diabetes on insulin pump therapy could fast safely during COVID 19 pandemic Ramadan - a telemonitoring experience in Bangladesh.** J Diabetes Investig 2020; Zabeen B, Ahmed B, Nahar J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098746>
18. **Factors associated with the poor outcomes in diabetic patients with COVID-19.** J Diabetes Metab Disord 2020:1-10Rastad H, Ejtahed HS, Mahdavi-Ghorabi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072634>
19. **Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.** J. Diabetes Sci. Technol. 2020:1932296820965203Jankovic I, Basina M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084380>
20. **Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19.** J Med Virol 2020; Yang P, Wang N, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073361>
21. **A nutritional web-based approach in obesity and diabetes before and during COVID-19 lockdown.** J Telemed Telecare 2020:1357633x20966933Fraticeilli F, Nicola MD, Vitacolonna E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081596>
22. **Use of Continuous Glucose Monitoring to Assess TPN-induced Hyperglycemia in an Adult Patient with Severe COVID-19.** JPEN J. Parenter. Enteral Nutr. 2020; Chow KW, Kelly DJ, Gupta R, Miller JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085780>
23. **High prevalence of Afro-Caribbean ethnicity and hypoglycaemia in patients with diabetes and end stage renal disease hospitalised with COVID-19.** Nephrology (Carlton) 2020; Corcillo A, Cohen S, Game D, Karalliedde J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099858>
24. **SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review.** Rev Cardiovasc Med 2020; 21:385-397Deravi N, Fathi M, Vakili K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070543>
25. **Admission Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a Pooled Analysis and Meta-summary of Literature.** SN Compr Clin Med 2020:1-6Sachdeva S, Desai R, Gupta U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073173>

Education and training and science (44 articles)

1. **The Impact of Science-Unbased Measures Against COVID-19 in Clinical Decision-Making Process.** AAPS PharmSciTech 2020; 21:293Pimentel JVC, TDOS ES, Filgueiras ABT, Neto MLR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098021>
2. **Necessity to Prioritize Research Activities for a Better Public Health Response to Coronavirus Disease-2019 Pandemic.** Adv Biomed Res 2020; 9:34Shrivastava SR, Shrivastava PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072646>
3. **Are we measuring the same thing? Psychometric and research considerations when adopting new testing modes in the time of COVID-19.** Alzheimers Dement 2020; Booth T, Murray A, Muniz-Terrera G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075205>

4. **The plight of COVID-19 pandemic on medical students and residency applicants.** Ann Med Surg (Lond) 2020; 60:1-4Tariq EF, Sah PK, Malik A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072311>
5. **COVID-19's Impact on the 2020-2021 Resident Match: A Survey of Otolaryngology Program Directors.** Ann. Otol. Rhinol. Laryngol. 2020:3489420967045Kasle DA, Torabi SJ, Izreig S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090015>
6. **The impact and evaluation of COVID-19 pandemic on the teaching model of medical molecular biology course for undergraduates major in pharmacy.** Biochem Mol Biol Educ 2020; Jiang X, Ning Q.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080661>
7. **Students engage in primary literature in molecular biology techniques using an online journal club format.** Biochem Mol Biol Educ 2020; Oxford JT, Jorczyk CL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080662>
8. **Cardiology on the cutting edge: updates from the European Society of Cardiology (ESC) Congress 2020.** BMC Cardiovasc. Disord. 2020; 20:448Gallego-Colon E, Bonaventura A, Vecchié A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070781>
9. **Medical student support for vulnerable patients during COVID-19 - a convergent mixed-methods study.** BMC Med. Educ. 2020; 20:377Hughes T, Beard E, Bowman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092586>
10. **Chinese public's knowledge, perceived severity, and perceived controllability of COVID-19 and their associations with emotional and behavioural reactions, social participation, and precautionary behaviour: a national survey.** BMC Public Health 2020; 20:1589Li JB, Yang A, Dou K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087109>
11. **College Students' Experience of Emergency Remote Teaching due to COVID-19.** Child Youth Serv Rev 2020; 119:105578Eun Shim T, Yi Lee S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071405>
12. **College students' experience of emergency remote teaching due to COVID-19.** Child Youth Serv Rev 2020; 119:105578Shim TE, Lee SY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071405>
13. **Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination.** Clin Infect Dis 2020; Oldoni E, van Gool A, García Bermejo L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091118>
14. **Knowledge of COVID-19 and its prevention among residents of the Gedeo zone, South Ethiopia. Sources of information as a factor.** Curr. Med. Res. Opin. 2020:1-6Aweke Z, Jemal B, Mola S, Hussen R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33044091>
15. **Urology Virtual Education Programs During the COVID-19 Pandemic.** Curr Urol Rep 2020; 21:50Smigelski M, Movassaghi M, Small A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090272>
16. **Data on factors characterizing the eLearning experience of secondary schoolteachers and university undergraduate students in Jordan.** Data Brief 2020; 33:106402Obidat AH, Alquraan M, Obeidat MH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072820>
17. **Impact of COVID-19 Pandemic on Training: Global Perceptions of Gastroenterology and Hepatology Fellows in the USA.** Dig. Dis. Sci. 2020:1-

- 5Clarke K, Bilal M, Sánchez-Luna SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073333>
18. **Online support information for students with disabilities in colleges and universities during the COVID-19 pandemic.** Disabil Health J 2020;101013Meleo-
Erwin Z, Kollia B, Fera J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082111>
 19. **Knowledge, awareness and practices regarding novel coronavirus among a sample of Pakistani population, a cross-sectional study.** Disaster Med Public Health Prep 2020;1-20Tariq S, Tariq S, Baig M, Saeed M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092681>
 20. **Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection.** Emerg Microbes Infect 2020;1-19Rathnasinghe R, Strohmeier S, Amanat F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073694>
 21. **Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown.** Eur. J. Neurol. 2020; Zrzavy T, Wimmer I, Rommer PS, Berger T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090599>
 22. **The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days.** F1000Res 2020; 9:1193Janiaud P, Axfors C, Van't Hooft J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082937>
 23. **Teacher Learning in Difficult Times: Examining Foreign Language Teachers' Cognitions About Online Teaching to Tide Over COVID-19.** Front. Psychol. 2020; 11:549653Gao LX, Zhang LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071866>
 24. **Peer support for junior doctors: a positive outcome of the COVID-19 pandemic?** Future Healthc J 2020; 7:e64-e66Behrman S, Baruch N, Stegen G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094259>
 25. **Keep calm and carry on learning: using Microsoft Teams to deliver a medical education programme during the COVID-19 pandemic.** Future Healthc J 2020; 7:e67-e70Henderson D, Woodcock H, Mehta J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094260>
 26. **Cross-skilling training to support medical redeployment in the COVID-19 pandemic.** Future Healthc J 2020; 7:e41-e44Hettle D, Sutherland K, Miles E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094252>
 27. **COVID-19 pandemic personal development plan: A model for maximising higher specialty training.** Future Healthc J 2020; 7:e80-e83Minhas JS, Pan D, Sze S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094263>
 28. **The Evolving Impact of COVID-19 on Medical Student Orthopedic Education: Perspectives From Medical Students in Different Phases of the Curriculum.** Geriatr Orthop Surg Rehabil 2020; 11:2151459320951721Richardson MA, Islam W, Magruder M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083098>
 29. **Buffering Academic Stress during the COVID-19 Pandemic Related Social Isolation: Grit and Growth Mindset as Protective Factors against the Impact of Loneliness.** Int J Appl Posit Psychol 2020;1-16Mosanya M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083519>
 30. **Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19).** Int J Environ Res Public Health 2020; 17Martinez-Perez C, Alvarez-Peregrina C, Villa-Collar C, Sánchez-Tena M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096796>
 31. **A national survey on the impact of the COVID-19 pandemic upon burnout and career satisfaction among neurosurgery residents.** J. Clin. Neurosci. 2020;

- 80:137-142Khalafallah AM, Lam S, Gami A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33099336>
32. **A descriptive pilot study of the immediate impacts of COVID-19 on dental and dental hygiene students' readiness and wellness.** J. Dent. Educ. 2020; Akinkugbe AA, Garcia DT, Smith CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084054>
 33. **Preprint manuscripts and servers in the era of coronavirus disease 2019.** J. Eval. Clin. Pract. 2020; Nabavi Nouri S, Cohen YA, Madhavan MV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094906>
 34. **Pharmacy Students Perceptions of Their Distance Online Learning Experience During the COVID-19 Pandemic: A Cross-Sectional Survey Study.** J Med Educ Curric Dev 2020; 7:2382120520963039Shawaqfeh MS, Al Bekairy AM, Al-Azayzih A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088916>
 35. **Evaluation of academic integrity of online open book assessments implemented in an undergraduate medical radiation science course during COVID-19 pandemic.** J Med Imaging Radiat Sci 2020; Ng CKC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077414>
 36. **Using Benford's law to assess the quality of COVID-19 register data in Brazil.** J Public Health (Oxf) 2020; Silva L, Figueiredo Filho D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33097928>
 37. **UNLV Health Sciences Library's Initial Response to the COVID-19 Pandemic: How a Versatile Environment, Online Technologies, and Liaison Expertise Prepared Library Faculty in Supporting Its User Communities.** Med. Ref. Serv. Q. 2020; 39:344-358Weeks A, Houk KM, Nugent RL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085950>
 38. **Student Perspectives on Remote Medical Education in Clinical Core Clerkships During the COVID-19 Pandemic.** Med Sci Educ 2020:1-8Coffey CS, MacDonald BV, Shahrivini B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078085>
 39. **The Orthopedic Residency Program at Hamad Medical Corporation During COVID-19 Crisis: an Evolving Educational Strategy.** Med Sci Educ 2020:1-4Salameh M, Alhammoud A, Al Dosari MAA, AlHaneedi GA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078080>
 40. **Knowledge, attitude, practice and psychological response toward COVID-19 among nurses during the COVID-19 outbreak in Northern Ethiopia, 2020.** New Microbes New Infect 2020:100787Tadesse DB, Gebrewahd GT, Gebre GT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072339>
 41. **Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience.** Parkinsonism Relat. Disord. 2020; Tan EK, Albanese A, Chaudhuri K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071183>
 42. **Impact of COVID-19 outbreak on the mental health status of undergraduate medical students in a COVID-19 treating medical college: a prospective longitudinal study.** PeerJ 2020; 8:e10164Saraswathi I, Saikarthik J, Senthil Kumar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088628>
 43. **The impact of comprehension of disease-related information and perceptions regarding effects and controllability on protective and social solidarity behaviors with regard to COVID-19.** Z Gesundh Wiss 2020:1-8Danayiyen A, Kavsar Z, Baysan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083202>

44. **Sources of information in times of health crisis: evidence from Turkey during COVID-19.** Z Gesundh Wiss 2020;1-7Geçer E, Yıldırım M, Akgül Ö.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072495>

Elderly (7 articles)

1. **Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions.** Aging (Albany NY) 2020; 12Blanch-Rubió J, Soldevila-Domenech N, Tío L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080571>
2. **Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering Aging and Frailty.** Front Med (Lausanne) 2020; 7:558835Palermo S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072783>
3. **Geriatric Population During the COVID-19 Pandemic: Problems, Considerations, Exigencies, and Beyond.** Front Public Health 2020; 8:574198Dhama K, Patel SK, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072713>
4. **Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada.** Infection 2020; Hoffmann C, Wolf E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098532>
5. **Assessing the Distribution of Elderly Requiring Care: A Case Study on the Residents in Barcelona and the Impact of COVID-19.** Int J Environ Res Public Health 2020; 17Arvelo E, de Armas J, Guillen M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33076238>
6. **Approach to critical illness myopathy and polyneuropathy in the older SARS-CoV-2 patients.** J. Clin. Neurosci. 2020; 79:241-245McClafferty B, Umer I, Fye G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070904>
7. **[Coronavirus disease 2019 (COVID-19) and ageism: a narrative review of the literature].** Rev Esp Geriatr Gerontol 2020; Tarazona-Santabalbina FJ, de la Cámara de Las Heras JM, Vidán MT, García Navarro JA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077254>

Epidemiology (99 articles)

1. **Stochastic mathematical model for the spread and control of Corona virus.** Adv Differ Equ 2020; 2020:574Hussain S, Zeb A, Rasheed A, Saeed T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078063>
2. **Serological Survey following SARS-COV-2 Outbreaks at Long Term Care Facilities in Metro Vancouver, British Columbia: Implications for Outbreak Management and Infection Control Policies.** Am. J. Infect. Control 2020; Vijh R, Ghafari C, Hayden A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086096>
3. **[Epidemiological specificities of COVID-19 in Africa: Current or future public health concern?].** Ann. Pharm. Fr. 2020; Hardy É J, Flori P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091399>
4. **Modelling a pandemic with asymptomatic patients, impact of lockdown and herd immunity, with applications to SARS-CoV-2.** Annu Rev Control 2020; Ansumali S, Kaushal S, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071595>

5. **Assessing countries' performances against COVID-19 via WSIDEA and machine learning algorithms.** *Appl Soft Comput* 2020; 97:106792Aydin N, Yurdakul G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071686>
6. **Blockchain for COVID-19: Review, Opportunities, and a Trusted Tracking System.** *Arab J Sci Eng* 2020;1-17Marbough D, Abbasi T, Maasmi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072472>
7. **A Foundational Assessment of the Effects of the Spread of COVID-19 Virus Infection and Related Activity Restrictions on Mental and Physical Health, Psychological Distress, and Suicidal Ideation in Japan.** *Asia Pac. J. Public Health* 2020;1010539520965449Kiuchi K, Kishi K, Araki K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070620>
8. **Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features.** *BMC Infect. Dis.* 2020; 20:775De Angelis G, Posteraro B, Biscetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076874>
9. **Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.** *BMC Med* 2020; 18:332Russell TW, Golding N, Hellewell J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087179>
10. **The COVID-19 pandemic in Norway and Sweden - threats, trust, and impact on daily life: a comparative survey.** *BMC Public Health* 2020; 20:1597Helsing LM, Refsum E, Gjrstein DK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097011>
11. **Immediate impact of stay-at-home orders to control COVID-19 transmission on mental well-being in Bangladeshi adults: Patterns, Explanations, and future directions.** *BMC Res. Notes* 2020; 13:494Ali M, Ahsan GU, Khan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092649>
12. **Understanding and responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of interventions.** *BMJ Open* 2020; 10:e043010Lyons J, Akbari A, Torabi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087383>
13. **Assessing the progression of the COVID-19 pandemic in Canada using testing data and time-dependent reproduction numbers.** *Can. J. Public Health.* 2020; Edjoc R, Atchessi N, Lien A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090361>
14. **Analyzing the impact of the media campaign and rapid testing for COVID-19 as an optimal control problem in East Java, Indonesia.** *Chaos Solitons Fractals* 2020;110364Aldila D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082625>
15. **'When will I be free': Lessons from COVID-19 for Child Protection in South Africa.** *Child Abuse Negl.* 2020;104715Haffejee S, Levine DT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071025>
16. **Implications of COVID-19-induced nationwide lockdown on children's behaviour in Punjab, India.** *Child Care Health Dev.* 2020; Sama BK, Kaur P, Thind PS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33047842>
17. **Different transmission dynamics of COVID-19 and influenza suggest the relative efficiency of isolation/quarantine and social distancing against COVID-19 in China.** *Clin Infect Dis* 2020; Lei H, Wu X, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080000>
18. **COVID-19 Australia: Epidemiology Report 27: Fortnightly reporting period ending 11 October 2020.** *Commun Dis Intell (2018)* 2020; 44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087023>

19. **Uncertainty quantification in epidemiological models for the COVID-19 pandemic.** Comput. Biol. Med. 2020; 125:104011 Taghizadeh L, Karimi A, Heitzinger C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091766>
20. **Corona COVID-19 Spread- a Nonlinear Modeling and Simulation.** Comput Electr Eng 2020;106884 Harb AM, Harb SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078033>
21. **COVID-19 Modeling in Saudi Arabia Using the Modified Susceptible-Exposed-Infectious-Recovered (SEIR) Model.** Cureus 2020; 12:e10452 Ahmad N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072460>
22. **COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region.** Curr. Diabetes Rev. 2020; Al Dawish MA, Robert AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087031>
23. **Differences in COVID-19 risk between occupational groups and employment sectors in Germany.** Deutsches Arzteblatt International 2020; 117:641-642 Möhner M, Wolik A.
24. **Effects of COVID-19 pandemic lockdown on gestational diabetes mellitus: A retrospective study.** Diabetes Metab. 2020; Ghesquière L, Garabedian C, Drumez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33069845>
25. **Decentralized COVID-19 measures in Brazil were ineffective to protect people with diabetes.** Diabetes Metab Syndr 2020; 14:1973-1978 Ugliara Barone MT, Harnik SB, Chaluppe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075740>
26. **Dynamics of SARS-CoV-2 transmission among Indian nationals evacuated from Iran.** Disaster Med Public Health Prep 2020;1-20 Saurabh S, Kumar R, Kumar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087205>
27. **Exposing Empirical Links between COVID-19 Situation Report and Available Data: The Case of Nigeria.** Diseases 2020; 8 Zakariya YF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092059>
28. **COVID-19: The impact of social distancing policies, cross-country analysis.** Econ Disaster Clim Chang 2020;1-25 Castex G, Dechter E, Lorca M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078135>
29. **COVID-19 pandemic-related lockdown: response time is more important than its strictness.** EMBO Mol Med 2020:e13171 Loewenthal G, Abadi S, Avram O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073919>
30. **Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy.** Emerg Infect Dis 2020; 27 Guzzetta G, Riccardo F, Marziano V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080168>
31. **Aspergillosis Complicating Severe Coronavirus Disease.** Emerg Infect Dis 2020; 27 Marr KA, Platt A, Tornheim JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084566>
32. **Coronavirus Disease among Workers in Food Processing, Food Manufacturing, and Agriculture Workplaces.** Emerg Infect Dis 2020; 27 Waltenburg MA, Rose CE, Victoroff T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075274>
33. **Impact of COVID-19 'circuit-breaker' measures on emergency medical service (EMS) utilisation and out-of-hospital cardiac arrest (OHCA) outcomes in Singapore.** Emerg. Med. Australas. 2020; Ng QX, Lee EZH, Tay JAM, Arulanandam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074594>

34. **What to expect for the influenza season 2020/21 with the ongoing COVID-19 pandemic in the World Health Organization European Region.** Euro Surveill 2020; 25:Adlhoch C, Pebody R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094719>
35. **A large national outbreak of COVID-19 linked to air travel, Ireland, summer 2020.** Euro Surveill 2020; 25:Murphy N, Boland M, Bambury N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094715>
36. **How to Understand "Herd Immunity" in COVID-19 Pandemic.** Front Cell Dev Biol 2020; 8:547314Xia Y, Zhong L, Tan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072741>
37. **Effect of Population Lockdown on Pediatric Emergency Room Demands in the Era of COVID-19.** Front Pediatr 2020; 8:521Valitutti F, Zenzeri L, Mauro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072657>
38. **Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future.** Front. Pharmacol. 2020; 11:1205Ogunleye OO, Basu D, Mueller D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071775>
39. **Epidemiological and Genomic Analysis of SARS-CoV-2 in 10 Patients From a Mid-Sized City Outside of Hubei, China in the Early Phase of the COVID-19 Outbreak.** Front Public Health 2020; 8:567621Chen J, Hilt EE, Li F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072702>
40. **Lessons From Italy's and Sweden's Policies in Fighting COVID-19: The Contribution of Biomedical and Social Competences.** Front Public Health 2020; 8:563397Farina M, Lavazza A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072701>
41. **COMOKIT: A Modeling Kit to Understand, Analyze, and Compare the Impacts of Mitigation Policies Against the COVID-19 Epidemic at the Scale of a City.** Front Public Health 2020; 8:563247Gaudou B, Huynh NQ, Philippon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072700>
42. **Protective Behavior in Course of the COVID-19 Outbreak-Survey Results From Germany.** Front Public Health 2020; 8:572561Lüdecke D, von dem Knesebeck O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072712>
43. **COVID-19 Management in Iran as One of the Most Affected Countries in the World: Advantages and Weaknesses.** Front Public Health 2020; 8:510Rassouli M, Ashrafizadeh H, Shirinabadi Farahani A, Akbari ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072688>
44. **Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany.** Front Public Health 2020; 8:570543Solbach W, Schiffner J, Backhaus I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072707>
45. **China's global engagement to fight the novel coronavirus pandemic.** Glob Health Res Policy 2020; 5:44Song W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083550>
46. **Perceived Impacts of the COVID-19 Pandemic on Pediatric Care in Canada: A Roundtable Discussion.** Glob Pediatr Health 2020; 7:2333794x20957652Nicholas DB, Belletrutti M, Dimitropoulos G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088851>
47. **Impact of COVID-19 prevalence and mode of transmission on mortality cases over WHO regions.** Health Inf Sci Syst 2020; 8:35Makinde OS, Olusola-Makinde OO, Olamide EI, Abiodun GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078072>

48. **COVID-19 prevalence estimation: Four most affected African countries.** Infect Dis Model 2020; 5:827-838 Lukman AF, Rauf RI, Abiodun O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073068>
49. **Spatiotemporal dynamics of the COVID-19 pandemic in the arctic: early data and emerging trends.** Int. J. Circumpolar Health 2020; 79:1835251 Petrov AN, Welford M, Golosov N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074067>
50. **Lessons Learned from Battling COVID-19: The Korean Experience.** Int J Environ Res Public Health 2020; 17 Lee SM, Lee D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081367>
51. **Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: an Egyptian pilot model in a university with 12 public hospitals and medical centers.** Int J Epidemiol 2020; Mostafa A, Kandil S, El-Sayed MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094320>
52. **India's Response to the COVID-19 Pandemic: A Frontal Assault on the "Historically Dispossessed".** Int J Health Serv 2020; 20731420968438 Mohan M, Mishra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092455>
53. **A Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital.** Int J Infect Dis 2020; Herzberg J, Vollmer T, Fischer B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075538>
54. **Africa's low COVID-19 mortality rate: A paradox?** Int J Infect Dis 2020; Lawal Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075535>
55. **Characteristics of COVID-19 epidemic and control measures to curb transmission in Malaysia.** Int J Infect Dis 2020; Ng CFS, Seposo XT, Moi ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075527>
56. **Monitoring the mortality impact of COVID-19 in Europe: What can be learned from 2009 influenza H1N1p mortality studies?** Int J Infect Dis 2020; Staaedegaard L, Taylor RJ, Spreeuwenberg P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075528>
57. **SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic.** Int J Infect Dis 2020; Venugopal U, Jilani N, Rabah S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075539>
58. **First Cases of SARS-CoV-2 in Iran, 2020: Case Series Report.** Iran J. Public Health 2020; 49:1564-1568 Yavarian J, Shafiei-Jandaghi NZ, Sadeghi K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083334>
59. **Demographic and Socioeconomic Characteristics of COVID-19 Patients Treated in the Emergency Department of a New York City Hospital.** J. Community Health 2020; James MK, Kishore M, Lee SW.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090305>
60. **Spatiotemporal analysis and hotspots detection of COVID-19 using geographic information system (March and April, 2020).** J Environ Health Sci Eng 2020; 1-9 Shariati M, Mesgari T, Kasraee M, Jahangiri-Rad M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072340>
61. **Transmission of SARS-CoV-2 in the Karaoke Room: An Outbreak of COVID-19 in Guangzhou, China, 2020.** J Epidemiol Glob Health 2020; Gu Y, Lu J, Su W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33095983>
62. **"Andrà tutto bene": Associations Between Character Strengths, Psychological Distress and Self-efficacy During Covid-19 Lockdown.** J Happiness Stud

- 2020:1-20Casali N, Feraco T, Ghisi M, Meneghetti C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071624>
63. **The bumpy road to achieve herd immunity in COVID-19.** J. Immunoassay Immunochem. 2020:1-18Neagu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086932>
 64. **Child and Family Outcomes Following Pandemics: A Systematic Review and Recommendations on COVID-19 Policies.** J. Pediatr. Psychol. 2020; V CF, Iarocci G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083817>
 65. **Systematic screening for SARS-CoV-2 in pregnant women admitted for delivery in a Portuguese maternity.** J. Perinat. Med. 2020; Figueiredo R, Tavares S, Moucho M, Ramalho C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085639>
 66. **Usefulness of COVID-19 screen-and-test approach in pregnant women: an experience from a country with low COVID-19 burden.** J. Perinat. Med. 2020; Šterbenc A, Premru Sršen T, Lučovnik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090969>
 67. **Forecasting of COVID-19 infections in E7 countries and proposing some policies based on the Stringency Index.** J. Popul. Ther. Clin. Pharmacol. 2020; 27:e76-e84Kayral İ E, Buzrul S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084261>
 68. **COVID-19 screening center models in South Korea.** J. Public Health Policy 2020; Kim JE, Lee JH, Lee H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087849>
 69. **The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic.** mBio 2020; 11Good MF, Hawkes MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097654>
 70. **Superspreaders, asymptomatics and COVID-19 elimination.** Med. J. Aust. 2020; Kault D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099287>
 71. **Impact of population density on Covid-19 infected and mortality rate in India.** Model Earth Syst Environ 2020:1-7Bhadra A, Mukherjee A, Sarkar K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072850>
 72. **Retrospective overview of the coronavirus disease 2019 (COVID-19) outbreak in Mauritania.** New Microbes New Infect 2020:100788El Vally A, Bollahi MA, Ould Ahmedou Salem MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082959>
 73. **Analysis of second outbreak of COVID-19 after relaxation of control measures in India.** Nonlinear Dyn 2020:1-19Yu X, Qi G, Hu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071458>
 74. **Locally Informed Modeling to Predict Hospital and Intensive Care Unit Capacity During the COVID-19 Epidemic.** Ochsner J 2020; 20:285-292Fort D, Seoane L, Unis GD, Price-Haywood EG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071661>
 75. **Prevention and control of COVID-19 in pastoral community through One Health Approach.** One Health 2020:100181Yousuf A, Arifin SRM, Musa R, Isa MLM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072837>
 76. **Characteristics and Outcomes of Latinx Patients With COVID-19 in Comparison With Other Ethnic and Racial Groups.** Open Forum Infect Dis 2020; 7:ofaa401Izzy S, Tahir Z, Cote DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088846>
 77. **Incidence of Health Care-Associated COVID-19 During Universal Testing of Medical and Surgical Admissions in a Large US Health System.** Open Forum

- Infect Dis 2020; 7:ofaa435Long DR, O'Reilly-Shah V, Rustagi AS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33088847>
78. **COVID-19 in pastoral contexts in the greater Horn of Africa: Implications and recommendations.** Pastoralism 2020; 10:22Griffith EF, Pius L, Manzano P, Jost CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072249>
 79. **Fate control and ingroup bias in donation for the fight with the coronavirus pandemic: The mediating role of risk perception of COVID-19.** Pers. Individ. Dif. 2020;110456Li WQ, Li LMW, Jiang D, Liu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071411>
 80. **The relationship between government trust and preventive behaviors during the COVID-19 pandemic in China: Exploring the roles of knowledge and negative emotion.** Prev. Med. 2020;106288Min C, Shen F, Yu W, Chu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091414>
 81. **Acceleration of plague outbreaks in the second pandemic.** Proc Natl Acad Sci U S A 2020; Earn DJD, Ma J, Poinar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077604>
 82. **Study of global dynamics of COVID-19 via a new mathematical model.** Results Phys 2020; 19:103468Din RU, Seadawy AR, Shah K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078091>
 83. **Study of transmission dynamics of COVID-19 mathematical model under ABC fractional order derivative.** Results Phys 2020; 19:103507Thabet STM, Abdo MS, Shah K, Abdeljawad T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072498>
 84. **Evaluating the plausible application of advanced machine learnings in exploring determinant factors of present pandemic: A case for continent specific COVID-19 analysis.** Sci Total Environ 2020;142723Chakraborti S, Maiti A, Pramanik S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077215>
 85. **Relationship Between the Number of Patients Visiting Emergency Department and Tokyo Health System's Capacity During Early Stages of the First Wave of COVID-19.** SN Compr Clin Med 2020;1-3Ishikawa Y, Hifumi T, Otani N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073172>
 86. **Precautionary Measures and Illness Attitudes toward COVID-19 among a Sample of the Kuwaiti Population.** Soc Work Public Health 2020;1-10Al-Sejari MM, Al-Ma'Seb HB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092492>
 87. **COVID-19, the Swedish 'Experiment', and Me.** Stud. Health Technol. Inform. 2020; 273:211-216Dowie J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087614>
 88. **Modelling of COVID-19 Morbidity in Russia.** Stud. Health Technol. Inform. 2020; 273:262-265Kopanitsa G, Metsker O, Yakovlev A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087624>
 89. **An estimation of airborne SARS-CoV-2 infection transmission risk in New York City nail salons.** Toxicol. Ind. Health 2020;748233720964650Harrichandra A, Ierardi AM, Pavilonis B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085569>
 90. **Google Trends Data and COVID-19 in Europe: correlations and model enhancement are European wide.** Transbound Emerg Dis 2020; Sulyok M, Ferenci T, Walker M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085851>
 91. **Incidence of COVID-19 among returning travelers in quarantine facilities: A longitudinal study and lessons learned.** Travel Med Infect Dis 2020; 38:101901Al-Tawfiq JA, Sattar A, Al-Khadra H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33049360>

92. **Impact of lockdown on air quality over major cities across the globe during COVID-19 pandemic.** Urban Clim 2020; 34:100719Kumari P, Toshniwal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083215>
93. **Coronavirus testing in women attending antenatal care.** Women Birth 2020; Rolnik DL, Korman TM, Rindt A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092997>
94. **Global analysis of daily new COVID-19 cases reveals many static-phase countries including the United States potentially with unstoppable epidemic.** World J Clin Cases 2020; 8:4431-4442Long C, Fu XM, Fu ZF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083402>
95. **Recent perspectives and awareness on transmission, clinical manifestation, quarantine measures, prevention and treatment of COVID-19 among people living in Malaysia in 2020.** Z Gesundh Wiss 2020:1-10Alabed AAA, Elengoe A, Anandan ES, Almahdi AY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078089>
96. **Early school closures can reduce the first-wave of the COVID-19 pandemic development.** Z Gesundh Wiss 2020:1-7Klimek-Tulwin M, Tulwin T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078090>
97. **[Interpretation for the group standards in the handling of accidental leak coronavirus disease 2019 sample].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1378-1380Chen M, Mu XQ, Zhang XA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076587>
98. **[Analysis on transmission chain of a cluster epidemic of COVID-19, Nanchang].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1420-1423Deng ZQ, Xia W, Fan YB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076591>
99. **[World Health Organization's response mechanisms for COVID-19].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1385-1389Jing WZ, Liu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076589>

Gastro-enterology (22 articles)

1. **The changing landscape of hepatology and gastroenterology.** Acta Gastroenterol. Belg. 2020; 83:371-372Lanthier N, Vanuytsel T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094581>
2. **Prevalence of liver injury in patients with coronavirus disease 2019 (COVID-19) : a systematic review and meta-analysis.** Acta Gastroenterol. Belg. 2020; 83:454-460Merola E, Pravadelli C, de Pretis G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094594>
3. **Diarrhea as a Presenting Symptom of Coronavirus Disease 2019 in Children.** Adv Biomed Res 2020; 9:35Moradveisi B, Ataei P, Ghaffarieh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072647>
4. **Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).** Ann. Hepatol. 2020; Lopez-Mendez I, Aquino-Matus J, Gall SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099028>
5. **Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis.** Ann. Hepatol. 2020; Sharma A, Jaiswal P, Kerakhan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075578>
6. **Bowel Ischemia in a Patient With SARS CoV-2-Like Illness and Negative Real-Time Reverse Transcription Polymerase Chain Reaction Test Results During**

- the Peak of the Pandemic.** *Cureus* 2020; 12:e10442Almafrefji I, Ranganath S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072452>
7. **Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19.** *Cureus* 2020; 12:e10447Daid SS, Toribio AD, Lakshmanan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072456>
 8. **Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?** *Dig. Dis. Sci.* 2020;1-10Scribano ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073335>
 9. **COVID-19 and Cytomegalovirus Co-infection: A Challenging Case of a Critically Ill Patient with Gastrointestinal Symptoms.** *Eur J Case Rep Intern Med* 2020; 7:001911Amaral PH, Ferreira BM, Roll S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083369>
 10. **Patient perspectives on social-media-delivered telemedicine for inflammatory bowel disease.** *Future Healthc J* 2020; 7:241-244O'Neill P, Shandro B, Poullis A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094237>
 11. **MiR-146a rs2910164 G > C polymorphism modulates Notch-1/IL-6 signaling during infection: a possible risk factor for Crohn's disease.** *Gut Pathog.* 2020; 12:48Keewan E, Naser SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072191>
 12. **Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.** *Inflamm. Bowel Dis.* 2020; Burke KE, Kochar B, Allegretti JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089863>
 13. **Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research.** *Int. J. Clin. Oncol.* 2020;1-10Takahari D, Shinozaki E, Wakatsuki T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085057>
 14. **Liver Dysfunction and Its Association with the Risk of Death in COVID-19 Patients: A Prospective Cohort Study.** *J Clin Transl Hepatol* 2020; 8:246-254Fu L, Fei J, Xu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083246>
 15. **Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.** *J Crohns Colitis* 2020; 14:S807-s814De Lima-Karagiannis A, Juillerat P, Sebastian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085970>
 16. **Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.** *J Crohns Colitis* 2020; Derikx L, Lantinga MA, de Jong DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079178>
 17. **International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases.** *J Crohns Colitis* 2020; 14:S780-s784Lewin S, Lees C, Regueiro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085971>
 18. **COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal.** *J Crohns Colitis* 2020; 14:S791-s797Ng SC, Mak JWY, Hitz L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085973>
 19. **Pancreatitis in Pediatric Patients with COVID-19.** *J Pediatric Infect Dis Soc* 2020; Samies NL, Yarbrough A, Boppana S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075134>
 20. **Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of**

- care.** United European Gastroenterol J 2020:2050640620964132Saibeni S, Scucchi L, Dragoni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070758>
21. **Liver injury in COVID-19: A minireview.** World J Clin Cases 2020; 8:4303-4310Zhao JN, Fan Y, Wu SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083389>
22. **Review of inflammatory bowel disease and COVID-19.** World J. Gastroenterol. 2020; 26:5534-5542Sultan K, Mone A, Durbin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088153>

Guidelines (7 articles)

1. **Review and comparison of HVAC operation guidelines in different countries during the COVID-19 pandemic.** Build. Environ. 2020:107368Guo BM, Xu P, Xiao T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071439>
2. **The changing paradigm of an aesthetic practice during the COVID-19 pandemic - An expert consensus.** Dermatol Ther 2020:e14382Kandhari R, Kohli M, Trasi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090637>
3. **Preventive Measures for COVID-19 in Dental Treatments.** Disaster Med Public Health Prep 2020:1-13Guo J, Xie H, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092676>
4. **Guidelines for Resuming Elective Hip and Knee Surgical Activity Following the COVID-19 Pandemic: An Italian Perspective.** HSS J. 2020:1-6D'Ambrosi R, Biazio A, Masia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071683>
5. **An Overview on Guidelines on COVID-19 Virus and Natural and Assisted Reproductive Techniques Pregnancies.** Int J Fertil Steril 2020; 14:264-271Pirjani R, Rabiei M, Abiri A, Moini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098398>
6. **Longitudinal Quantitative Analysis of Radiation Oncology Staff Illness in a New York City Center during COVID-19: The Impact of New Guidelines on Operations and Employee Health.** Int J Part Ther 2020; 7:21-27Hasan S, Press RH, Chhabra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094132>
7. **Clinical protocols in dental practice: Post-COVID-19.** J Conserv Dent 2019; 22:408-410Hegde MN, Qaiser S, Hegde ND. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082652>

Imaging (24 articles)

1. **Multivariate analysis of CT imaging, laboratory, and demographical features for prediction of acute kidney injury in COVID-19 patients: a Bi-centric analysis.** Abdom Radiol (NY) 2020; Hectors SJ, Riyahi S, Dev H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098478>
2. **Neuroinvasive potential of SARS-CoV2 with neuroradiological and neuropathological findings: is the brain a target or a victim?** APMIS 2020; Franca RA, Uggla L, Guadagno E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098147>
3. **MH-COVIDNet: Diagnosis of COVID-19 using deep neural networks and meta-heuristic-based feature selection on X-ray images.** Biomed. Signal Process. Control 2021; 64:102257Canayaz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33042210>
4. **A model based on CT radiomic features for predicting RT-PCR becoming negative in coronavirus disease 2019 (COVID-19) patients.** BMC Med. Imaging

- 2020; 20:118Cai Q, Du SY, Gao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081700>
5. **The importance of imaging - Perspectives from redeployment.** Clin Imaging 2020; 69:380-383Atallah J, Shah S, Toy D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099069>
 6. **Value of chest computed tomography scan in diagnosis of COVID-19; a systematic review and meta-analysis.** Clin Transl Imaging 2020:1-13Hossein H, Ali KM, Hosseini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072656>
 7. **COVID-19: What Iodine Maps From Perfusion CT can reveal-A Prospective Cohort Study.** Crit Care 2020; 24:619Santamarina MG, Boisier Riscal D, Beddings I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087155>
 8. **Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study.** ESC Heart Fail 2020; Lassen MCH, Skaarup KG, Lind JN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089972>
 9. **Lung ultrasound findings in pediatric patients with COVID-19.** Eur. J. Pediatr. 2020; Guitart C, Suárez R, Girona M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089388>
 10. **Comparison of admission chest computed tomography and lung ultrasound performance for diagnosis of COVID-19 pneumonia in populations with different disease prevalence.** Eur J Radiol 2020; 133:109344Colombi D, Petrini M, Maffi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091835>
 11. **Imaging differences between coronavirus disease 2019, severe acute respiratory syndrome, and Middle East respiratory syndrome.** Eur J Radiol Open 2020; 7:100277Kheiralla OAM, Tajaldeen AA, Bakheet AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078129>
 12. **Predictive value of initial CT scan for various adverse outcomes in patients with COVID-19 pneumonia.** Heart Lung 2020; Khosravi B, Aghaghazvini L, Sorouri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097297>
 13. **Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study.** Intensive Care Med 2020; Chiumello D, Busana M, Coppola S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089348>
 14. **The role of lung ultrasound as a frontline diagnostic tool in the era of COVID-19 outbreak.** Intern Emerg Med 2020; Sorlini C, Femia M, Nattino G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090353>
 15. **The use of lung ultrasound during the COVID-19 pandemic: A narrative review with specific focus on its role in pregnancy.** J. Popul. Ther. Clin. Pharmacol. 2020; 27:e64-e75Youssef A, Cavalera M, Azzarone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084260>
 16. **Telerobotic ultrasound to provide obstetrical ultrasound services remotely during the COVID-19 pandemic.** J Telemed Telecare 2020:1357633x20965422Adams SJ, Burbridge B, Chatterson L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076753>
 17. **Unforeseen COVID-19 on Oncologic Bone Scan with SPECT/CT in a High Prevalence Area.** Mol Imaging Radionucl Ther 2020; 29:139-142Gill SM, Hassan A, Bashir H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094579>
 18. **Overview of chest involvement at computed tomography in children with coronavirus disease 2019 (COVID-19).** Pediatr Radiol 2020:1-9Peng X, Guo Y, Xiao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084963>

19. **Implementation of Convolutional Neural Network Approach for COVID-19 Disease Detection.** Physiol Genomics 2020; Irmak E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094700>
20. **Spanish radiographers' concerns about the COVID-19 pandemic.** Radiography (Lond) 2020; Ruiz C, Llopis D, Roman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087309>
21. **Impact of COVID-19 pandemic on radiographers in the Republic of Cyprus. A questionnaire survey.** Radiography (Lond) 2020; Zervides C, Sassi M, Kefala-Karli P, Sassis L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092995>
22. **How to perform and interpret the lung ultrasound by the obstetricians in pregnant women during the SARS-CoV-2 pandemic.** Turk J Obstet Gynecol 2020; 17:225-232 Yassa M, Mutlu MA, Kalafat E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072428>
23. **Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients.** Ultrasound Med. Biol. 2020; Bennett D, De Vita E, Mezzasalma F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082053>
24. **The chest CT features of coronavirus disease 2019 (COVID-19) in China: a meta-analysis of 19 retrospective studies.** Virol J 2020; 17:159 Yang H, Lan Y, Yao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087181>

Immune response (35 articles)

1. **Immunity and Coagulation/Fibrinolytic Processes may Reduce the Risk of Severe Illness in Pregnant Women with COVID-19.** Am J Obstet Gynecol 2020; Zhong Y, Cao Y, Zhong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098813>
2. **Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.** Ann. Natl. Acad. Med. Sci. 2020; 56:112-115 Shekhar S, Copacino CE, Barrera FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082620>
3. **Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2.** Ann Oncol 2020; Marra A, Generali D, Zagami P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098994>
4. **Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19.** Cell 2020; Meckiff BJ, Ramírez-Suástegui C, Fajardo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096020>
5. **The N gene of SARS-CoV-2 was the main positive component in repositive samples from a cohort of COVID-19 patients in Wuhan, China.** Clin Chim Acta 2020; Zhang X, Li M, Zhang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096033>
6. **Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.** Curr. Drug Targets 2020; Vieira C, Nery L, Martins L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081670>
7. **Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?** Dig. Dis. Sci. 2020:1-10 Scribano ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073335>
8. **Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A**

- treatment proposal for COVID-19 patients.** *Electromagn. Biol. Med.* 2020;1-15 Vergallo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073612>
9. **Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020.** *Emerg Infect Dis* 2020; 26 Chan PKS, Lui G, Hachim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089772>
 10. **The duration of SARS-CoV-2 shedding in patients recovering from COVID-19.** *Epidemiol. Mikrobiol. Imunol.* 2020; 69:148-151 Cimrman Š, Macková L, Král V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086857>
 11. **Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to six months post disease onset.** *Eur. J. Immunol.* 2020; Figueiredo-Campos P, Blankenhaus B, Mota C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084029>
 12. **Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 patients.** *Eur. J. Immunol.* 2020; Oja AE, Saris A, Ghandour CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073359>
 13. **Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy.** *Eur J Intern Med* 2020; Benfaremo D, Perini L, Marconi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092952>
 14. **Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown.** *Eur. J. Neurol.* 2020; Zrzavy T, Wimmer I, Rommer PS, Berger T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090599>
 15. **Immunopathology of galectin-3: an increasingly promising target in COVID-19.** *F1000Res* 2020; 9:1078 Caniglia JL, Asuthkar S, Tsung AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082935>
 16. **Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology.** *Front. Immunol.* 2020; 11:560381 Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072099>
 17. **Immunopathogenesis of COVID-19: Summary and Possible Interventions.** *Front. Immunol.* 2020; 11:564925 Jacques FH, Apedaile E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072103>
 18. **Effect of Population Lockdown on Pediatric Emergency Room Demands in the Era of COVID-19.** *Front Pediatr* 2020; 8:521 Valitutti F, Zenzeri L, Mauro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072657>
 19. **The CHIR Score for Evaluating the Hyperimmune Response in COVID-19: A Preliminary Concept.** *Front Public Health* 2020; 8:550933 Goyal DK, Mansab F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072695>
 20. **Inflammasome formation in the lungs of patients with fatal COVID-19.** *Inflamm Res* 2020;1-4 Toldo S, Bussani R, Nuzzi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079210>
 21. **Immune system changes during COVID-19 recovery play key role in determining disease severity.** *Int. J. Immunopathol. Pharmacol.* 2020; 34:2058738420966497 Fathi F, Sami R, Mozafarpour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076729>
 22. **Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19.** *Int. J. Lab. Hematol.* 2020; Liu L, Zheng Y, Cai L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099889>

23. **Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children: A Call to Action.** J Am Coll Cardiol 2020; 76:1962-1964 Friedman KG, Harrild DM, Newburger JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092731>
24. **Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World.** J Clin Med 2020; 9Augustine R, Das S, Hasan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096742>
25. **Prolonged SARS-CoV-2 replication in an immunocompromised patient.** J Infect Dis 2020; Baang JH, Smith C, Mirabelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089317>
26. **Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: A living systematic review.** J Med Virol 2020; Bwire GM, Njiro BJ, Mwakawanga DL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090535>
27. **Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China.** J Med Virol 2020; Chen Y, Ke Y, Liu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085103>
28. **Preventing the development of severe CoVID 19 by modifying immunothrombosis.** Life Sci 2020:118617 Morris G, Bortolaschi CC, Puri BK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096114>
29. **The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals.** Med. Hypotheses 2020; 145:110345 Cañas CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080459>
30. **Superspreaders, asymptomatics and COVID-19 elimination.** Med. J. Aust. 2020; Kault D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099287>
31. **Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.** Pathology 2020; Tan SS, Saw S, Chew KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092816>
32. **Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein.** Stem Cell Rev Rep 2020; Ropa J, Cooper S, Capitano ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089452>
33. **Sex-biased Immune Responses Following SARS-CoV-2 Infection.** Trends Microbiol. 2020; Ursin RL, Shapiro JR, Klein SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077340>
34. **COVID-19 vaccine and boosted immunity: Nothing ad interim to do?** Vaccine 2020; Roncati L, Vadalà M, Corazzari V, Palmieri B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071005>
35. **Enhancing innate immunity against virus in times of COVID-19: trying to untangle facts from fictions.** World Allergy Organ J 2020:100476 Larenas-Linnemann D, Rodríguez-Pérez N, Arias-Cruz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072240>

Management miscellaneous diseases (92 articles)

1. **[Letter to the Editor Regarding Torres-Costa et al "SARS-CoV-2 in Ophtalmology: Current Evidence and Recommendations for Clinical Practice"].** Acta Med Port 2020; Martins T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092689>

2. **Drop for drop: A descriptive analysis of blood product usage in a South African tertiary care setting during the Covid-19 pandemic.** Afr J Emerg Med 2020; Shead DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083210>
3. **Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions.** Aging_(Albany_NY)_2020; 12Blanch-Rubió J, Soldevila-Domenech N, Tío L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080571>
4. **Management of patients with chronic rhinosinusitis during the COVID-19 pandemic - An EAACI Position Paper.** Allergy_2020; Klimek L, Jutel M, Bousquet J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075144>
5. **Surge activation by the emergency department for COVID-19.** Am J Emerg Med 2020; Schmidt AR, Pham PK, Liu DR, Goldberg BS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071090>
6. **Transcutaneous laryngeal ultrasonography: A promising tool for otolaryngologists during COVID-19.** Am. J. Otolaryngol. 2020; 42:102772Sciancalepore PI, Anzivino R, Petrone P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099229>
7. **The effect of COVID-19 on general anaesthesia rates for caesarean section. A cross sectional analysis of six hospitals in the north-west of England.** Anaesthesia 2020; Bhatia K, Columb M, Bewlay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073371>
8. **[Impact of the COVID-19 pandemic on the activities of the cardiology department of the Ignace Deen National Hospital at the Conakry University Hospital].** Ann. Cardiol. Angeiol. (Paris)_2020; Barry IS, Baldé EY, Béavogui M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071020>
9. **Single centre concept of 'cold site' elective surgery during the peak of COVID-19 pandemic : A cohort study.** Ann Med Surg_(Lond)_2020; 59:245-250Iqbal MR, Dhahri AA, Darwish NMM, Vijay V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33042534>
10. **Does elective orthopaedic surgery in the pandemic era increase the risk of developing COVID-19? A combined analysis of retrospective and prospective study at a national tertiary hospital in Jakarta, Indonesia.** Ann Med Surg_(Lond) 2020; Kamal AF, Widodo W, Kuncoro MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078074>
11. **Oncology in times of COVID-19: Interdisciplinarity and interprofessionalism are more important than ever.** Arzneimitteltherapie 2020; 38:407Christ MM.
12. **COVID-19 patients with bronchial tumors: Chemotherapy leads to a higher mortality risk.** Arzneimitteltherapie 2020; 38:427-428Junker A.
13. **Covid-19: What is the best approach in gynecological oncology patient management during the coronavirus pandemic?** Asia Pac. J. Clin. Oncol. 2020; Hasanzadeh M, Azad A, Farazestanian M, Mousavi Seresht L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079477>
14. **Management of autoimmune disease during the COVID-19 pandemic.** Aust Prescr 2020; 43:146-147Robinson PC, Bursle EC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093739>
15. **Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.** Br. J. Clin. Pharmacol. 2020; Rajoli RKR, Pertinez H, Arshad U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085781>

16. **Challenges in management of idiopathic granulomatous mastitis during the pandemic of COVID-19.** Breast J 2020; Dağ A, Edizsoy A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073462>
17. **Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic.** Cancer Med 2020; Madan A, Siglin J, Khan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078903>
18. **The Experience of Oncology Healthcare Providers in the Central Italy during the COVID-19 Lockdown.** Cancers (Basel) 2020; 12Fabi A, Pugliese P, Falbo PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081044>
19. **Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective.** Crit. Rev. Oncol. Hematol. 2020; 156:103120Bakhribah H, Zeitouni M, Daghistani RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33099232>
20. **Treatment of retinal detachment during the COVID-19 pandemic : Did patients with retinal detachment seek treatment later during the COVID-19 pandemic? Results from a German university eye hospital.** Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2020; Kaupke N, Spitzer MS, Kromer R.
21. **The changing paradigm of an aesthetic practice during the COVID-19 pandemic - An expert consensus.** Dermatol Ther 2020:e14382Kandhari R, Kohli M, Trasi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090637>
22. **Cancer disease progression and death during the COVID-19 pandemic: a multidisciplinary analysis for the Peruvian setting.** Ecancermedicalscience 2020; 14:1098Astigueta-Pérez J, Abad-Licham M, Chávez-Chirinos C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082848>
23. **SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review.** Ecancermedicalscience 2020; 14:1100Haradaa G, Antonacio FF, Gongora AB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082850>
24. **The ongoing COVID-19 pandemic will create a disease surge among cancer patients.** Ecancermedicalscience 2020; 14:ed105Meyer M, Bindelglas E, Kupferman ME, Eggermont AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082857>
25. **Cancer treatment during the COVID-19 pandemic in the Kurdistan Region of northern Iraq.** Ecancermedicalscience 2020; 14:1096Nidhamalddin SJ, Hasan RO, Abubakr GO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082846>
26. **Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial mesenchymal transition.** Ecancermedicalscience 2020; 14:1099Saha A, Anirvan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082849>
27. **Understanding the impact of interruptions to HIV services during the COVID-19 pandemic: A modelling study.** EClinicalMedicine 2020; 26:100483Jewell BL, Smith JA, Hallett TB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089116>
28. **Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report.** Eur Heart J Case Rep 2020; 4:1-6Li A, Garcia-Bengochea Y, Stechel R, Azari BM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089055>

29. **COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm.** Eur J Case Rep Intern Med 2020; 7:001922Daniel P, Raad M, Waked R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083371>
30. **Emergency surgical management of cervical spine fracture-dislocation with acute paraplegia in COVID-19 (Coronavirus disease 2019)-suspected patient: first experience from a German spine centre.** Eur. Spine J. 2020; Alhashash M, Elsebaity W, Farag M, Shousha M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095369>
31. **Maintaining stroke care in Europe during the COVID-19 pandemic: Results from an international survey of stroke professionals and practice recommendations from the European Stroke Organisation.** Eur Stroke J 2020; 5:230-236Aguiar de Sousa D, van der Worp HB, Caso V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072876>
32. **Stroke care in Italy: An overview of strategies to manage acute stroke in COVID-19 time.** Eur Stroke J 2020; 5:222-229Zedde M, Pezzella FR, Paciaroni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072875>
33. **Managing blood disorders during the Covid-19 pandemic: current pharmacological insights.** Expert Rev. Clin. Pharmacol. 2020; Karunakaran P, Nampoothiri RV, Sahu KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089736>
34. **Arrhythmogenic syncope leading to cardiac rhythm management procedures during COVID-19 lockdown.** Expert Rev. Med. Devices 2020; Russo V, Pafundi PC, Rapacciuolo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090884>
35. **Management of Immunity Alteration-Induced Chronic Pain During the Coronavirus Disease-2019 (COVID-19) Pandemic.** Front. Microbiol. 2020; 11:572318Sun W, Gao H, Luo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072033>
36. **SABR-BRIDGE: Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-Stage Lung Cancer or Oligometastases During the COVID-19 Pandemic.** Front. Oncol. 2020; 10:580189Kidane B, Spicer J, Kim JO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072612>
37. **Managing high-acuity outpatient services during the COVID-19 pandemic: lessons from the acute diabetes foot service.** Future Healthcare J 2020; 7:e77-e79Deogon GS, Robbins T, Randeva MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094262>
38. **COVID-19 pandemic: How to ensure surgical care services?** Geburtshilfe Frauenheilkd. 2020; 80:964-965.
39. **Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts.** Gen. Hosp. Psychiatry 2020; 67:100-106Yang J, Landrum MB, Zhou L, Busch AB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091782>
40. **Comments about: COVID-19: Initial experience of an international group of hand surgeons.** Hand Surg Rehabil 2020; Kiely J, Fleet M, Tan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075508>
41. **Head and neck surgery during the coronavirus-19 pandemic: The University of California San Francisco experience.** Head Neck 2020; Wai KC, Xu MJ, Lee RH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098178>
42. **Guidelines for Resuming Elective Hip and Knee Surgical Activity Following the COVID-19 Pandemic: An Italian Perspective.** HSS J. 2020;1-6D'Ambrosi R,

- Biazzo A, Masia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071683>
43. **Metronomic chemotherapy for scheduling oral cancer surgery during the COVID-19 pandemic.** *Indian J. Cancer* 2020; 57:481-484Rajan S, Kumar V, Akhtar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078758>
 44. **Nuclear Medicine in India: Are We Pandemic Ready?** *Indian J. Nucl. Med.* 2020; 35:197-199Puranik AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082673>
 45. **'Return to the New Normal': Innovative Solutions for Safe Ponseti Casting in Clubfoot Clinics during the COVID-19 Pandemic.** *Indian J. Orthop.* 2020:1-6Aroojis A, Pragadeeswaran V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071303>
 46. **COVID-19-Positive Report Posing a Delay in Treatment Course in a Middle-Aged Metastatic Neuroendocrine Tumor Patient.** *Indian J. Palliat. Care* 2020; 26:S173-s175Krishnapriya V, Rathore P, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088115>
 47. **Palliative Care Delivery in Cancer Patients in the Era of Covid-19 Outbreak: Unique Needs, Barriers, and Tools for Solutions.** *Indian J. Palliat. Care* 2020; 26:S130-s141Mishra S, Biswas S, Bhatnagar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088103>
 48. **Homecare and the COVID-19 Pandemic - Experience at an Urban Specialist Cancer Palliative Center.** *Indian J. Palliat. Care* 2020; 26:S63-s69Page N, Naik V, Singh P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088091>
 49. **Palliative Care Challenges and Strategies for the Management Amid COVID-19 Pandemic in India: Perspectives of Palliative Care Nurses, Cancer Patients, and Caregivers.** *Indian J. Palliat. Care* 2020; 26:S121-s125Pai RR, Nayak MG, Sangeetha N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088101>
 50. **A Child with Acute Lymphoblastic Leukemia in Institutional Isolation during the COVID Pandemic: A Multifaceted Responsibility.** *Indian J. Palliat. Care* 2020; 26:S170-s172Rathore P, Kumar S, Shweta *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088114>
 51. **Providing Palliative Home Care during COVID-19 Pandemic Lockdown in India.** *Indian J. Palliat. Care* 2020; 26:S56-s57Sharma R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088089>
 52. **Concerns of a Post-Chemotherapy/Radiotherapy Patient of Nasopharyngeal Carcinoma Presenting with Sustained COVID-19 Infection.** *Indian J. Palliat. Care* 2020; 26:S148-s149Shweta, Vig S, Rathore P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088106>
 53. **Colorectal Services in Covid-19 Times: Minimally Invasive Surgery and Enhanced Recovery, the Need of the Hour.** *Indian J Surg Oncol* 2020:1-5Sukumar V, Pandey D, Kumar BR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071520>
 54. **Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing2.** *Infect. Agent. Cancer* 2020; 15:61Ajenifuja KO, Belinson J, Goldstein A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072179>
 55. **Health and social effects of the COVID-19 pandemic on patients with cystic fibrosis.** *Int Forum Allergy Rhinol* 2020; Osterbauer B, Hasday S, Lin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080113>
 56. **Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research.** *Int. J. Clin. Oncol.* 2020:1-10Takahari

- D, Shinozaki E, Wakatsuki T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085057>
57. **Practical nursing recommendations for palliative care for people with dementia living in long-term care facilities during the COVID-19 pandemic: A rapid scoping review.** *Int. J. Nurs. Stud.* 2020; 113:103781 Bolt SR, van der Steen JT, Mujezinović I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080475>
 58. **Longitudinal Quantitative Analysis of Radiation Oncology Staff Illness in a New York City Center during COVID-19: The Impact of New Guidelines on Operations and Employee Health.** *Int J Part Ther* 2020; 7:21-27 Hasan S, Press RH, Chhabra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094132>
 59. **Proton Therapy in a Pandemic: An Operational Response to the COVID-19 Crisis.** *Int J Part Ther* 2020; 7:54-57 McGovern SL, Wages C, Dimmitt A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094136>
 60. **Impact of covid-19 pandemic on dermatology practice: results of a web-based, global survey.** *Int J Womens Dermatol* 2020; Bhargava S, McKeever C, Kroumpouzos G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072835>
 61. **Hospital organization and thoracic oncological patient management during the coronavirus disease-2019 outbreak: a brief report from a nationwide survey of the Italian Society of Thoracic Surgery.** *Interact. Cardiovasc. Thorac. Surg.* 2020; Viggiano D, Lococo F, Dell'Amore A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089301>
 62. **Rethinking the Role of Advance Care Planning in the Context of Infectious Disease.** *J Aging Soc Policy* 2020:1-7 Moorman S, Boerner K, Carr D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081625>
 63. **Estimating COVID-19 prevalence and infection control practices among US dentists.** *J. Am. Dent. Assoc.* 2020; Estrich CG, Mikkelsen M, Morrissey R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071007>
 64. **Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma.** *J. Cancer Res. Clin. Oncol.* 2020:1-11 Yang S, Dong D, Gu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078214>
 65. **Collateral damage caused by COVID-19: Change in volume and spectrum of neurosurgery patients.** *J. Clin. Neurosci.* 2020; 80:156-161 Goyal N, Venkataram T, Singh V, Chaturvedi J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099339>
 66. **Clinical protocols in dental practice: Post-COVID-19.** *J Conserv Dent* 2019; 22:408-410 Hegde MN, Qaiser S, Hegde ND. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082652>
 67. **A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.** *J Eur Acad Dermatol Venereol* 2020; Hansel K, Zangrilli A, Bianchi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080112>
 68. **Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups.** *J Gynecol Oncol* 2020; 31:e92 Bogani G, Apolone G, Ditto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078597>
 69. **Low impact of SARS-CoV-2 infection among paediatric acute respiratory disease hospitalizations.** *J Infect* 2020; Melé M, Henares D, Pino R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098956>
 70. **The Impact of COVID-19 on the Use of Radiology Resources in a Tertiary Hospital.** *J Korean Med Sci* 2020; 35:e368 Cho J, Lee S, Gu BS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075859>

71. **Response of an oncology unit in the midst of the COVID-19 outbreak.** J. Oncol. Pharm. Pract. 2020;1078155220967973Liontos M, Kastitis E, Migkou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092498>
72. **Visitor Restriction Policy on Pediatric Wards during Novel Coronavirus (COVID-19) Outbreak: A Survey Study across North America.** J Pediatric Infect Dis Soc 2020; Kitano T, Piché-Renaud PP, Groves HE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090211>
73. **Needs assessment and impact of COVID-19 on pharmacy professionals in 31 commonwealth countries.** J Pharm Policy Pract 2020; 13:72Ashiru-Oredope D, Chan AHY, Olaoye O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093963>
74. **Plastic physicians: The surgical salamanders of the COVID-19 pandemic.** J. Plast. Reconstr. Aesthet. Surg. 2020; Hughes BA, Hassan S, Stallard J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097434>
75. **Impact of the COVID-19 pandemic during Spain's state of emergency on the diagnosis of colorectal cancer.** J. Surg. Oncol. 2020; Suárez J, Mata E, Guerra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078425>
76. **Impact of COVID-19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy.** J. Surg. Oncol. 2020; Vissio E, Falco EC, Collemi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084056>
77. **Impact of COVID-19 on people with HIV: A Review.** J Virus Erad 2020;100019Prabhu S, Poongulali S, Kumarasamy N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083001>
78. **Environmentally sustainable health care: now is the time for action.** Med. J. Aust. 2020; Capon A, Madden DL, Truskett PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089490>
79. **B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection?** Neurol. Neurochir. Pol. 2020; Mycko MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073348>
80. **Is Covid-19 lockdown related to an increase of accesses for seizures in the emergency department? An observational analysis of a paediatric cohort in the Southern Italy.** Neurol Sci 2020; Palladino F, Merolla E, Solimeno M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095368>
81. **[Patient satisfaction during the COVID-19 pandemic in an emergency department].** Orv. Hetil. 2020; 161:1819-1823Deák A, Fusz K, Kanizsai P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099511>
82. **Use of In Situ Simulation to Improve Emergency Department Readiness for the COVID-19 Pandemic.** Prehosp. Disaster Med. 2020;1-26Aljahany M, Alassaf W, Alibrahim AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081859>
83. **COVID-19 Pandemic: The Role of EMS Physicians in a Community Response Effort.** Prehosp. Emerg. Care 2020;1-8Cabañas JG, Williams JG, Gallagher JM, Brice JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074060>
84. **Where have the children with epilepsy gone? An observational study of seizure-related accesses to emergency department at the time of COVID-19.** Seizure 2020; 83:38-40Davico C, Marcotulli D, Lux C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080483>
85. **Endoscopic endonasal skull base surgery during the COVID-19 pandemic: A developing country perspective.** Surg. Neurol. Int. 2020; 11:310Soliman MAR,

- Elbaroody M, Elsamman AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093987>
86. **The Impact of COVID-19 on Transfusion-Dependent Thalassemia Patients of Karachi, Pakistan: A Single-Center Experience.** *Transfus. Clin. Biol.* 2020; Ali SA, Azim D, Hassan HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091482>
 87. **Assessment of blood supply and usage pre- and during COVID-19 pandemic; a lesson from non-voluntary donation.** *Transfus. Clin. Biol.* 2020; Ogar CO, Okoroiwu HU, Obeagu EI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080420>
 88. **The effects of COVID-19 on Physical Medicine and Rehabilitation in Turkey in the first month of pandemic.** *Turk J Phys Med Rehabil* 2020; 66:244-251 Yağcı İ, Sarıkaya S, Ayhan FF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089080>
 89. **Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care.** *United European Gastroenterol J* 2020:2050640620964132 Saibeni S, Scucchi L, Dragoni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070758>
 90. **Managing acute appendicitis during the COVID-19 pandemic in Jiaying, China.** *World J Clin Cases* 2020; 8:4349-4359 Zhou Y, Cen LS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083394>
 91. **Effects of the COVID-19 Pandemic on the Management of Spinal Disorders - Results of a National Survey.** *Z. Orthop. Unfall.* 2020; Winking M, Conzen M, Flechtenmacher J, Pumberger M.
 92. **[Epidemiological characteristics of asymptomatic infection cases of COVID-19 in Guangdong province].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:1406-1410 Xie SL, Huang JH, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076590>

Management (78 articles)

1. **Palliative care in the emergency department during a COVID-19 pandemic.** *Am J Emerg Med* 2020; Eygnor JK, Rosenau AM, Burmeister DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071097>
2. **Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS.** *Am J Emerg Med* 2020; Lentz S, Roginski MA, Montrieff T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071092>
3. **Attitudes of Front-Line Nurses Toward Hospice Care During the COVID-19 Pandemic.** *Am. J. Hosp. Palliat. Care* 2020:1049909120968533 Liu Q, Tao J, Gao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089700>
4. **The powder keg: Lessons learned about clinical staff preparedness during the early phase of the COVID-19 pandemic.** *Am. J. Infect. Control* 2020; Aliyu S, Norful A, Schroeder K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091508>
5. **Medical Staff Responses to Covid-19 "Data": Have We Misplaced Our Skeptic's Eye?** *Am. J. Med.* 2020; Meisenberg BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091390>
6. **Effect of PEEP and Proning on Ventilation and Perfusion in COVID-19 ARDS.** *Am J Respir Crit Care Med* 2020; Perier F, Tuffet S, Maraffi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075235>
7. **[COVID-19 and mechanical circulatory support].** *Ann. Cardiol. Angeiol. (Paris)* 2020; Hekimian G, Frere C, Collet JP. <http://www.ncbi.nlm.nih.gov/pubmed/?>

term=33092785

8. **COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?** Basic Clin. Pharmacol. Toxicol. 2020; Saeedi-Boroujeni A, Mahmoudian-Sani MR, Bahadoram M, Alghasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099890>
9. **Experience on how to implement a preanalytical and POCT unit in Madrid's IFEMA field hospital during this unprecedented COVID-19 emergency.** Biochem. Med. (Zagreb) 2020; 30:030403Díaz-Garzón J, Oliver P, Crespo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071554>
10. **Zinc and COVID-19: Basis of Current Clinical Trials.** Biol. Trace Elem. Res. 2020; Pal A, Squitti R, Picozza M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094446>
11. **A cross-sectional survey assessing the preparedness of the long-term care sector to respond to the COVID-19 pandemic in Ontario, Canada.** BMC Geriatr. 2020; 20:421Siu HY, Kristof L, Elston D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092541>
12. **Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol.** BMJ Open 2020; 10:e041383Regmi K, Lwin CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093038>
13. **Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population - a Danish cohort study.** Br. J. Clin. Pharmacol. 2020; Nørgård BM, Nielsen J, Knudsen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098713>
14. **The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620960797Wijaya I, Andhika R, Huang I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079569>
15. **The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis.** Clin Infect Dis 2020; Xu J, Teng Y, Shang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079200>
16. **The COVID-19 Cohort Ward Experience: All Hands on Deck.** Clin Infect Pract 2020:100047Yen Tan S, Mei Fong Chien J, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073233>
17. **Enteral feeding and non-invasive ventilation during the COVID-19 crisis: A new snorkeling mask specially-fit to provide both concomitantly.** Clin. Nutr. 2020; Lemyze M, Mascot M, Orfi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071011>
18. **Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study.** Clin. Nutr. 2020; Li G, Zhou CL, Ba YM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077274>
19. **Considerations for nutrition support in critically ill children with COVID-19 and paediatric inflammatory multisystem syndrome temporally associated with COVID-19.** Clin. Nutr. 2020; Marino LV, Valla FV, Tume LN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097307>
20. **Post-Extubation Stridor Complicating COVID-19-Associated Acute Respiratory Distress Syndrome: A Case Series.** Cureus 2020; 12:e10492Moran JV, Godil SA, Goldner B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083191>

21. **Incubation period of SARS-CoV-2: A systematic review and meta-analysis.** Curr. Ther. Res. Clin. Exp. 2020;100607Wassie GT, Azene AG, Bantie GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071295>
22. **Caring for Blind and Vision Impaired Dermatological Patients During the COVID-19 Pandemic.** Dermatol Ther 2020; Chang MJ, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098607>
23. **Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications.** Dermatol Ther 2020; Szolnoky G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078864>
24. **Rational therapeutic decisions in intensive care patients.** Deutsche Medizinische Wochenschrift 2020; 145:1470-1475Riessen R, Haap M, Marckmann G, Mahling M.
25. **Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study.** Diabetes Metab. 2020; Cariou B, Goronflot T, Rimbert A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091555>
26. **Feasibility of Treatment Planning System in Localizing the COVID-19 Pneumonia Lesions and Evaluation of Volume Indices of Lung Involvement.** Dose Response 2020; 18:1559325820962600Ghahramani-Asl R, Porouhan P, Mehrpouyan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088245>
27. **Protecting the most vulnerable during COVID-19 and beyond: a case report on the remote management of heart failure patients with cardiac implantable electronic devices.** Eur Heart J Case Rep 2020; 4:1-6Ahmed FZ, Crosbie C, Kahn M, Motwani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089059>
28. **A case report of unusually long episodes of asystole in a severe COVID-19 patient treated with a leadless pacemaker.** Eur Heart J Case Rep 2020; 4:1-6Cakulev I, Sahadevan J, Osman MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089056>
29. **COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm.** Eur J Case Rep Intern Med 2020; 7:001922Daniel P, Raad M, Waked R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083371>
30. **High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.** Eur J Clin Microbiol Infect Dis 2020:1-9Monreal E, Sainz de la Maza S, Natera-Villalba E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083917>
31. **Probiotics in Medicine: A Long Debate.** Front. Immunol. 2020; 11:2192Stavropoulou E, Bezirtzoglou E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072084>
32. **Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.** Front Med (Lausanne) 2020; 7:539Chaudhary S, Natt B, Bime C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072773>
33. **COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?** Front. Pharmacol. 2020; 11:581840Silveira D, Prieto-Garcia JM, Boylan F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071794>
34. **Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19.** Front. Physiol. 2020; 11:555039Al Heialy S, Hachim MY, Senok A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071815>

35. **Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality-Perspectives.** Front Public Health 2020; 8:444Arokiaraj MC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072682>
36. **Remodelling elective hospital services in the COVID-19 era - designing the new normal.** Future Healthc J 2020; 7:e60-e63King LA, Hothi SS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094258>
37. **Collaborative working on a 7-day rota reduces length of stay.** Future Healthc J 2020; 7:e84Koizia LJ, Dani M, Sritharan G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094264>
38. **Respiratory specialists working in different ways: Development of a GP hotline and respiratory support service during the COVID-19 pandemic.** Future Healthc J 2020; 7:e88-e92Kumar K, Mak V, Groom K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094266>
39. **Rostering in a pandemic: Sustainability is key.** Future Healthc J 2020; 7:e54-e56Roycroft M, Bhala NB, Brockbank S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094256>
40. **Care of the dying person before and during the COVID-19 pandemic: A quality improvement project.** Future Healthc J 2020; 7:e50-e53Tavabie S, Bass S, Stewart E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094255>
41. **Virtual visiting and other technological adaptations for critical care.** Future Healthc J 2020; 7:e93-e95Webb H, Parson M, Hodgson LE, Daswani K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094267>
42. **Between Crisis and Convention: How Should We Address Contingency?** Hastings Cent Rep 2020; 50:17-19Bibler T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095490>
43. **Metronomic chemotherapy for scheduling oral cancer surgery during the COVID-19 pandemic.** Indian J. Cancer 2020; 57:481-484Rajan S, Kumar V, Akhtar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078758>
44. **Palliative Care Interventions from a Social Work Perspective and the Challenges Faced by Patients and Caregivers during COVID-19.** Indian J. Palliat. Care 2020; 26:S58-s62Dhavale P, Koparkar A, Fernandes P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33088090>
45. **Unraveling the Role of Palliative Surgery in the Era of COVID-19 Pandemic.** Indian J. Palliat. Care 2020; 26:S153-s155Gupta R, Karthik AR, Rustagi K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33088108>
46. **To Study the Barriers in Palliative Care to Nonmalignant Cases in COVID-19 Crisis in a Tertiary Health-Care Center.** Indian J. Palliat. Care 2020; 26:S76-s80Jain T, Jain R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088093>
47. **COVID 19: The New Normal in the Clinic: Overcoming Challenges in Palliative Care.** Indian J. Palliat. Care 2020; 26:S81-s85Khurana DK, Raheja SG, Dayal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088094>
48. **Challenges Encountered While Providing Holistic Care to a Cluster of COVID-19 Patients.** Indian J. Palliat. Care 2020; 26:S53-s55Kumar S, Rathore P, Shweta *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088088>
49. **Running Palliative Care Services at the Institute of Palliative Medicine, Kozhikode, Amid COVID-19 Pandemic: A Strengths, Weaknesses, Opportunities, and Threats Analysis.** Indian J. Palliat. Care 2020; 26:S48-s52Mathews L, Immanuel T, Krishnadas N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088087>

50. **Lessons Learned from Battling COVID-19: The Korean Experience.** Int J Environ Res Public Health 2020; 17:Lee SM, Lee D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081367>
51. **How to ventilate obese patients in the ICU.** Intensive Care Med 2020; De Jong A, Wrigge H, Hedenstierna G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095284>
52. **Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.** Intern Emerg Med 2020;1-11Yahyavi A, Hemmati N, Derakhshan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085063>
53. **Mitigating the transmission of infection and death due to SARS-CoV-2 through non-pharmaceutical interventions and repurposing drugs.** ISA Trans. 2020; Mondal C, Adak D, Majumder A, Bairagi N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070984>
54. **Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.** J Am Coll Cardiol 2020; 76:2024-2035Mechanick JI, Rosenson RS, Pinney SP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092738>
55. **Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.** J Biomol Struct Dyn 2020;1-8Elzupir AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094705>
56. **Nitric Oxide Ventilation Improves Recirculation and Right Ventricular Function During Venovenous Extracorporeal Membrane Oxygenation in a COVID-19 Patient.** J Cardiothorac Vasc Anesth 2020; Heuts S, Ubben JF, Banks-Gonzales V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077329>
57. **Awake prone positioning for COVID-19 hypoxemic respiratory failure: A rapid review.** J Crit Care 2020; 61:63-70Weatherald J, Solverson K, Zuege DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096347>
58. **Operation and Management of Seoul Metropolitan City Community Treatment Center for Mild Condition COVID-19 Patients.** J Korean Med Sci 2020; 35:e367Lee SY, Song KJ, Lim CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075858>
59. **Mitigating the effects of COVID-19 pandemic on controlling vascular risk factors among participants in a carotid stenosis trial.** J. Stroke Cerebrovasc. Dis. 2020;105362Turan TN, Meschia JF, Chimowitz MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071206>
60. **Clinical Nutrition Research and the COVID-19 Pandemic: A Scoping Review of the ASPEN COVID-19 Nutrition Taskforce.** JPEN J. Parenter. Enteral Nutr. 2020; Mechanick JI, Carbone S, Dickerson RN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094848>
61. **Preventing the development of severe COVID 19 by modifying immunothrombosis.** Life Sci 2020;118617Morris G, Bortolasci CC, Puri BK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096114>
62. **Committing to endangerment: medical teams in the age of corona in Jewish ethics.** Med. Health Care Philos. 2020;1-8Rashi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078287>
63. **ECG: essential in care of patients with COVID-19.** Med. J. Aust. 2020; Lam K, McClelland S, Dallo MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098111>
64. **Tenecteplase (and common sense) in short supply during the COVID-19 pandemic.** Med. J. Aust. 2020; Parsons M, Churilov L, Schutte AE, Levi C.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099288>
65. **Mediterranean diet as a nutritional approach for COVID-19.** Metabolism 2020;154407Angelidi AM, Kokkinos A, Katechaki E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080270>
66. **Role of micronutrients in the management of COVID-19.** New Microbes New Infect 2020;100782AbdAllah M, Elarab HE, Raslan E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072335>
67. **What can we learn from U.S. military nursing and COVID-19?** Nurs. Inq. 2020; 27:e12384Anders RL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098733>
68. **Nurses confronting the coronavirus: Challenges met and lessons learned to date.** Nurs. Outlook 2020; Ulrich CM, Rushton CH, Grady C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33097227>
69. **A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?** Pharmacol Res Perspect 2020; 8:e00666Kurdi A, Abutheraa N, Akil L, Godman B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33084232>
70. **Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID-19.** Pharmacotherapy 2020; Adams CD, Altshuler J, Barlow BL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33068459>
71. **Challenges for the female health-care workers during the COVID-19 pandemic: the need for protection beyond the mask.** Pulmonology 2020; Crimi C, Carlucci A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087308>
72. **Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.** Rev Cardiovasc Med 2020; 21:339-344Zhang J, McCullough PA, Tecson KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070539>
73. **Critically ill COVID-19 patients attended by anesthesiologists in northwestern Spain: a multicenter prospective observational study.** Rev. Esp. Anesthesiol. Reanim. 2020; Taboada M, Rama P, Pita-Romero R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077309>
74. **Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?** Sex Med Rev 2020; Mostafa T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077403>
75. **Precautionary Measures and Illness Attitudes toward COVID-19 among a Sample of the Kuwaiti Population.** Soc Work Public Health 2020;1-10Al-Sejari MM, Al-Ma'Seb HB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092492>
76. **An eHealth Platform for the Holistic Management of COVID-19.** Stud. Health Technol. Inform. 2020; 273:182-188Kouroubali A, Kondylakis H, Kavlentakis G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087610>
77. **Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study.** Ther. Adv. Respir. Dis. 2020; 14:1753466620963016Procopio G, Cancelliere A, Trecarichi EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070706>
78. **The impact of comprehension of disease-related information and perceptions regarding effects and controllability on protective and social solidarity behaviors with regard to COVID-19.** Z Gesundh Wiss 2020;1-8Danayiyen A, Kavsar Z, Baysan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083202>

Mental – public health (107 articles)

1. **Association of the Covid-19 lockdown with smoking, drinking, and attempts to quit in England: an analysis of 2019-2020 data.** Addiction 2020; Jackson SE, Garnett C, Shahab L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089562>
2. **Necessity to Prioritize Research Activities for a Better Public Health Response to Coronavirus Disease-2019 Pandemic.** Adv Biomed Res 2020; 9:34Shrivastava SR, Shrivastava PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072646>
3. **Psychological Distress Among HIV Healthcare Providers During the COVID-19 Pandemic in China: Mediating Roles of Institutional Support and Resilience.** AIDS Behav. 2020; Tam CC, Sun S, Yang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089356>
4. **Alcohol Use Disorder: A Pre-existing Condition for COVID-19?** Alcohol 2020; Bailey KL, Samuelson DR, Wyatt TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080339>
5. **Are we measuring the same thing? Psychometric and research considerations when adopting new testing modes in the time of COVID-19.** Alzheimers Dement 2020; Booth T, Murray A, Muniz-Terrera G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075205>
6. **A Foundational Assessment of the Effects of the Spread of COVID-19 Virus Infection and Related Activity Restrictions on Mental and Physical Health, Psychological Distress, and Suicidal Ideation in Japan.** Asia Pac. J. Public Health 2020;1010539520965449Kiuchi K, Kishi K, Araki K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070620>
7. **Higher Executive Control Network Coherence Buffers Against Puberty-Related Increases in Internalizing Symptoms During the COVID-19 Pandemic.** Biol Psychiatry Cogn Neurosci Neuroimaging 2020; Chahal R, Kirshenbaum JS, Miller JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097469>
8. **Anxiety, depression, traumatic stress and COVID-19-related anxiety in the UK general population during the COVID-19 pandemic.** BJPsych Open 2020; 6:e125Shevlin M, McBride O, Murphy J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070797>
9. **The immediate effect of COVID-19 pandemic on children and adolescents with obsessive compulsive disorder.** BMC Psychiatry 2020; 20:511Nissen JB, Højgaard D, Thomsen PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081741>
10. **Chinese public's knowledge, perceived severity, and perceived controllability of COVID-19 and their associations with emotional and behavioural reactions, social participation, and precautionary behaviour: a national survey.** BMC Public Health 2020; 20:1589Li JB, Yang A, Dou K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087109>
11. **The burden of anxiety among people living with HIV during the COVID-19 pandemic in Pune, India.** BMC Public Health 2020; 20:1598Marbaniang I, Sangle S, Nimkar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097028>
12. **Immediate impact of stay-at-home orders to control COVID-19 transmission on mental well-being in Bangladeshi adults: Patterns, Explanations, and future directions.** BMC Res. Notes 2020; 13:494Ali M, Ahsan GU, Khan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092649>
13. **Sleep disturbances among physicians during COVID-19 pandemic.** BMC Res. Notes 2020; 13:493Alnofaiey YH, Alshehri HA, Alosaimi MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087166>

14. **Protecting the front line: a cross-sectional survey analysis of the occupational factors contributing to healthcare workers' infection and psychological distress during the COVID-19 pandemic in the USA.** BMJ Open 2020; 10:e042752 Firew T, Sano ED, Lee JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087382>
15. **COVID-19 outbreak-related psychological distress among healthcare trainees: a cross-sectional study in China.** BMJ Open 2020; 10:e041671 Wang Y, Li Y, Jiang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082197>
16. **Resilience during uncertainty? Greater social connectedness during COVID-19 lockdown is associated with reduced distress and fatigue.** Br. J. Health Psychol. 2020; Nitschke JP, Forbes PAG, Ali N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099800>
17. **Chronic pain in the time of COVID-19: Stress aftermath and central sensitization.** Br. J. Health Psychol. 2020; Serrano-Ibáñez ER, Esteve R, Ramírez-Maestre C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099793>
18. **Sudden and persistent disphonia in the framework of COVID-19: the case report of a nurse.** Brain Behav Immun Health 2020;100160 Buselli R, Corsi M, Necciari G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078141>
19. **The cognitive consequences of the COVID-19 epidemic: collateral damage?** Brain Commun 2020; 2:fcaa069 Ritchie K, Chan D, Watermeyer T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074266>
20. **[Not Available].** Can. J. Psychiatry. 2020;706743720963917 Roxanne L, Julia GB, Mathilde L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084359>
21. **Emotional Response of US Breast Cancer Survivors During the COVID-19 Pandemic.** Cancer Invest. 2020;1-13 Papautsky EL, Hamlish T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095660>
22. **How societal responses to COVID-19 could contribute to child neglect.** Child Abuse Negl. 2020;104761 Bérubé A, Clément M, Lafantaisie V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077248>
23. **Invisible children and non-essential workers: Child protection during COVID-19 in Israel according to policy documents and media coverage.** Child Abuse Negl. 2020;104770 Katz C, Cohen N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071026>
24. **Family violence against children in the wake of COVID-19 pandemic: a review of current perspectives and risk factors.** Child Adolesc Psychiatry Ment Health 2020; 14:40 Pereda N, Díaz-Faes DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088340>
25. **A child's right to protection during the COVID-19 crisis: An exploratory study of the Child Protective Services of Estonia.** Child Youth Serv Rev 2020; 119:105568 Toros K, Falch-Eriksen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071404>
26. **High Levels of Stress Due to the SARS-CoV-2 Pandemic among Parents of Children with and without Chronic Conditions across the USA.** Children (Basel) 2020; 7M ALvT, Edlynn E, Maddaloni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096787>
27. **Increased Resilience Weakens the Relationship between Perceived Stress and Anxiety on Sleep Quality: A Moderated Mediation Analysis of Higher Education Students from 7 Countries.** Clocks Sleep 2020; 2:334-353 Du C, Zan MCH, Cho MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089208>

28. **Challenges Experienced by Behavioral Health Organizations in New York Resulting from COVID-19: A Qualitative Analysis.** Community Ment. Health J. 2020; Murphy AA, Karyczak S, Dolce JN *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33095331>
29. **The psychological impact of the coronavirus disease pandemic on hospital workers in Daegu, South Korea.** Compr. Psychiatry 2020; 103:152213Jo SH, Koo BH, Seo WS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096399>
30. **Role of Mass Media and Public Health Communications in the COVID-19 Pandemic.** Cureus 2020; 12:e10453Anwar A, Malik M, Raees V, Anwar A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072461>
31. **COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region.** Curr. Diabetes Rev. 2020; Al Dawish MA, Robert AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087031>
32. **Psychometric data on knowledge and fear of coronavirus disease 2019 and perceived stress among workers of filipino origin in Hong Kong.** Data Brief 2020; 33:106395Li DCY, Leung L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072830>
33. **Psyche and COVID-19: Commitment to plurality in discourse.** Deutsches Arzteblatt International 2020; 117:A1754Bechtold A.
34. **Leadership principles to decrease psychological casualties in COVID-19 and other disasters of uncertainty.** Disaster Med Public Health Prep 2020:1-10Everly GS, Wu AW, Crumpsty-Fowler CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087209>
35. **Psychological Impairment and Coping Strategies during the COVID-19 Pandemic among Students in Pakistan: A Cross-Sectional Analysis.** Disaster Med Public Health Prep 2020:1-22Salman M, Asif N, Mustafa ZU *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087206>
36. **The impact of nationwide alcohol ban during the COVID-19 lockdown on alcohol use-related internet searches and behaviour in India: An infodemiology study.** Drug Alcohol Rev 2020; Singh S, Sharma P, Balhara YPS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090596>
37. **Mental Health Presentations to Christchurch Hospital Emergency Department During COVID-19 Lockdown.** Emerg. Med. Australas. 2020; Joyce LR, Richardson SK, McCombie A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078509>
38. **[The silent psychological impact of the COVID-19 pandemic in Sudan].** Ethics Med Public Health 2020:100604Musa HH, Musa TH, Musa IH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078130>
39. **Epidemiology of mental health problems in COVID-19: a review.** F1000Res 2020; 9:636Hossain MM, Tasnim S, Sultana A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33093946>
40. **Home-Based Transcranial Direct Current Stimulation (tDCS) to Prevent and Treat Symptoms Related to Stress: A Potential Tool to Remediate the Behavioral Consequences of the COVID-19 Isolation Measures?** Front. Integr. Neurosci. 2020; 14:46Castelo-Branco L, Fregni F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071764>
41. **Identifying the Associated Risk Factors of Sleep Disturbance During the COVID-19 Lockdown in Bangladesh: A Web-Based Survey.** Front Psychiatry

- 2020; 11:580268Ara T, Rahman MM, Hossain MA, Ahmed A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33093839>
42. **Moderation Effect of Physical Activity on the Relationship Between Fear of COVID-19 and General Distress: A Pilot Case Study in Arabic Countries.** *Front. Psychol.* 2020; 11:570085Alsah TA, Aljaloud SO, Chalghaf N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071900>
 43. **A Longitudinal Study on the Emotional Impact Cause by the COVID-19 Pandemic Quarantine on General Population.** *Front. Psychol.* 2020; 11:565688Canet-Juric L, Andrés ML, Del Valle M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071893>
 44. **Psychological, Behavioral, and Interpersonal Effects and Clinical Implications for Health Systems of the Coronavirus (COVID-19) Pandemic: A Call for Research.** *Front. Psychol.* 2020; 11:2146Castelnuovo G, De Giorgio A, Manzoni GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071842>
 45. **Adolescents in Quarantine During COVID-19 Pandemic in Italy: Perceived Health Risk, Beliefs, Psychological Experiences and Expectations for the Future.** *Front. Psychol.* 2020; 11:559951Commodari E, La Rosa VL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071884>
 46. **Risk Perceptions and Psychological Effects During the Italian COVID-19 Emergency.** *Front. Psychol.* 2020; 11:580053Lanciano T, Graziano G, Curci A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071920>
 47. **The Psychosocial Fuzziness of Fear in the Coronavirus (COVID-19) Era and the Role of Robots.** *Front. Psychol.* 2020; 11:2245Marchetti A, Di Dio C, Massaro D, Manzi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071853>
 48. **Loneliness in the Era of COVID-19.** *Front. Psychol.* 2020; 11:2219Miller ED.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071848>
 49. **Factors Influencing Mental Health of Medical Workers During the COVID-19 Outbreak.** *Front Public Health* 2020; 8:491Zhang Y, Xie S, Wang P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072685>
 50. **Improving wellbeing among UK doctors redeployed during the COVID-19 pandemic.** *Future Healthc J* 2020; 7:e71-e76Faderani R, Monks M, Peprah D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094261>
 51. **China's mental health support in response to COVID-19: progression, challenges and reflection.** *Global Health* 2020; 16:102Ju Y, Zhang Y, Wang X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092606>
 52. **Prevalence and risk factors of COVID-19 suicidal behavior in Bangladeshi population: are healthcare professionals at greater risk?** *Heliyon* 2020; 6:e05259Mamun MA, Akter T, Zohra F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072926>
 53. **COVID-19 pandemic against mental health services for genocide survivors during commemoration week in Rwanda.** *Heliyon* 2020; 6:e05229Ngamije J, Yadufashije C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072924>
 54. **The mediating effect of the cyberchondria and anxiety sensitivity in the association between problematic internet use, metacognition beliefs, and fear of COVID-19 among Iranian online population.** *Heliyon* 2020; 6:e05135Seyed Hashemi SG, Hosseinneshad S, Dini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072911>
 55. **Breathing CORONA into the PSYCHE: An Interesting Case Series During COVID-19 Pandemic.** *Indian J Otolaryngol Head Neck Surg* 2020;1-4Upadhyay M,

- Tomar LK, Patra P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078126>
56. **Eating disorder pathology and compulsive exercise during the COVID-19 public health emergency: Examining risk associated with COVID-19 anxiety and intolerance of uncertainty.** *Int. J. Eat. Disord.* 2020; Scharmer C, Martinez K, Gorrell S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098579>
 57. **Health-Care Services as a Platform for Building Community Resilience among Minority Communities: An Israeli Pilot Study during the COVID-19 Outbreak.** *Int J Environ Res Public Health* 2020; 17Cohen O, Mahagna A, Shamia A, Slobodin O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081120>
 58. **Prevalence of Stress in Healthcare Professionals during the COVID-19 Pandemic in Northeast Mexico: A Remote, Fast Survey Evaluation, Using an Adapted COVID-19 Stress Scales.** *Int J Environ Res Public Health* 2020; 17Delgado-Gallegos JL, Montemayor-Garza RJ, Padilla-Rivas GR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086744>
 59. **The Use of New Digital Information and Communication Technologies in Psychological Counseling during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Dores AR, Geraldo A, Carvalho IP, Barbosa F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096650>
 60. **The Combined Effect of Perceived COVID-19 Infection Risk at Work and Identification with Work Community with Psychosocial Wellbeing among Finnish Social Sector and Health Care Workers.** *Int J Environ Res Public Health* 2020; 17Finell E, Vainio A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086738>
 61. **Risk Assessment on Continued Public Health Threats: Evidence from China's Stock Market.** *Int J Environ Res Public Health* 2020; 17Gu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096757>
 62. **Association between Physical Activity and Mood States of Children and Adolescents in Social Isolation during the COVID-19 Epidemic.** *Int J Environ Res Public Health* 2020; 17Zhang X, Zhu W, Kang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096659>
 63. **Hospital staff well-being during the first wave of COVID-19: Staff perspectives.** *Int. J. Ment. Health Nurs.* 2020; Digby R, Winton-Brown T, Finlayson F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098222>
 64. **Mental Health and the COVID-19 Crisis: The Hopes and Concerns for Children as Schools Re-open.** *Interchange (Tor : 1984)* 2020:1-16Fontenelle-Tereshchuk D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071449>
 65. **Different impacts of COVID-19-related information sources on public worry: An online survey through social media.** *Internet Interv* 2020:100350Ho HY, Chen YL, Yen CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072524>
 66. **Comparison of hospital worker anxiety in COVID-19 treating and non-treating hospitals in the same city during the COVID-19 pandemic.** *Isr J Health Policy Res* 2020; 9:55Milgrom Y, Tal Y, Finestone AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087169>
 67. **Increases in Loneliness Among Young Adults During the COVID-19 Pandemic and Association With Increases in Mental Health Problems.** *J. Adolesc. Health* 2020; 67:714-717Lee CM, Cadigan JM, Rhew IC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099414>
 68. **The Impact of Physical Distancing Policies During the COVID-19 Pandemic on Health and Well-Being Among Australian Adolescents.** *J. Adolesc. Health* 2020;

- 67:653-661 Munasinghe S, Sperandei S, Freebairn L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33099413>
69. **Mental health and its correlates among children and adolescents during COVID-19 school closure: The importance of parent-child discussion.** *J. Affect. Disord.* 2020; 279:353-360 Tang S, Xiang M, Cheung T, Xiang YT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33099049>
 70. **Cognitive Impairment Is a Common Comorbidity in Deceased COVID-19 Patients: A Hospital-Based Retrospective Cohort Study.** *J. Alzheimers Dis.* 2020; Martín-Jiménez P, Muñoz-García MI, Seoane D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074239>
 71. **Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia.** *J. Alzheimers Dis.* 2020; Matias-Guiu JA, Pytel V, Matías-Guiu J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33074240>
 72. **Impact on Participants of Family Connect, a Novel Program Linking COVID-19 Inpatients' Families With the Frontline Providers.** *J Am Coll Radiol* 2020; Taffel MT, Hochman KA, Chhor CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091384>
 73. **Perceptions of Families of Individuals with Autism Spectrum Disorder during the COVID-19 Crisis.** *J. Autism Dev. Disord.* 2020; Manning J, Billian J, Matson J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090358>
 74. **Predicting Perceived Stress Related to the Covid-19 Outbreak through Stable Psychological Traits and Machine Learning Models.** *J Clin Med* 2020; 9Flesia L, Monaro M, Mazza C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086558>
 75. **Psychological Functioning of Patients Undergoing Oral Surgery Procedures during the Regime Related with SARS-CoV-2 Pandemic.** *J Clin Med* 2020; 9Pylińska-Dąbrowska D, Starzyńska A, Cubała WJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081004>
 76. **An Assessment of the Novel COVISTRESS Questionnaire: COVID-19 Impact on Physical Activity, Sedentary Action and Psychological Emotion.** *J Clin Med* 2020; 9Ugbolue UC, Duclos M, Urzeala C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33086648>
 77. **National Well-Being Measures Before and During the COVID-19 Pandemic in Online Samples.** *J Gen Intern Med* 2020; 1-3VanderWeele TJ, Fulks J, Plake JF, Lee MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078296>
 78. **Mental Health Disorders During the COVID-19 Outbreak in Cyprus.** *J. Med. Life* 2020; 13:300-305 Stylianou N, Samouti G, Samoutis G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072200>
 79. **The Experiences and Perceptions of Health-Care Workers During the COVID-19 Pandemic in Muscat, Oman: A Qualitative Study.** *J. Prim. Care Community Health* 2020; 11:2150132720967514 Al Ghafri T, Al Ajmi F, Anwar H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089729>
 80. **Letter to the editor: Training mental health professionals to provide support in brief telepsychotherapy and telepsychiatry for health workers in the SARS-CoV-2 pandemic.** *J. Psychiatr. Res.* 2020; 131:269-270 Salum GA, Spanemberg L, Hartmann de Souza L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33069059>
 81. **Validation of the COVID-19 Fears Questionnaires for Chronic Medical Conditions: A Scleroderma Patient-centered Intervention Network COVID-19 Cohort study.** *J. Psychosom. Res.* 2020; 139:110271 Wu Y, Kwakkenbos L, Henry RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096402>

82. **Neuroticism and Emotional Risk During the COVID-19 Pandemic.** J Res Pers 2020:104038Kroencke L, Geukes K, Utesch T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071370>
83. **Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada.** J. Subst. Abuse Treat. 2020:108165Wendt DC, Marsan S, Parker D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33097315>
84. **Public health crises and the need for accessible information.** Med. J. Aust. 2020; Meltzer A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089505>
85. **Physical activity moderates the association between parenting stress and quality of life in working mothers during the COVID-19 pandemic.** Ment Health Phys Act 2020; 19:100358Limbers CA, McCollum C, Greenwood E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072187>
86. **Bereavement in Times of COVID-19: A Review and Theoretical Framework.** Omega (Westport) 2020:30222820966928Stroebe M, Schut H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33086903>
87. **Impact of COVID-19 outbreak on the mental health status of undergraduate medical students in a COVID-19 treating medical college: a prospective longitudinal study.** PeerJ 2020; 8:e10164Saraswathi I, Saikarthik J, Senthil Kumar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088628>
88. **Emotional responses to prosocial messages increase willingness to self-isolate during the COVID-19 pandemic.** Pers. Individ. Dif. 2021; 170:110420Heffner J, Vives ML, FeldmanHall O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082614>
89. **The impact of the COVID-19 pandemic on subjective mental well-being: The interplay of perceived threat, future anxiety and resilience.** Pers. Individ. Dif. 2021; 170:110455Paredes MR, Apaolaza V, Fernandez-Robin C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071413>
90. **Health anxiety during the early phases of COVID-19 pandemic in Turkey and its relationship with postpandemic attitudes, hopelessness, and psychological resilience.** Perspect. Psychiatr. Care 2020; Kazan Kızılkurt O, Yılmaz A, Noyan CO, Dilbaz N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073870>
91. **Relationship between the social support and psychological resilience levels perceived by nurses during the COVID-19 pandemic: A study from Turkey.** Perspect. Psychiatr. Care 2020; Kılınç T, Sis Çelik A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33073874>
92. **Disparities in Health Care for Black Patients in Physical Medicine and Rehabilitation in the United States: A Narrative Review.** Pm r 2020; Odonkor CA, Esparza R, Flores LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090686>
93. **Stigmatization of psychiatric and justice-involved populations during the COVID-19 pandemic.** Prog. Neuropsychopharmacol. Biol. Psychiatry 2020:110150Chaimowitz GA, Upfold C, Géa LP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098908>
94. **The Early Impact of the COVID-19 Pandemic on Acute Care Mental Health Services.** Psychiatr. Serv. 2020:appips202000467Abbas MJ, Kronenberg G, McBride M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076794>
95. **Mental Health Status in the Community during the COVID-19-Pandemic.** Psychiatr. Prax. 2020; 47:361-369Kuehner C, Schultz K, Gass P *et al.*

96. **Short report: factors determining perceived stress among medical staff in radiology departments during the COVID-19 outbreak.** Psychol Health Med 2020;1-6Huang L, Wang Y, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080151>
97. **Group teletherapy for first-episode psychosis: Piloting its integration with coordinated specialty care during the COVID-19 pandemic.** Psychol. Psychother. 2020; Wood HJ, Gannon JM, Chengappa KNR, Sarpal DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078496>
98. **Long-term health-related quality of life concerns related to the COVID-19 pandemic: a call to action.** Qual. Life Res. 2020;1-3Bryson WJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073307>
99. **Impact of COVID-19 outbreak on mental health and perceived strain among caregivers tending children with special needs.** Res. Dev. Disabil. 2020; 107:103790Dhiman S, Sahu PK, Reed WR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091712>
100. **Sense of coherence, engagement, and work environment as precursors of psychological distress among non-health workers during the COVID-19 pandemic in Spain.** Saf Sci 2021; 133:105033Ruiz-Frutos C, Ortega-Moreno M, Allande-Cussó R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33046949>
101. **Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study.** Schizophr. Bull. 2020; Fond G, Pauly V, Leone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089862>
102. **Spiritual Health and Stress in Pregnant Women During the Covid-19 Pandemic.** SN Compr Clin Med 2020;1-7Nodoushan RJ, Alimoradi H, Nazari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083694>
103. **Precautionary Measures and Illness Attitudes toward COVID-19 among a Sample of the Kuwaiti Population.** Soc Work Public Health 2020;1-10Al-Sejari MM, Al-Ma'Seb HB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092492>
104. **Efficacy of an online cognitive behavioral therapy program developed for healthcare workers during the COVID-19 pandemic: the REduction of STress (REST) study protocol for a randomized controlled trial.** Trials 2020; 21:870Weiner L, Berna F, Nourry N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087178>
105. **Anxiety levels and obsessive compulsion symptoms of pregnant women during the COVID-19 pandemic.** Turk J Obstet Gynecol 2020; 17:155-160Yassa M, Yassa A, Yirmibeş C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072418>
106. **The impact of comprehension of disease-related information and perceptions regarding effects and controllability on protective and social solidarity behaviors with regard to COVID-19.** Z Gesundh Wiss 2020;1-8Danayiyen A, Kavsar Z, Baysan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083202>
107. **[Clinical and pathogenetic aspects of nervous system impairments in COVID-19].** Zh. Nevrol. Psikiatr. Im. S. S. Korsakova 2020; 120:130-136Kutlubaev MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081458>

Meta-analyses - systematic reviews (18 articles)

1. **Prevalence of liver injury in patients with coronavirus disease 2019 (COVID-19) : a systematic review and meta-analysis.** Acta Gastroenterol. Belg. 2020; 83:454-

- 460Merola E, Pravadelli C, de Pretis G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094594>
2. **The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis.** *Am J Emerg Med* 2020; Sun CY, Sun YL, Li XM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071103>
 3. **Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis.** *Ann. Hepatol.* 2020; Sharma A, Jaiswal P, Kerakhan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075578>
 4. **Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol.** *BMJ Open* 2020; 10:e041383Regmi K, Lwin CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093038>
 5. **Neurological manifestations in COVID-19: a systematic review and meta-analysis.** *Brain Inj.* 2020:1-20Chua TH, Xu Z, King NKK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074036>
 6. **Prevalence and Risk Factors of Thromboembolism among Patients With Coronavirus Disease-19: A Systematic Review and Meta-Analysis.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620967083Kefale B, Tegegne GT, Degu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074717>
 7. **The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis.** *Clin Infect Dis* 2020; Xu J, Teng Y, Shang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079200>
 8. **Value of chest computed tomography scan in diagnosis of COVID-19; a systematic review and meta-analysis.** *Clin Transl Imaging* 2020:1-13Hossein H, Ali KM, Hosseini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072656>
 9. **Incubation period of SARS-CoV-2: A systematic review and meta-analysis.** *Curr. Ther. Res. Clin. Exp.* 2020:100607Wassie GT, Azene AG, Bantie GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071295>
 10. **Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.** *Indian J. Pharmacol.* 2020; 52:313-323Bhattacharyya A, Kumar S, Sarma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078733>
 11. **Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.** *Indian Pacing Electrophysiol J* 2020; Agstam S, Yadav A, Praveen Kumar M, Gupta A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075484>
 12. **Factors Associated with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Iran J. Public Health* 2020; 49:1211-1221Sepandi M, Taghdir M, Alimohamadi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083287>
 13. **Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** *J. Clin. Lab. Anal.* 2020:e23618Cheng L, Li H, Li L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078400>
 14. **The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis.** *J Med Virol* 2020; Wang Y, Chen B, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095513>
 15. **Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions.** *Neurol Sci* 2020; Favas TT, Dev P, Chaurasia RN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089477>

16. **A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?** Pharmacol Res Perspect 2020; 8:e00666Kurdi A, Abutheraa N, Akil L, Godman B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084232>
17. **Critical complications of COVID-19: A descriptive meta-analysis study.** Rev Cardiovasc Med 2020; 21:433-442Vakili K, Fathi M, Pezeshgi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070547>
18. **Admission Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a Pooled Analysis and Meta-summary of Literature.** SN Compr Clin Med 2020;1-6Sachdeva S, Desai R, Gupta U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073173>

Mortality (29 articles)

1. **Correlates of death among SARS-CoV-2 positive veterans: The contribution of lifetime tobacco use.** Addict. Behav. 2020; 113:106692Raines AM, Tock JL, McGrew SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099250>
2. **Evolution to Online Education around the globe during a SARS-CoV-2 Coronavirus (COVID-19) Pandemic: Do develop and underdeveloped cope alike?** Child Youth Serv Rev 2020;105582Qazi J, Naseer K, Qazi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071406>
3. **The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620960797Wijaya I, Andhika R, Huang I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079569>
4. **Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19.** Clin. Cardiol. 2020; Li L, Zhang S, He B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094522>
5. **COVID-19 after heart transplant: Risk of severe progressions and mortality are probably significantly increased.** Deutsches Arzteblatt International 2020; 117:A1814-A1815Siegmund-Schultze N.
6. **Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study.** Diabetes Metab. 2020; Cariou B, Goronflot T, Rimbert A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091555>
7. **Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).** EClinicalMedicine 2020;100591Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078138>
8. **Death due to COVID-19 in an Infant with Combined Immunodeficiencies.** Endocr. Metab. Immune Disord. Drug Targets 2020; Ahanchian H, Moazzen N, Joghatayi SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087035>
9. **Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality.** Eur Heart J Qual Care Clin Outcomes 2020; Mohamed MO, Banerjee A, Clarke S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079204>
10. **Decrease in Hospitalizations and Increase in Deaths during the Covid-19 Epidemic in a Pediatric Hospital, Yaounde-Cameroon and Prediction for the**

- Coming Months.** *Fetal Pediatr Pathol* 2020;1-14 Chelo D, Mekone Nkwelle I, Nguefack F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078968>
11. **Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality-Perspectives.** *Front Public Health* 2020; 8:444 Arokiaaraj MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072682>
 12. **Care of the dying person before and during the COVID-19 pandemic: A quality improvement project.** *Future Healthc J* 2020; 7:e50-e53 Tavabie S, Bass S, Stewart E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094255>
 13. **Impact of COVID-19 prevalence and mode of transmission on mortality cases over WHO regions.** *Health Inf Sci Syst* 2020; 8:35 Makinde OS, Olusola-Makinde OO, Olamide EI, Abiodun GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078072>
 14. **Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada.** *Infection* 2020; Hoffmann C, Wolf E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098532>
 15. **Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.** *Int J Environ Res Public Health* 2020; 17 Faes C, Abrams S, Beckhoven DV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080869>
 16. **Africa's low COVID-19 mortality rate: A paradox?** *Int J Infect Dis* 2020; Lawal Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075535>
 17. **Monitoring the mortality impact of COVID-19 in Europe: What can be learned from 2009 influenza H1N1p mortality studies?** *Int J Infect Dis* 2020; Staadegaard L, Taylor RJ, Spreeuwenberg P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075528>
 18. **Factors Associated with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Iran J. Public Health* 2020; 49:1211-1221 Sepandi M, Taghdir M, Alimohamadi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083287>
 19. **Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia.** *J. Alzheimers Dis.* 2020; Matias-Guiu JA, Pytel V, Matias-Guiu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074240>
 20. **Liver Dysfunction and Its Association with the Risk of Death in COVID-19 Patients: A Prospective Cohort Study.** *J Clin Transl Hepatol* 2020; 8:246-254 Fu L, Fei J, Xu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083246>
 21. **Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study.** *J Epidemiol Glob Health* 2020; Alharthy A, Aletreby W, Faqihi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095982>
 22. **A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality.** *J Infect Public Health* 2020; Serin I, Sari ND, Dogu MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071210>
 23. **Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19.** *J Med Virol* 2020; Yang P, Wang N, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073361>
 24. **Impact of population density on Covid-19 infected and mortality rate in India.** *Model Earth Syst Environ* 2020;1-7 Bhadra A, Mukherjee A, Sarkar K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072850>
 25. **Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults.** *Pathog*

- Immun 2020; 5:312-326Hornick A, Tashtish N, Osnard M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089037>
26. **Transcriptional and proteomic insights into the host response in fatal COVID-19 cases.** Proc Natl Acad Sci U S A 2020; Wu M, Chen Y, Xia H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082228>
 27. **Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study.** Schizophr. Bull. 2020; Fond G, Pauly V, Leone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089862>
 28. **Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach.** Sci Total Environ 2020;142810Li M, Zhang Z, Cao W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097268>
 29. **Survival Analysis of COVID-19 Patients in Russia Using Machine Learning.** Stud. Health Technol. Inform. 2020; 273:223-227Metsker O, Kopanitsa G, Yakovlev A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087616>

Online – IT – Apps (81 articles)

1. **The Impact of Science-Unbased Measures Against COVID-19 in Clinical Decision-Making Process.** AAPS PharmSciTech 2020; 21:293Pimentel JVC, TDOS ES, Filgueiras ABT, Neto MLR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098021>
2. **Blockchain for COVID-19: Review, Opportunities, and a Trusted Tracking System.** Arab J Sci Eng 2020;1-17Marbough D, Abbasi T, Maasmi F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072472>
3. **Understanding and responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of interventions.** BMJ Open 2020; 10:e043010Lyons J, Akbari A, Torabi F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087383>
4. **[Not Available].** Can. J. Psychiatry 2020;706743720963917Roxanne L, Julia GB, Mathilde L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084359>
5. **Analyzing the impact of the media campaign and rapid testing for COVID-19 as an optimal control problem in East Java, Indonesia.** Chaos Solitons Fractals 2020;110364Aldila D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082625>
6. **A Survey on Artificial Intelligence Approaches in Supporting Frontline Workers and Decision Makers for COVID-19 Pandemic.** Chaos Solitons Fractals 2020;110337Rasheed J, Jamil A, Hameed AA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071481>
7. **Evolution to Online Education around the globe during a SARS-CoV-2 Coronavirus (COVID-19) Pandemic: Do develop and underdeveloped cope alike?** Child Youth Serv Rev 2020;105582Qazi J, Naseer K, Qazi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071406>
8. **College students' experience of emergency remote teaching due to COVID-19.** Child Youth Serv Rev 2020; 119:105578Shim TE, Lee SY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071405>
9. **Development, evaluation, and validation of machine learning models for COVID-19 detection based on routine blood tests.** Clin Chem Lab Med 2020; Cabitza F, Campagner A, Ferrari D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079698>

10. **Role of Mass Media and Public Health Communications in the COVID-19 Pandemic.** *Cureus* 2020; 12:e10453Anwar A, Malik M, Raees V, Anwar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072461>
11. **Global Interest in Telehealth During COVID-19 Pandemic: An Analysis of Google Trends™.** *Cureus* 2020; 12:e10487Arshad Ali S, Bin Arif T, Maab H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083187>
12. **Urology Virtual Education Programs During the COVID-19 Pandemic.** *Curr Urol Rep* 2020; 21:50Smigelski M, Movassaghi M, Small A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090272>
13. **A stance data set on polarized conversations on Twitter about the efficacy of hydroxychloroquine as a treatment for COVID-19.** *Data Brief* 2020; 33:106401Mutlu EC, Oghaz T, Jasser J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088880>
14. **Data on factors characterizing the eLearning experience of secondary schoolteachers and university undergraduate students in Jordan.** *Data Brief* 2020; 33:106402Obidat AH, Alquraan M, Obeidat MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072820>
15. **Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber.** *Ecancermedicalscience* 2020; 14:ed104Poudyal BS, Gyawali B, Rondelli D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082856>
16. **Beyond privacy vs. health: a justification analysis of the contact-tracing apps debate in the Netherlands.** *Ethics Inf Technol* 2020;1-5Siffels LE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071607>
17. **Telemedicine in Audiology. Best practice recommendations from the French Society of Audiology (SFA) and the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL).** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Thai-Van H, Bakhos D, Bouccara D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097467>
18. **Telemedicine comes of age during coronavirus disease 2019 (COVID-19): An international survey of oculoplastic surgeons.** *Eur. J. Ophthalmol.* 2020;1120672120965471Assayag E, Tsessler M, Wasser LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073613>
19. **Teacher Learning in Difficult Times: Examining Foreign Language Teachers' Cognitions About Online Teaching to Tide Over COVID-19.** *Front. Psychol.* 2020; 11:549653Gao LX, Zhang LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071866>
20. **Factors Predicting Willingness to Share COVID-19 Misinformation.** *Front. Psychol.* 2020; 11:566108Lobato EJC, Powell M, Padilla LMK, Holbrook C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071894>
21. **Fake News Affecting the Adherence of National Response Measures During the COVID-19 Lockdown Period: The Experience of Vietnam.** *Front Public Health* 2020; 8:589872Nguyen TTP, Nguyen DC, Nguyen ATT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072716>
22. **Utilising video technology in the cardiac catheter lab and operating theatre during the COVID-19 pandemic.** *Future Healthc J* 2020; 7:e39-e40Dulai R, Hadjivassilev S, Veasey RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094251>
23. **Communication in the time of COVID.** *Future Healthc J* 2020; 7:e36-e38Ellis CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094250>

24. **Keep calm and carry on learning: using Microsoft Teams to deliver a medical education programme during the COVID-19 pandemic.** Future Healthc J 2020; 7:e67-e70Henderson D, Woodcock H, Mehta J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094260>
25. **COVID-19 recognition and digital risk stratification.** Future Healthc J 2020; 7:e47-e49Hodgson LE, Leckie T, Hunter A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094254>
26. **Rapid deployment of virtual ICU support during the COVID-19 pandemic.** Future Healthc J 2020; 7:181-184Igra A, McGuire H, Naldrett I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094219>
27. **Remodelling elective hospital services in the COVID-19 era - designing the new normal.** Future Healthc J 2020; 7:e60-e63King LA, Hothi SS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094258>
28. **Respiratory specialists working in different ways: Development of a GP hotline and respiratory support service during the COVID-19 pandemic.** Future Healthc J 2020; 7:e88-e92Kumar K, Mak V, Groom K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094266>
29. **Patient perspectives on social-media-delivered telemedicine for inflammatory bowel disease.** Future Healthc J 2020; 7:241-244O'Neill P, Shandro B, Poullis A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094237>
30. **Virtual visiting and other technological adaptations for critical care.** Future Healthc J 2020; 7:e93-e95Webb H, Parson M, Hodgson LE, Daswani K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094267>
31. **Spine Patient Satisfaction With Telemedicine During the COVID-19 Pandemic: A Cross-Sectional Study.** Global Spine J 2020;2192568220965521Satin AM, Shenoy K, Sheha ED *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089712>
32. **Toward a human-centered use of technology: a stakeholder analysis of harm reduction and CBO staff.** Harm Reduct J 2020; 17:77Aronson ID, Bennett AS, Freeman R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076911>
33. **How can social media analytics assist authorities in pandemic-related policy decisions? Insights from Australian states and territories.** Health Inf Sci Syst 2020; 8:37Yigitcanlar T, Kankanamge N, Preston A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078073>
34. **Smartphone-Based Telemedicine Service at Palliative Care Unit during Nationwide Lockdown: Our Initial Experience at a Tertiary Care Cancer Hospital.** Indian J. Palliat. Care 2020; 26:S31-s35Biswas S, Adhikari SD, Gupta N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088083>
35. **Can google trends search inform us about the population response and public health impact of abrupt change in alcohol policy? - a case study from india during the covid-19 pandemic.** Int. J. Drug Policy 2020; 87:102984Ghosh A, F ER, Krishnan NC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091762>
36. **The Use of New Digital Information and Communication Technologies in Psychological Counseling during the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Dores AR, Geraldo A, Carvalho IP, Barbosa F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33096650>
37. **Spatiotemporal Big Data for PM(2.5) Exposure and Health Risk Assessment during COVID-19.** Int J Environ Res Public Health 2020; 17He H, Shen Y, Jiang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096649>

38. **Is digital technology the magic bullet for performing work at home? Lessons learned for post COVID-19 recovery in hospitality management.** Int J Hosp Manag 2020;102718Chadee D, Ren S, Tang G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071425>
39. **Is digital technology the magic bullet for performing work at home? Lessons learned for post COVID-19 recovery in hospitality management.** Int J Hosp Manag 2021; 92:102718Chadee D, Ren S, Tang G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071425>
40. **Satisfaction with the use of telehealth during COVID-19: An integrative review.** Int J Nurs Stud Adv 2020; 2:100008Andrews E, Berghofer K, Long J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083791>
41. **Rapid telemedicine implementation in the context of the COVID-19 pandemic in an academic pediatric otolaryngology practice.** Int J Pediatr Otorhinolaryngol 2020; 139:110447Govil N, Raol N, Tey CS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080471>
42. **Impact of covid-19 pandemic on dermatology practice: results of a web-based, global survey.** Int J Womens Dermatol 2020; Bhargava S, McKeever C, Kroumpouzou G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072835>
43. **The use of short message service (SMS) to reduce outpatient attendance in ophthalmic clinics during the coronavirus pandemic.** Int. Ophthalmol. 2020;1-8Lai THT, Lee M, Au AKH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078227>
44. **On the fly: Adapting quickly to emergency remote instruction in a family literacy programme.** Int Rev Educ 2020;1-23Kaiper-Marquez A, Wolfe E, Clymer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071304>
45. **Different impacts of COVID-19-related information sources on public worry: An online survey through social media.** Internet Interv 2020;100350Ho HY, Chen YL, Yen CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072524>
46. **The future of telemedicine visits after COVID-19: perceptions of primary care pediatricians.** Isr J Health Policy Res 2020; 9:53Grossman Z, Chodick G, Reingold SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081834>
47. **Synchronous Telemedicine in Allergy: Lessons Learned and Transformation of Care During the COVID-19 Pandemic.** J Allergy Clin Immunol Pract 2020; Thomas I, Siew LQC, Rutkowski K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091636>
48. **Racial and Socioeconomic Disparities in Access to Telehealth.** J Am Geriatr Soc 2020; Rivera V, Aldridge MD, Ornstein K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075143>
49. **Perspective on the increasing role of optical wearables and remote patient monitoring in the COVID-19 era and beyond.** J. Biomed. Opt. 2020; 25Roblyer D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089674>
50. **The Value of Telemedicine for the Follow-up of Patients with New Onset Type 1 Diabetes Mellitus During COVID-19 Pandemic in Turkey: A Report of Eight Cases.** J. Clin. Res. Pediatr. Endocrinol. 2020; Evin F, Er E, Ata A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33084289>
51. **Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic.** J Clin Transl Endocrinol 2020;100238Fung A, Irvine M, Ayub A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072519>

52. **International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases.** J Crohns Colitis 2020; 14:S780-s784Lewin S, Lees C, Regueiro M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085971>
53. **Young people with type 1 diabetes on insulin pump therapy could fast safely during COVID 19 pandemic Ramadan - a telemonitoring experience in Bangladesh.** J Diabetes Investig 2020; Zabeen B, Ahmed B, Nahar J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098746>
54. **Off the Shelf: Rapid Deployment of an Emergency Department Telemedicine Platform Using Readily Available Consumer Products.** J. Emerg. Med. 2020; Lowe J, Shen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097352>
55. **National Well-Being Measures Before and During the COVID-19 Pandemic in Online Samples.** J Gen Intern Med 2020;1-3VanderWeele TJ, Fulks J, Plake JF, Lee MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078296>
56. **Pharmacy Students Perceptions of Their Distance Online Learning Experience During the COVID-19 Pandemic: A Cross-Sectional Survey Study.** J Med Educ Curric Dev 2020; 7:2382120520963039Shawaqfeh MS, Al Bekairy AM, Al-Azayzih A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088916>
57. **Connecting at the Webside: Rapid Telehealth Implementation for Musculoskeletal Clinicians.** J. Orthop. Sports Phys. Ther. 2020;1-14Rethorn ZD, Lee AC, Rethorn TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076758>
58. **Benefits and barriers to pediatric tele-urolgy during the COVID-19 pandemic.** J. Pediatr. Urol. 2020; Winkelman AJ, Beller HL, Morgan KE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077389>
59. **Letter to the editor: Training mental health professionals to provide support in brief telepsychotherapy and telepsychiatry for health workers in the SARS-CoV-2 pandemic.** J. Psychiatr. Res. 2020; 131:269-270Salum GA, Spanemberg L, Hartmann de Souza L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33069059>
60. **Telerobotic ultrasound to provide obstetrical ultrasound services remotely during the COVID-19 pandemic.** J Telemed Telecare 2020;1357633x20965422Adams SJ, Burbridge B, Chatterson L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33076753>
61. **A nutritional web-based approach in obesity and diabetes before and during COVID-19 lockdown.** J Telemed Telecare 2020;1357633x20966933Fratlicelli F, Nicola MD, Vitacolonna E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081596>
62. **Disparities in use of telehealth at the onset of the COVID-19 public health emergency.** J Telemed Telecare 2020;1357633x20963893Pierce RP, Stevermer JJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081595>
63. **Advanced Machine Learning-Based Analytics on COVID-19 Data Using Generative Adversarial Networks.** Mater Today Proc 2020; Vijay Kumar J, Harshavardhan A, Bhukya H, Krishna Prasad AV.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078094>
64. **Public health crises and the need for accessible information.** Med. J. Aust. 2020; Meltzer A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089505>
65. **UNLV Health Sciences Library's Initial Response to the COVID-19 Pandemic: How a Versatile Environment, Online Technologies, and Liaison Expertise Prepared Library Faculty in Supporting Its User Communities.** Med. Ref. Serv. Q. 2020; 39:344-358Weeks A, Houk KM, Nugent RL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085950>

66. **Social Media Survey and Web Posting Assessment of the COVID-19 Response in China: Health Worker Attitudes Toward Preparedness and Personal Protective Equipment Shortages.** Open Forum Infect Dis 2020; 7:ofaa400Huang D, Shu W, Li M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088845>
67. **Emotional responses to prosocial messages increase willingness to self-isolate during the COVID-19 pandemic.** Pers. Individ. Dif. 2021; 170:110420Heffner J, Vives ML, FeldmanHall O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082614>
68. **Implementation of Convolutional Neural Network Approach for COVID-19 Disease Detection.** Physiol Genomics 2020; Irmak E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094700>
69. **Group teletherapy for first-episode psychosis: Piloting its integration with coordinated specialty care during the COVID-19 pandemic.** Psychol. Psychother. 2020; Wood HJ, Gannon JM, Chengappa KNR, Sarpal DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078496>
70. **The role of advanced technologies supplemented with traditional methods in pharmacovigilance sciences.** Recent Pat Biotechnol 2020; Naidu MVS, Sushma DS, Jaiswal V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087036>
71. **Nanotechnology research and patents on coronavirus and COVID-19: a review.** Recent Pat Nanotechnol 2020; Aranda P, Wicklein B, Ruiz-Garcia C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087037>
72. **Usefulness of machine learning in COVID-19 for the detection and prognosis of cardiovascular complications.** Rev Cardiovasc Med 2020; 21:345-352Zimmerman A, Kalra D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070540>
73. **Evaluating the plausible application of advanced machine learnings in exploring determinant factors of present pandemic: A case for continent specific COVID-19 analysis.** Sci Total Environ 2020;142723Chakraborti S, Maiti A, Pramanik S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077215>
74. **Teleophthalmology in the Era of COVID-19: Characteristics of Early Adopters at a Large Academic Institution.** Telemed J E Health 2020; Aguwa UT, Aguwa CJ, Repka M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074795>
75. **Utilization of Asynchronous and Synchronous Teledermatology in a Large Health Care System During the COVID-19 Pandemic.** Telemed J E Health 2020; Kazi R, Evankovich MR, Liu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074786>
76. **How has the COVID-19 pandemic affected tobacco users in India: Lessons from an ongoing tobacco cessation program.** Tob Prev Cessat 2020; 6:53Gupte HA, Mandal G, Jagiasi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083681>
77. **Google Trends Data and COVID-19 in Europe: correlations and model enhancement are European wide.** Transbound Emerg Dis 2020; Sulyok M, Ferenci T, Walker M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085851>
78. **Novel Coronavirus (COVID-19): telemedicine and remote care delivery in a time of medical crisis, implementation, and challenges.** Transl. Behav. Med. 2020; Kronenfeld JP, Penedo FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098426>
79. **Efficacy of an online cognitive behavioral therapy program developed for healthcare workers during the COVID-19 pandemic: the REDuction of STress (REST) study protocol for a randomized controlled trial.** Trials 2020;

- 21:870Weiner L, Berna F, Nourry N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087178>
80. **Sources of information in times of health crisis: evidence from Turkey during COVID-19.** Z Gesundh Wiss 2020:1-7Geçer E, Yıldırım M, Akgül Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072495>
81. **Scoping Review of the Effectiveness of Screen-to-Screen-Therapy compared to Face-to-Face-Therapy on Naming Performance for Patients with Aphasia.** Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2020; Cordes L, Loukanova S, Forstner J.

Other – Miscellaneous (82 articles)

1. **A Perspective About the Construction of the "Hospital de Campanha Porto."** Acta Med Port 2020; Araújo A, Vaz FM, Duarte M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079057>
2. **Effect of COVID-19 outbreak on urban health and environment.** Air Qual Atmos Health 2020:1-9Girdhar A, Kapur H, Kumar V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072226>
3. **Association of COVID-19 distribution with air quality, sociodemographic factors, and comorbidities: an ecological study of US states.** Air Qual Atmos Health 2020:1-11Sarmadi M, Moghaddam VK, Dickerson AS, Martelletti L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078068>
4. **The Concerns, Difficulties, and Stressors of Caring for Pets during COVID-19: Results from a Large Survey of U.S. Pet Owners.** Animals (Basel) 2020; 10Applebaum JW, Tomlinson CA, Matijczak A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076475>
5. **Camping, glamping, and coronavirus in the United States.** Ann Tour Res 2020:103071Craig CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082612>
6. **COVID-19: quarantine, isolation, and lifestyle diseases.** Arch. Physiol. Biochem. 2020:1-5Rehman H, Ahmad MI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086018>
7. **Airborne particulate matter, population mobility and COVID-19: a multi-city study in China.** BMC Public Health 2020; 20:1585Wang B, Liu J, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087097>
8. **Stockpiling in the time of COVID-19.** Br. J. Health Psychol. 2020; Micalizzi L, Zambrotta NS, Bernstein MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080090>
9. **Applying an Indigenous and gender-based lens to the exploration of public health and human rights implications of COVID-19 in Canadian correctional facilities.** Can. J. Public Health. 2020:1-4Ryan C, Sabourin H, Ali A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074479>
10. **Double Trouble: Combined Cardiovascular Effects of Particulate Matter Exposure and COVID-19.** Cardiovasc Res 2020; Tanwar V, Adelstein JM, Wold LE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084879>
11. **Minor covid-19 association with crime in Sweden.** Crime Sci 2020; 9:19Gerell M, Kardell J, Kindgren J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072489>
12. **Impact of people's behavior on the energy sustainability of the residential sector in emergency situations caused by COVID-19.** Energy Build 2020:110532Cvetković D, Nešović A, Terzić I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071442>

13. **Electricity demand during pandemic times: The case of the COVID-19 in Spain.** Energy Policy 2021; 148:111964Santiago I, Moreno-Munoz A, Quintero-Jiménez P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071429>
14. **Time-frequency co-movement between COVID-19, crude oil prices, and atmospheric CO(2) emissions: Fresh global insights from partial and multiple coherence approach.** Environ Dev Sustain 2020:1-21Habib Y, Xia E, Fareed Z, Hashmi SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071606>
15. **Infectious Waste Management Strategy during COVID-19 Pandemic in Africa: an Integrated Decision-Making Framework for Selecting Sustainable Technologies.** Environ. Manage. 2020; Belhadi A, Kamble SS, Khan SAR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095317>
16. **[Not Available].** Ethics Med Public Health 2020:100605Agha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078131>
17. **Micronutrients and bioactive compounds in the immunological pathways related to SARS-CoV-2 (adults and elderly).** Eur. J. Nutr. 2020:1-21Arruda de Souza Monnerat J, Ribeiro de Souza P, Monteiro da Fonseca Cardoso L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084959>
18. **A large national outbreak of COVID-19 linked to air travel, Ireland, summer 2020.** Euro Surveill 2020; 25Murphy N, Boland M, Bambury N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094715>
19. **COVID-19 Highlighting Inequalities in Access to Healthcare in England: A Case Study of Ethnic Minority and Migrant Women.** Fem Leg Stud 2020:1-10Germain S, Yong A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071485>
20. **Learning from SARS: Return and Volatility Connectedness in COVID-19.** Financ Res Lett 2020:101796Bissoondoyal-Bheenick E, Do H, Hu X, Zhong A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082720>
21. **Viewpoint: The future of work in agri-food.** Food Policy 2020:101963Christiaensen L, Rutledge Z, Taylor JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071436>
22. **Airborne Particulate Matter and SARS-CoV-2 Partnership: Virus Hitchhiking, Stabilization and Immune Cell Targeting - A Hypothesis.** Front. Immunol. 2020; 11:579352Farhangrazi ZS, Sancini G, Hunter AC, Moghimi SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072124>
23. **Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context.** Front. Psychol. 2020; 11:565128Bertin P, Nera K, Delouvée S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071892>
24. **Would You Sacrifice Your Privacy to Protect Public Health? Prosocial Responsibility in a Pandemic Paves the Way for Digital Surveillance.** Front. Psychol. 2020; 11:578618Kokkoris MD, Kamleitner B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071918>
25. **Factors Predicting Willingness to Share COVID-19 Misinformation.** Front. Psychol. 2020; 11:566108Lobato EJC, Powell M, Padilla LMK, Holbrook C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071894>
26. **Linguistic Markers of the Emotion Elaboration Surrounding the Confinement Period in the Italian Epicenter of COVID-19 Outbreak.** Front. Psychol. 2020; 11:568281Negri A, Andreoli G, Barazzetti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071896>

27. **The 2020 Coronavirus Pandemic as a Change-Event in Sport Performers' Careers: Conceptual and Applied Practice Considerations.** Front. Psychol. 2020; 11:567966 Samuel RD, Tenenbaum G, Galily Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071895>
28. **Assessing the Impact of Neighborhood Socioeconomic Characteristics on COVID-19 Prevalence Across Seven States in the United States.** Front Public Health 2020; 8:571808 Hatef E, Chang HY, Kitchen C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072710>
29. **With Corona Outbreak: Nature Started Hitting the Reset Button Globally.** Front Public Health 2020; 8:569353 Kumar A, Malla MA, Dubey A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072704>
30. **Editorial: Risk-Based Evidence for Animal Health Policy.** Front Vet Sci 2020; 7:595 Boden LA, Auty HK, Delgado A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088827>
31. **Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2): A Perspective Through the Lens of the Veterinary Diagnostic Laboratory.** Front Vet Sci 2020; 7:576267 Stokol T, McAloose D, Terio KA, Salguero FJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33088836>
32. **The contributions of NHS healthcare workers who are shielding or working from home during COVID-19.** Future Healthc J 2020; 7:e57-e59 Chattopadhyay I, Davies G, Adhiyaman V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094257>
33. **Gender balance in an unprecedented time.** Future Healthc J 2020; 7:212-213 Penfold R, Magee L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094230>
34. **Data and cooperation required for Venezuela's refugee crisis during COVID-19.** Global Health 2020; 16:103 Standley CJ, Chu E, Kathawala E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092609>
35. **Adaptation and destabilization of interpersonal relationships in sport and music during the Covid-19 lockdown.** Heliyon 2020; 6:e05212 Antonini Philippe R, Schiavio A, Biasutti M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072923>
36. **Climatic influence on the magnitude of COVID-19 outbreak: a stochastic model-based global analysis.** Int. J. Environ. Health Res. 2020:1-16 Pramanik M, Chowdhury K, Rana MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090891>
37. **Food Sovereignty of the Indigenous Peoples in the Arctic Zone of Western Siberia: Response to COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17:Bogdanova E, Andronov S, Morell IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080982>
38. **Tourism under the Early Phase of COVID-19 in Four APEC Economies: An Estimation with Special Focus on SARS Experiences.** Int J Environ Res Public Health 2020; 17:Tran BL, Chen CC, Tseng WC, Liao SY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081403>
39. **The future of the chef occupation and the food and beverage sector after the COVID-19 outbreak: Opinions of Turkish chefs.** Int J Hosp Manag 2021; 92:102682 Bucak T, Yiğit S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071426>
40. **Is digital technology the magic bullet for performing work at home? Lessons learned for post COVID-19 recovery in hospitality management.** Int J Hosp Manag 2020:102718 Chadee D, Ren S, Tang G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071425>
41. **Income assurances are a crucial factor in determining public compliance with self-isolation regulations during the COVID-19 outbreak - cohort study in**

- Israel.** Isr J Health Policy Res 2020; 9:54Bodas M, Peleg K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081833>
42. **Sleeping Within Six Feet: Challenging Oregon's Labor Housing COVID-19 Guidelines.** J Agromedicine 2020:1-4Accorsi EK, Samples J, McCauley LA, Shadbeh N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079005>
 43. **Racial and Socioeconomic Disparities in Access to Telehealth.** J Am Geriatr Soc 2020; Rivera V, Aldridge MD, Ornstein K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075143>
 44. **The Post-Pandemic World: between Constitutionalized and Authoritarian Orders - China's Narrative-Power Play in the Pandemic Era.** J Chin Polit Sci 2020:1-39Chang YY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071536>
 45. **Correlations between Meteorological Indicators, Air Quality and the COVID-19 Pandemic in 12 Cities across China.** J Environ Health Sci Eng 2020:1-8Huang H, Liang X, Huang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082960>
 46. **Intersectional Disparities Among Hispanic Groups in COVID-19 Outcomes.** J Immigr Minor Health 2020; Poulson M, Neufeld M, Geary A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090300>
 47. **Reconfiguring and ramping-up ventilator production in the face of COVID-19: Can robots help?** J Manuf Syst 2020; Malik AA, Masood T, Kousar R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082617>
 48. **Susceptibility of livestock and companion animals to COVID-19.** J Med Virol 2020; Sreenivasan CC, Thomas M, Wang D, Li F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090532>
 49. **Impact of Social Distancing on Incidence of Vaccine-Preventable Diseases, South Korea.** J Med Virol 2020; Yun HE, Ryu BY, Choe YJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33079384>
 50. **Cultivating ethical leadership in the recovery of COVID-19.** J. Nurs. Manag. 2020; Markey K, Ventura CAA, C OD, Doody O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098735>
 51. **COVID-19 and its relationship to particulate matter pollution - case study from part of greater chennai, india.** Mater Today Proc 2020; Laxmipriya S, Narayanan RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072525>
 52. **Environmentally sustainable health care: now is the time for action.** Med. J. Aust. 2020; McGain F, Chamberlin M, Milburn J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089530>
 53. **Analysis of robust control method for the flexible manipulator in reliable operation of medical robots during COVID-19 pandemic.** Microsyst Technol 2020:1-14Jayaswal K, Palwalia DK, Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082624>
 54. **The first page.** MMW-Fortschritte der Medizin 2020; 162:3Einecke D.
 55. **Quotations from the time of corona - Travel returnees: Newly rested and shameless.** MMW-Fortschritte der Medizin 2020; 162:35Gieselmann G.
 56. **Corona pandemic: 15-day doctor's note when a parent takes care of a sick child is allowed.** MMW-Fortschritte der Medizin 2020; 162:34Zimmermann GW.
 57. **Coronavirus disease 2019 pandemic promotes the sense of professional identity among nurses.** Nurs. Outlook 2020; Li Z, Zuo Q, Cheng J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077203>
 58. **The impact of COVID-19 on globalization.** One Health 2020:100180Shrestha N, Shad MY, Ulvi O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072836>

59. **Analysis of pedestrian activity before and during COVID-19 lockdown, using webcam time-lapse from Cracow and machine learning.** PeerJ 2020; 8:e10132Szczepanek R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083150>
60. **Fate control and ingroup bias in donation for the fight with the coronavirus pandemic: The mediating role of risk perception of COVID-19.** Pers. Individ. Dif. 2020:110456Li WQ, Li LMW, Jiang D, Liu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071411>
61. **Acceleration of plague outbreaks in the second pandemic.** Proc Natl Acad Sci U S A 2020; Earn DJD, Ma J, Poinar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077604>
62. **Initial economic damage from the COVID-19 pandemic in the United States is more widespread across ages and geographies than initial mortality impacts.** Proc Natl Acad Sci U S A 2020; Polyakova M, Kocks G, Udaloa V, Finkelstein A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082229>
63. **The pandemic exposes human nature: 10 evolutionary insights.** Proc Natl Acad Sci U S A 2020; Seitz BM, Aktipis A, Buss DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093198>
64. **Moving more and sitting less - Now more than ever, an important message for the prevention and treatment of chronic disease and pandemics.** Prog Cardiovasc Dis 2020; Arena R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098845>
65. **Simone de Beauvoir and a period of transition.** Prospects (Paris) 2020:1-7Durygin M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078032>
66. **The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany.** Q. Rev. Econ. Finance 2020; Gandjour A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071532>
67. **Gender differentiated economic responses to crises in developing countries: insights for COVID-19 recovery policies.** Rev Econ Househ 2020:1-16Mohapatra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078059>
68. **Impact of lockdown on particulate matter concentrations in Colombia during the COVID-19 pandemic.** Sci Total Environ 2020:142874Arregocés HA, Rojano R, Restrepo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077220>
69. **No SARS-CoV-2 detected in air samples (pollen and particulate matter) in Leipzig during the first spread.** Sci Total Environ 2020:142881Dunker S, Hornick T, Szczepankiewicz G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097263>
70. **Coronavirus (SARS-CoV-2) in the environment: Occurrence, persistence, analysis in aquatic systems and possible management.** Sci Total Environ 2020:142698Patel M, Chaubey AK, Pittman CU, Jr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097261>
71. **Has COVID-19 halted winter-spring wildfires in the Mediterranean? Insights for wildfire science under a pandemic context.** Sci Total Environ 2020:142793Rodrigues M, Gelabert PJ, Ameztegui A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092845>
72. **Urban wildlife in times of COVID-19: What can we infer from novel carnivore records in urban areas?** Sci Total Environ 2020:142713Silva-Rodríguez EA, Gálvez N, Swan GJF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077221>
73. **Are all voices heard in the COVID-19 debate?** Scientometrics 2020:1-4Benjamins S, de Meijer VE, Pol RA, Haring MPD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071386>

74. **The impact of Covid-19, associated behaviours and policies on the UK economy: A computable general equilibrium model.** SSM Popul Health 2020;100651Keogh-Brown MR, Jensen HT, Edmunds WJ, Smith RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072839>
75. **The International Patient Summary Standard and the Extensibility Requirement.** Stud. Health Technol. Inform. 2020; 273:54-62Kay S, Cangiali G, Nusbaum M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087592>
76. **Unemployment in Switzerland in the wake of the Covid-19 pandemic: an intertemporal perspective.** Swiss J Econ Stat 2020; 156:8Sheldon G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072633>
77. **Tobacco smoking and smoking cessation in times of COVID-19.** Tob Prev Cessat 2020; 6:39Elling JM, Crutzen R, Talhout R, de Vries H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083672>
78. **Behavioral medicine challenges in the shadow of a global pandemic.** Transl. Behav. Med. 2020; Brooks AT, Allen HK, Thornton L, Trevorrow T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098423>
79. **Impact of lockdown on air quality over major cities across the globe during COVID-19 pandemic.** Urban Clim 2020; 34:100719Kumari P, Toshniwal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083215>
80. **COVID-19 and the call for 'Safe Hands': Challenges facing the under-resourced municipalities that lack potable water access - A case study of Chitungwiza municipality, Zimbabwe.** Water Res X 2020; 9:100074Zvobgo L, Do P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089132>
81. **The market-reach of pandemics: Evidence from female workers in Ethiopia's ready-made garment industry.** World Dev 2021; 137:105179Meyer CJ, Hardy M, Witte M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071434>
82. **The impact of comprehension of disease-related information and perceptions regarding effects and controllability on protective and social solidarity behaviors with regard to COVID-19.** Z Gesundh Wiss 2020:1-8Danayiyen A, Kavsar Z, Baysan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083202>

Pathology (8 articles)

1. **Neuroinvasive potential of SARS-CoV2 with neuroradiological and neuropathological findings: is the brain a target or a victim?** APMIS 2020; Franca RA, Uggla L, Guadagno E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098147>
2. **Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19.** Clin Infect Dis 2020; Basile K, McPhie K, Carter I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098412>
3. **German and Chinese dataset on attitudes regarding COVID-19 policies, perception of the crisis, and belief in conspiracy theories.** Data Brief 2020:106384Rieger MO, He-Ulbricht Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072819>
4. **Acute respiratory syndrome in COVID-19: Autopsies show some pathophysiological differences to influenza.** Deutsches Arzteblatt International 2020; 117:A1746Siegmund-Schultze N.
5. **The practice of cytopathology during the era of COVID-19: challenges and changes.** Diagn. Histopathol. (Oxf.) 2020; Baskota SU, Chandra A, Cross P.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072189>

6. **Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing2.** *Infect. Agent. Cancer* 2020; 15:61Ajenifuja KO, Belinson J, Goldstein A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072179>
7. **Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.** *Pathology* 2020; Kaufer AM, Theis T, Lau KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070960>
8. **Transcriptional and proteomic insights into the host response in fatal COVID-19 cases.** *Proc Natl Acad Sci U S A* 2020; Wu M, Chen Y, Xia H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082228>

Protection (36 articles)

1. **Daylight-Induced Antibacterial and Antiviral Cotton Cloth for Offensive Personal Protection.** *ACS Appl Mater Interfaces* 2020; Tang P, Zhang Z, El-Moghazy AY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090782>
2. **[Lack of Personal Protective Equipment in Brazil].** *Acta Med Port* 2020; Coelho da Maia ME, Dreer M, Baggio A, Marcon CEM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092688>
3. **Reprocessing N95s with Hydrogen peroxide vaporization: A robust system from collection to dispensing.** *Am. J. Infect. Control* 2020; Weinheimer CM, Ellsworth M, Ferguson L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091511>
4. **Peri-operative COVID-19 infection in urgent elective surgery during a pandemic surge period: a retrospective observational cohort study.** *Anaesthesia* 2020; Kane AD, Paterson J, Pokhrel S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090469>
5. **Does elective orthopaedic surgery in the pandemic era increase the risk of developing COVID-19? A combined analysis of retrospective and prospective study at a national tertiary hospital in Jakarta, Indonesia.** *Ann Med Surg (Lond)* 2020; Kamal AF, Widodo W, Kuncoro MW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078074>
6. **Oral hygiene habits and possible transmission of COVID-19 among cohabitants.** *BMC Oral Health* 2020; 20:286González-Olmo MJ, Delgado-Ramos B, Ruiz-Guillén A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076880>
7. **Scale validation for the identification of falsified hand sanitizer: public and regulatory authorities perspectives from United Arab Emirates.** *BMC Public Health* 2020; 20:1595Jairoun AA, Al-Hemyari SS, Shahwan M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33092568>
8. **Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol.** *BMJ Open* 2020; 10:e041383Regmi K, Lwin CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33093038>
9. **SARS CoV-2 Surveillance and Exposure in the Perioperative Setting with Universal testing and Personal Protective Equipment (PPE) Policies.** *Clin Infect Dis* 2020; Aslam A, Singh J, Robilotti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090210>
10. **The pharmaceutical practice of mask distribution by pharmacists in Taiwan's community pharmacies under the Mask Real-Name System, in response to the**

- COVID-19 outbreak.** Cost Eff Resour Alloc 2020; 18:45Lin CH, Lin YW, Wang JY, Lin MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088224>
11. **New data about Sexually transmitted COVID19.** Dermatol Ther 2020:e14426Tatu AL, Nadasdy T, Nwabudike LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073446>
 12. **Preventive Measures for COVID-19 in Dental Treatments.** Disaster Med Public Health Prep 2020:1-13Guo J, Xie H, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092676>
 13. **COVID-19 Creating another problem? Sustainable solution for PPE disposal through LCA approach.** Environ Dev Sustain 2020:1-15Kumar H, Azad A, Gupta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071605>
 14. **How can we minimize the potential risk of viral contamination during laparoscopic procedures for suspected or infected COVID-19 patients?** Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 255:63-66Chene G, Bouvet L, Cerruto E, Nohuz E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086141>
 15. **Initial COVID-19 Transmissibility and Three Gaseous Air Pollutants (NO(2), SO(2), and CO): A Nationwide Ecological Study in China.** Front Med (Lausanne) 2020; 7:575839Ran J, Zhao S, Han L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072788>
 16. **Utilising video technology in the cardiac catheter lab and operating theatre during the COVID-19 pandemic.** Future Healthc J 2020; 7:e39-e40Dulai R, Hadjivassilev S, Veasey RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094251>
 17. **Environmental contamination in a COVID-19 intensive care unit (ICU) - what is the risk?** Infect Control Hosp Epidemiol 2020:1-28Ong SWX, Lee PH, Tan YK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081858>
 18. **Study on the Relationship between Leisure Activity Participation and Wearing a Mask among Koreans during COVID-19 Crisis: Using TPB Model.** Int J Environ Res Public Health 2020; 17Kim YJ, Cho JH, Kang SW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096689>
 19. **Breath-, air- and surface-borne SARS-CoV-2 in hospitals.** J Aerosol Sci 2020:105693Zhou L, Yao M, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078030>
 20. **Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2.** J Dent Res 2020:22034520967933Carrouel F, Gonçalves LS, Conte MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089717>
 21. **Use, reuse or discard: quantitatively defined variance in the functional integrity of N95 respirators following vaporized hydrogen peroxide decontamination during the COVID-19 pandemic.** J Hosp Infect 2020; Levine C, Grady C, Block T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075406>
 22. **The Effects of the Face Mask on the Skin Underneath: A Prospective Survey During the COVID-19 Pandemic.** J. Prim. Care Community Health 2020; 11:2150132720966167Techasatian L, Lebsing S, Uppala R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084483>
 23. **Personal protective equipment and infection prevention and control: a national survey of UK medical students and interim foundation doctors during the COVID-19 pandemic.** J Public Health (Oxf) 2020; Norton EJ, Georgiou I, Fung A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094815>

24. **Reusable masks for COVID-19: A missing piece of the microplastic problem during the global health crisis.** Mar. Pollut. Bull. 2020; 161:111777 Shruti VC, Pérez-Guevara F, Elizalde-Martínez I, Kutralam-Muniasamy G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099058>
25. **Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2.** mSphere 2020; 5Ueki H, Furusawa Y, Iwatsuki-Horimoto K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087517>
26. **Enhancing the filtration efficiency and wearing time of disposable surgical masks using TENG technology.** Nano Energy 2021; 79:105434 Zhang R, Xu Q, Bai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33042770>
27. **Social Media Survey and Web Posting Assessment of the COVID-19 Response in China: Health Worker Attitudes Toward Preparedness and Personal Protective Equipment Shortages.** Open Forum Infect Dis 2020; 7:ofaa400 Huang D, Shu W, Li M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088845>
28. **Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.** Pathology 2020; Kaufer AM, Theis T, Lau KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070960>
29. **Upper-room ultraviolet air disinfection might help to reduce COVID-19 transmission in buildings: a feasibility study.** PeerJ 2020; 8:e10196 Beggs CB, Avital EJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083158>
30. **Home-made masks with filtration efficiency for nano-aerosols for community mitigation of COVID-19 pandemic.** Public Health 2020; 188:42-50 Li IW, Fan JK, Lai AC, Lo CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075669>
31. **Spanish radiographers' concerns about the COVID-19 pandemic.** Radiography (Lond) 2020; Ruiz C, Llopis D, Roman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087309>
32. **Airborne spread of infectious SARS-CoV-2: Moving forward using lessons from SARS-CoV and MERS-CoV.** Sci Total Environ 2020:142802 da Silva PG, Nascimento MSJ, Soares RRG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071145>
33. **Assessing and managing the risks of COVID-19 in the workplace: Applying industrial hygiene (IH)/occupational and environmental health and safety (OEHS) frameworks.** Toxicol. Ind. Health 2020:748233720967522 Zisook RE, Monnot A, Parker J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085585>
34. **Hand Hygiene Knowledge and Practices among Domestic Hajj Pilgrims: Implications for Future Mass Gatherings Amidst COVID-19.** Trop Med Infect Dis 2020; 5Mahdi H, Alqahtani A, Barasheed O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081118>
35. **A new form of irritant rhinitis to filtering facepiece particle (FFP) masks (FFP2/N95/KN95 respirators) during COVID-19 pandemic.** World Allergy Organ J 2020; 13:100474 Klimek L, Huppertz T, Alali A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33042359>
36. **[Interpretation for the group standards in technical specification for health risk investigation of central air conditioning ventilation system during coronavirus disease 2019 epidemic].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1381-1384 Jia YP, Cao GQ, Zhao R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076588>

Pulmonary disease (23 articles)

1. **Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: Preliminary experience.** Am J Emerg Med 2020; Fang Y, Zhou J, Ding X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071084>
2. **Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?** Am J Respir Crit Care Med 2020; Caviades I, Soto R, Torres A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085901>
3. **Pulmonary Vasculature: A Target for COVID-19.** Am J Respir Crit Care Med 2020; Chen L, Tang R, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085902>
4. **Single-cell analysis identified lung progenitor cells in COVID-19 patients.** Cell Prolif. 2020:e12931 Zhao Z, Zhao Y, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094537>
5. **A Novel Case of Severe Respiratory Symptoms and Persistent Pulmonary Hypertension in a Saudi Neonate With SARS-CoV-2 Infection.** Cureus 2020; 12:e10472 Algadeeb KB, AlMousa HH, AlKadhem SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083174>
6. **Acute respiratory syndrome in COVID-19: Autopsies show some pathophysiological differences to influenza.** Deutsches Arzteblatt International 2020; 117:A1746 Siegmund-Schultze N.
7. **Aspergillosis Complicating Severe Coronavirus Disease.** Emerg Infect Dis 2020; 27:Marr KA, Platt A, Tornheim JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084566>
8. **Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients.** Febs j 2020; Zeng HL, Di C, Yan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098359>
9. **The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection.** Front Cell Infect Microbiol 2020; 10:550571 Branco A, Sato MN, Alberca RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072624>
10. **Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.** Front Med (Lausanne) 2020; 7:539 Chaudhary S, Natt B, Bime C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072773>
11. **Inflammasome formation in the lungs of patients with fatal COVID-19.** Inflamm Res 2020:1-4 Toldo S, Bussani R, Nuzzi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079210>
12. **Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).** Int J Occup Environ Med 2020; 11:157-178 Maveddat A, Mallah H, Rao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098401>
13. **Case report of sequential bilateral spontaneous pneumothorax in a never-ventilated, lung-healthy COVID-19-patient.** Int. J. Surg. Case Rep. 2020; 75:441-445 Caviessel C, Weiss L, Haessig G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076191>
14. **COVID-19 Pneumonia Resembling an Acute Exacerbation of Interstitial Pneumonia.** Intern Med 2020; Kitayama T, Kitamura H, Hagiwara E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087668>
15. **Microcirculation alterations in severe COVID-19 pneumonia.** J Crit Care 2020; 61:73-75 Kanoore Edul VS, Caminos Eguillor JF, Ferrara G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096349>
16. **COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema.** New Microbes New Infect 2020:100785 Zayet S,

- Klopfenstein T, Mezher C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072337>
17. **Spontaneous Pneumothorax in an Elderly Patient With Coronavirus Disease (COVID-19) Pneumonia.** Ochsner J 2020; 20:343-345 Rehman T, Josephson G, Sunbuli M, Chadaga AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071674>
 18. **SARS-CoV-2 in pleural fluid in a kidney transplant patient.** Postgrad. Med. 2020; Bennett D, Franchi F, De Vita E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070680>
 19. **Critically Ill Patients with COVID-19: A Narrative Review on Prone Position.** Pulm Ther 2020;1-14 Qadri SK, Ng P, Toh TSW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085052>
 20. **Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity.** Respir Med X 2020; 2:100023 Wigén J, Löfdahl A, Bjermer L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083782>
 21. **SARS-CoV-2 Detection on Bronchoalveolar Lavage: An Italian Multicenter experience.** Respiration 2020;1-9 Patrucco F, Albera C, Bellocchia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075793>
 22. **Letter from the UK.** Respirology 2020; Diver S, Brightling C, Ohri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078495>
 23. **Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients.** Ultrasound Med. Biol. 2020; Bennett D, De Vita E, Mezzasalma F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082053>

Renal disease (10 articles)

1. **Multivariate analysis of CT imaging, laboratory, and demographical features for prediction of acute kidney injury in COVID-19 patients: a Bi-centric analysis.** Abdom Radiol (NY) 2020; Hectors SJ, Riyahi S, Dev H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098478>
2. **Impact of obesity, fasting plasma glucose level, blood pressure, and renal function on the severity of COVID-19: a matter of sexual dimorphism?** Diabetes Res Clin Pract 2020;108515 Huh K, Lee R, Ji W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096185>
3. **The CHIR Score for Evaluating the Hyperimmune Response in COVID-19: A Preliminary Concept.** Front Public Health 2020; 8:550933 Goyal DK, Mansab F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072695>
4. **Psychosocial Burdens of a Renal Transplant Recipient with COVID-19.** Indian J. Palliat. Care 2020; 26:S168-s169 Haokip N, Rathore P, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088113>
5. **COVID-19 Infection in ESKD: Findings from a Prospective Disease Surveillance Program at Dialysis Facilities in New York City and Long Island.** J Am Soc Nephrol 2020; Weiss S, Bhat P, Del Pilar Fernandez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077614>
6. **Cardiorenal tissues express SARS-CoV-2 entry genes and basigin (BSG/CD147) increases with age in endothelial cells.** JACC Basic Transl Sci 2020; Ahmetaj-Shala B, Vaja R, Atanur SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073064>

7. **[Renal Replacement Therapy for Acute Kidney Injury in COVID-19 Patients in Latin America].** Kidney Blood Press. Res. 2020;1-9Claire-Del Granado R, Casas-Aparicio G, Rosa-Diez G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080608>
8. **Caring for Dialysis Patients in a Time of COVID-19.** Kidney Med 2020; Verma A, Patel AB, Tio MC, Waikar SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073227>
9. **High prevalence of Afro-Caribbean ethnicity and hypoglycaemia in patients with diabetes and end stage renal disease hospitalised with COVID-19.** Nephrology (Carlton) 2020; Corcillo A, Cohen S, Game D, Karalliedde J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099858>
10. **SARS-CoV-2 in pleural fluid in a kidney transplant patient.** Postgrad. Med. 2020; Bennett D, Franchi F, De Vita E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070680>

Reviews (36 articles)

1. **Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.** Acta Pharm Sin B 2020; Bian J, Li Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072500>
2. **Myocarditis Associated With COVID-19.** Am J Med Case Rep 2020; 8:498-502Oleszak F, Maryniak A, Botti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088905>
3. **Immunity and Coagulation/Fibrinolytic Processes may Reduce the Risk of Severe Illness in Pregnant Women with COVID-19.** Am J Obstet Gynecol 2020; Zhong Y, Cao Y, Zhong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098813>
4. **SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations.** Anal. Bioanal. Chem. 2020:1-23Jayamohan H, Lambert CJ, Sant HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073312>
5. **Hemoadsorption cartridge and coronavirus disease 2019 infections: A case report and brief literature review.** Artif. Organs 2020; Melegari G, Bertellini E, Melegari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084021>
6. **COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature.** Cardiorenal Med. 2020:1-8Mahajan P, Dass B, Radhakrishnan N, McCullough PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091905>
7. **Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment.** Cardiovasc. Drugs Ther. 2020:1-15Gasecka A, Borovac JA, Guerreiro RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074525>
8. **The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620960797Wijaya I, Andhika R, Huang I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079569>
9. **SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review.** Ecancermedicallscience 2020; 14:1100Haradaa G, Antonacio FF, Gongora AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082850>

10. **Atrial fibrillation in COVID-19: A review of possible mechanisms.** Faseb.j 2020; 34:11347-11354 Stone E, Kiat H, McLachlan CS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33078484>
11. **COVID-19 Pandemic and Neurological Disease: A Critical Review of the Existing Literature.** Hosp Pract Res 2020; 5:81-86 Assari S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33094214>
12. **A Viewpoint On Potential Biomarkers For Infectious COVID-19 severity: An Updated Literature Survey.** Infect Disord Drug Targets 2020; Mali SN, Mohajer F, Ziarani GM, Pratap AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076812>
13. **Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State, Nigeria.** Int J Infect Dis 2020; Abayomi A, Odukoya O, Osibogun A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075534>
14. **Satisfaction with the use of telehealth during COVID-19: An integrative review.** Int J Nurs Stud Adv 2020; 2:100008 Andrews E, Berghofer K, Long J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083791>
15. **Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review.** Int. J. Surg. Case Rep. 2020; 76:409-414 Rodriguez-Nakamura RM, Gonzalez-Calatayud M, Martinez Martinez AR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083204>
16. **Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar.** J Am Coll Cardiol 2020; 76:1999-2010 Pinney SP, Giustino G, Halperin JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092736>
17. **How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy.** J. Clin. Neurosci. 2020; 79:231-236 Armocida D, Palmieri M, Frati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070902>
18. **Awake prone positioning for COVID-19 hypoxemic respiratory failure: A rapid review.** J Crit Care 2020; 61:63-70 Weatherald J, Solverson K, Zuege DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096347>
19. **Child and Family Outcomes Following Pandemics: A Systematic Review and Recommendations on COVID-19 Policies.** J. Pediatr. Psychol. 2020; V CF, Iarocci G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083817>
20. **The use of lung ultrasound during the COVID-19 pandemic: A narrative review with specific focus on its role in pregnancy.** J. Popul. Ther. Clin. Pharmacol. 2020; 27:e64-e75 Youssef A, Cavalera M, Azzarone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084260>
21. **Clinical Nutrition Research and the COVID-19 Pandemic: A Scoping Review of the ASPEN COVID-19 Nutrition Taskforce.** JPEN J. Parenter. Enteral Nutr. 2020; Mechanick JI, Carbone S, Dickerson RN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094848>
22. **Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2.** Mayo Clin Proc Innov Qual Outcomes 2020; Stevens RW, Rivera CG, Saleh OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073177>
23. **A long known syndrome in a new disease.** MMW-Fortschritte der Medizin 2020; 162:28 Holzgreve H.
24. **Seizure And COVID-19: Association and Review of Potential Mechanism.** Neurol Psychiatry Brain Res 2020; Joseph R, Narula N, Daouk A *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071468>
25. **Seizure and COVID-19: Association and review of potential mechanism.** Neurol Psychiatry Brain Res 2020; 38:49-53 Narula N, Joseph R, Katyal N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071468>
 26. **Bereavement in Times of COVID-19: A Review and Theoretical Framework.** Omega (Westport) 2020;30222820966928 Stroebe M, Schut H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33086903>
 27. **Anti-inflammatory effects of cordycepin: A review.** Phytother. Res. 2020; Tan L, Song X, Ren Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090621>
 28. **Disparities in Health Care for Black Patients in Physical Medicine and Rehabilitation in the United States: A Narrative Review.** Pm r 2020; Odonkor CA, Esparza R, Flores LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090686>
 29. **Potential Neurological Manifestations of COVID-19: A Narrative Review.** Postgrad. Med. 2020; Pergolizzi JV, Jr., Raffa RB, Varrassi G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089707>
 30. **The pandemic exposes human nature: 10 evolutionary insights.** Proc Natl Acad Sci U S A 2020; Seitz BM, Aktipis A, Buss DM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33093198>
 31. **Nanotechnology research and patents on coronavirus and COVID-19: a review.** Recent Pat Nanotechnol 2020; Aranda P, Wicklein B, Ruiz-Garcia C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087037>
 32. **[Coronavirus disease 2019 (COVID-19) and ageism: a narrative review of the literature].** Rev Esp Geriatr Gerontol 2020; Tarazona-Santabalbina FJ, de la Cámara de Las Heras JM, Vidán MT, García Navarro JA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33077254>
 33. **Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review.** Rev Med Virol 2020; Comber L, Walsh KA, Jordan K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091200>
 34. **Three-tier stratification for CNS COVID-19 to help decide which patients should undergo lumbar puncture with CSF analysis: A case report and literature review.** Rom. J. Intern. Med. 2020; Ramakrishna JM, Libertin CR, Siegel J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098636>
 35. **Liver injury in COVID-19: A minireview.** World J Clin Cases 2020; 8:4303-4310 Zhao JN, Fan Y, Wu SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083389>
 36. **Review of inflammatory bowel disease and COVID-19.** World J. Gastroenterol. 2020; 26:5534-5542 Sultan K, Mone A, Durbin L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33088153>

Risk factors (51 articles)

1. **Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.** Acta Pharm Sin B 2020; Bian J, Li Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072500>
2. **Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis.** Ann. Hepatol. 2020; Sharma A, Jaiswal P, Kerakhan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075578>
3. **Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease.** Biochim Biophys Acta Mol Cell Biol Lipids 2020;

1866:158839Pimentel LL, Rodríguez-Alcalá LM.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33080357>

4. **A Biomarker Based Severity Progression Indicator for COVID-19: The Kuwait Prognosis Indicator Score.** Biomarkers 2020;1-21Jamal MH, Doi SA, AlYouha S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090050>
5. **The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study.** BMC Infect. Dis. 2020; 20:777Omrani AS, Almaslamani MA, Daghfal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076848>
6. **Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China.** BMC Med 2020; 18:330Yang R, Mei H, Zheng T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070775>
7. **Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19.** Clin. Cardiol. 2020; Li L, Zhang S, He B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094522>
8. **Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis.** Clin. Hemorheol. Microcirc. 2020; Nugroho J, Wardhana A, Mulia EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074221>
9. **Clinical Predictors of COVID-19 Disease Progression and Death: Analysis of 214 Hospitalized Patients from Wuhan, China.** Clin. Respir. J. 2020; Liu J, Liu Z, Jiang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090710>
10. **New data about Sexually transmitted COVID19.** Dermatol Ther 2020:e14426Tatu AL, Nadasdy T, Nwabudike LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073446>
11. **COVID-19 after heart transplant: Risk of severe progressions and mortality are probably significantly increased.** Deutsches Arzteblatt International 2020; 117:A1814-A1815Siegmond-Schultze N.
12. **Diabetes, D-dimer and COVID-19: The possible role of glucose control.** Diabetes Metab Syndr 2020; 14:1987Ceriello A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080539>
13. **The role of androgens in COVID-19.** Diabetes Metab Syndr 2020; 14:2003-2006Moradi F, Enjezab B, Ghadiri-Anari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091758>
14. **Impact of obesity, fasting plasma glucose level, blood pressure, and renal function on the severity of COVID-19: a matter of sexual dimorphism?** Diabetes Res Clin Pract 2020;108515Huh K, Lee R, Ji W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096185>
15. **Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients.** Electromagn. Biol. Med. 2020;1-15Vergallo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073612>
16. **Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 patients.** Eur. J. Immunol. 2020; Oja AE, Saris A, Ghandour CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073359>
17. **Renin angiotensin system at the interface of COVID-19 infection.** Eur. J. Pharmacol. 2020;173656Gul R, Uh-Hyun K, Alfadda AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086029>

18. **Alopecia and Gray Hair Are Associated with COVID-19 Severity.** Exp. Dermatol. 2020; Ramos PM, Ianhez M, Miot HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098701>
19. **The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection.** Front Cell Infect Microbiol 2020; 10:550571 Branco A, Sato MN, Alberca RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072624>
20. **Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China.** Front. Endocrinol. (Lausanne) 2020; 11:571037 Zhang N, Wang C, Zhu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071977>
21. **Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology.** Front. Immunol. 2020; 11:560381 Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072099>
22. **Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity.** Hum Genomics 2020; 14:40 Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092637>
23. **Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.** Inflamm. Bowel Dis. 2020; Burke KE, Kochar B, Allegretti JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089863>
24. **Immune system changes during COVID-19 recovery play key role in determining disease severity.** Int. J. Immunopathol. Pharmacol. 2020; 34:2058738420966497 Fathi F, Sami R, Mozafarpour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076729>
25. **Higher binding affinity of Furin to SARS-CoV-2 spike (S) protein D614G could be associated with higher SARS-CoV-2 infectivity.** Int J Infect Dis 2020; Mohammad A, Alshawaf E, Marafie SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075532>
26. **Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19.** Int. J. Lab. Hematol. 2020; Liu L, Zheng Y, Cai L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099889>
27. **Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19.** J. Cardiovasc. Pharmacol. Ther. 2020:1074248420967792 Salah HM, Mehta JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078623>
28. **Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** J. Clin. Lab. Anal. 2020:e23618 Cheng L, Li H, Li L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078400>
29. **Factors associated with clinical outcomes in patients with Coronavirus Disease 2019 in Guangzhou, China.** J Clin Virol 2020; 133:104661 Lei C, Lin W, Deng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096290>
30. **Factors associated with the poor outcomes in diabetic patients with COVID-19.** J Diabetes Metab Disord 2020:1-10 Rastad H, Ejtahed HS, Mahdavi-Ghorabi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072634>
31. **Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study.** J Epidemiol Glob Health 2020; Alharthy A, Aletreby W, Faqihi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095982>

32. **CoVA: An Acuity Score for Outpatient Screening that Predicts COVID-19 Prognosis.** J Infect Dis 2020; Sun H, Jain A, Leone MJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33098643>
33. **Associations between genetically predicted protein levels and COVID-19 severity.** J Infect Dis 2020; Zhu J, Wu C, Wu L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33083826>
34. **Early Clinical Factors Predicting the Development of Critical Disease in Japanese Patients with COVID-19: A Single-Center, Retrospective, Observational Study.** J Med Virol 2020; Higuchi T, Nishida T, Iwahashi H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33090527>
35. **Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19.** J Med Virol 2020; Yang P, Wang N, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073361>
36. **Why Does COVID-19 Affect Patients with Spinal Cord Injury Milder? A Case-Control Study: Results from Two Observational Cohorts.** J Pers Med 2020; 10Calvo E, Corbacho-Alonso N, Sastre-Oliva T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33096722>
37. **The potential use of ABO blood group system for risk stratification of COVID-19.** Med. Hypotheses 2020; 145:110343AbdelMassih AF, Mahrous R, Taha A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33086161>
38. **Integrative analysis for COVID-19 patient outcome prediction.** Med. Image Anal. 2020; 67:101844Chao H, Fang X, Zhang J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091743>
39. **High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19.** Mol. Immunol. 2020; 128:64-68Guirao JJ, Cabrera CM, Jiménez N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075636>
40. **High prevalence of Afro-Caribbean ethnicity and hypoglycaemia in patients with diabetes and end stage renal disease hospitalised with COVID-19.** Nephrology (Carlton) 2020; Corcillo A, Cohen S, Game D, Karalliedde J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33099858>
41. **Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults.** Pathog Immun 2020; 5:312-326Hornick A, Tashtish N, Osnard M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33089037>
42. **Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection.** An Pediatr (Engl Ed) 2020; Storch-de-Gracia P, Leoz-Gordillo I, Andina D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083499>
43. **Risk factors for the critical illness in SARS-CoV-2 infection: a multicenter retrospective cohort study.** Respir Res 2020; 21:277Cheng S, Wu D, Li J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33087114>
44. **Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.** Rev Cardiovasc Med 2020; 21:339-344Zhang J, McCullough PA, Tecson KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070539>
45. **Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy.** Rev Cardiovasc Med 2020; 21:315-319Zhang J, Tecson KM, McCullough PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070537>

46. **Can Traditional Chinese Medicine provide insights into controlling the COVID-19 pandemic: Serpentinization-induced lithospheric long-wavelength magnetic anomalies in Proterozoic bedrocks in a weakened geomagnetic field mediate the aberrant transformation of biogenic molecules in COVID-19 via magnetic catalysis.** Sci Total Environ 2020:142830Bility MT, Agarwal Y, Ho S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071142>
47. **Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach.** Sci Total Environ 2020:142810Li M, Zhang Z, Cao W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097268>
48. **EEG findings and clinical prognostic factors associated with mortality in a prospective cohort of inpatients with COVID-19.** Seizure 2020; 83:1-4Skorin I, Carrillo R, Perez CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075670>
49. **Admission Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a Pooled Analysis and Meta-summary of Literature.** SN Compr Clin Med 2020:1-6Sachdeva S, Desai R, Gupta U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073173>
50. **Pregnancy worsens the morbidity of COVID-19 and this effect becomes more prominent as pregnancy advances.** Turk J Obstet Gynecol 2020; 17:149-154Tug N, Yassa M, Köle E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072417>
51. **Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients.** World J Clin Cases 2020; 8:4370-4379Wang L, He WB, Yu XM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083396>

Safety (17 articles)

1. **COVID-19, Hypercoagulability and Cautiousness with Convalescent Plasma.** Am J Respir Crit Care Med 2020; Sanfilippo F, La Rosa V, Oliveri F, Astuto M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085908>
2. **Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.** Antiviral Res 2020:104955Choi SW, Shin JS, Park SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091434>
3. **The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.** BMC Infect. Dis. 2020; 20:786Gharebaghi N, Nejadrahim R, Mousavi SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087047>
4. **System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.** Chem. Biol. Interact. 2020:109299Khan AA, Khan Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098839>
5. **Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.** Eur Heart J Case Rep 2020; 4:1-5Semedo E, Kapel GF, van Opstal J, van Dessel P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089050>
6. **COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.** Eur Heart J Case Rep 2020; 4:1-6Wang LY, Ng GYP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089048>
7. **Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19.** Front. Physiol. 2020; 11:555039Al Heialy S, Hachim MY, Senok A *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071815>
8. **Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.** Indian J. Pharmacol. 2020; 52:313-323 Bhattacharyya A, Kumar S, Sarma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078733>
 9. **Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.** Indian Pacing Electrophysiol J 2020; Agstam S, Yadav A, Praveen Kumar M, Gupta A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075484>
 10. **Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.** Int Immunopharmacol 2020; 89:107093 Nili A, Zarei E, Ghamari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091817>
 11. **Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.** Int. J. Biol. Macromol. 2020; Liu P, Xie X, Gao L, Jin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080267>
 12. **Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.** Int J Cardiol 2020; Audrey F, Delphine V, Serena R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075384>
 13. **The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?** Int J Infect Dis 2020; Dauby N, Bottieau E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075529>
 14. **Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia.** Int J Infect Dis 2020; Mohana A, Sulaiman T, Mahmoud N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075525>
 15. **Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.** Intern Emerg Med 2020:1-11 Yahyavi A, Hemmati N, Derakhshan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085063>
 16. **Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:866 Panda PK, Bandyopadhyay A, Singh BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081849>
 17. **Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.** Vaccine 2020; Gurwith M, Condit RC, Excler JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070999>

Treatment options (88 articles)

1. **Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.** Acta Pharm Sin B 2020; Chen X, Wu Y, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072499>
2. **The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis.** Am J Emerg Med 2020; Sun CY, Sun YL, Li XM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071103>

3. **Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel?** Anaesth Crit Care Pain Med 2020; Montravers P, Kantor E, Gouel-Cheron A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096261>
4. **Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.** Antiviral Res 2020:104955Choi SW, Shin JS, Park SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091434>
5. **Hemoadsorption cartridge and coronavirus disease 2019 infections: A case report and brief literature review.** Artif. Organs 2020; Melegari G, Bertellini E, Melegari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084021>
6. **The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.** BMC Infect. Dis. 2020; 20:786Gharebaghi N, Nejadrahim R, Mousavi SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087047>
7. **MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.** Brief. Bioinform. 2020; Feng Z, Chen M, Xue Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078827>
8. **Monoclonal antibodies for anti-infective therapy.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020; Klug B, Schnierle B, Trebesch I.
9. **Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.** Cell. Mol. Bioeng. 2020:1-9Alagumuthu M, Rajpoot S, Baig MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072222>
10. **Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis.** Cell Prolif. 2020:e12939Li Z, Niu S, Guo B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098357>
11. **System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.** Chem. Biol. Interact. 2020:109299Khan AA, Khan Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098839>
12. **Rapid Response to Cytokine Storm Inhibition using Anakinra in a Patient with COVID-19 Myocarditis.** CJC Open 2020; Trpkov C, MacMullan P, Feuchter P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073222>
13. **Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19.** Clin. Exp. Pharmacol. Physiol. 2020; Qu J, Li GH, Wang JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090501>
14. **Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.** Clin Infect Dis 2020; Yang B, Fulcher JA, Ahn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079180>
15. **Polydatin and its potential protective effect on COVID-19.** Clin. Nutr. 2020; Bonucci M, Raggi R, Vacca RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097304>
16. **Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study.** Clin. Nutr. 2020; Li G, Zhou CL, Ba YM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077274>
17. **Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study.** Clin Transl Immunology 2020; 9:e1192Shao Z, Feng Y, Zhong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082954>

18. **A stance data set on polarized conversations on Twitter about the efficacy of hydroxychloroquine as a treatment for COVID-19.** Data Brief 2020; 33:106401 Mutlu EC, Oghaz T, Jasser J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088880>
19. **CD147 inhibitors as a treatment for melanoma: promising agents against SARS-CoV-2 infection.** Dermatol Ther 2020:e14449 Pourani MR, Nekooghadam SM, Youssefian L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098610>
20. **Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).** EClinicalMedicine 2020:100591 Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078138>
21. **Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients.** Electromagn. Biol. Med. 2020:1-15 Vergallo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073612>
22. **COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.** Eur Heart J Case Rep 2020; 4:1-6 Wang LY, Ng GYP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089048>
23. **High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.** Eur J Clin Microbiol Infect Dis 2020:1-9 Monreal E, Sainz de la Maza S, Natera-Villalba E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083917>
24. **Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown.** Eur. J. Neurol. 2020; Zrzavy T, Wimmer I, Rommer PS, Berger T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090599>
25. **Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.** Expert Opin Investig Drugs 2020; Zhou Z, Price CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094669>
26. **Immunopathology of galectin-3: an increasingly promising target in COVID-19.** F1000Res 2020; 9:1078 Caniglia JL, Asuthkar S, Tsung AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082935>
27. **Heme oxygenase-1 modulation: a potential therapeutic target for COVID-19 and associated complications.** Free Radic. Biol. Med. 2020; Singh D, Wasan H, Reeta KH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091573>
28. **Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.** Front. Immunol. 2020; 11:552925 Beeraka NM, Sadhu SP, Madhunapantula SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072093>
29. **Immunopathogenesis of COVID-19: Summary and Possible Interventions.** Front. Immunol. 2020; 11:564925 Jacques FH, Apedaile E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072103>
30. **Cell-Free Therapies: Novel Approaches for COVID-19.** Front. Immunol. 2020; 11:583017 Maron-Gutierrez T, Rocco PRM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072130>
31. **The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.** Front Med (Lausanne) 2020; 7:552991 Canevelli M, Remoli G, Trentin F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072781>

32. **Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.** Front. Oncol. 2020; 10:562625 Keiffer G, French Z, Wilde L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072589>
33. **Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study.** Front. Pharmacol. 2020; 11:560209 Fang J, Li H, Du W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071781>
34. **Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.** Front. Pharmacol. 2020; 11:574703 Rubsamen R, Burkholz S, Massey C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071786>
35. **Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context.** Front. Psychol. 2020; 11:565128 Bertin P, Nera K, Delouvée S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071892>
36. **Tocilizumab prescribing criteria for COVID-19 patients.** Hum Vaccin Immunother 2020:1 Al-Qaaneh AM, Al-Ghamdi FH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079613>
37. **Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.** Indian J. Pharmacol. 2020; 52:313-323 Bhattacharyya A, Kumar S, Sarma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078733>
38. **Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.** Indian Pacing Electrophysiol J 2020; Agstam S, Yadav A, Praveen Kumar M, Gupta A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075484>
39. **Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.** Int Immunopharmacol 2020; 89:107102 Malekzadeh R, Abedini A, Mohsenpour B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075713>
40. **Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.** Int Immunopharmacol 2020; 89:107093 Nili A, Zarei E, Ghamari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33091817>
41. **Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.** Int J Antimicrob Agents 2020:106192 Alkotaji M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33045350>
42. **Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.** Int. J. Biol. Macromol. 2020; Liu P, Xie X, Gao L, Jin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080267>
43. **Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.** Int J Cardiol 2020; Audrey F, Delphine V, Serena R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075384>
44. **The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?** Int J Infect Dis 2020; Dauby N, Bottieau E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075529>
45. **Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.** Intern

- Emerg Med 2020:1-11 Yahyavi A, Hemmati N, Derakhshan P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33085063>
46. **Antivirals Against SARS-CoV2: Relevance to the Treatment of Alzheimer's Disease.** J. Alzheimers Dis. 2020; Itzhaki RF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33074241>
 47. **Hydroxychloroquine prescribing habits and impact by the COVID-19 pandemic.** J Am Acad Dermatol 2020; Kuraitis D, Murina A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33075416>
 48. **Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia - A Case Report.** J. Ayurveda Integr. Med. 2020; Joshi JA, Puthiyedath R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071521>
 49. **Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.** J Biomol Struct Dyn 2020:1-8 Elzupir AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094705>
 50. **Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study.** J Biomol Struct Dyn 2020:1-14 Emirik M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078675>
 51. **Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.** J Biomol Struct Dyn 2020:1-14 Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094701>
 52. **A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.** J Biomol Struct Dyn 2020:1-12 Mandour YM, Zlotos DP, Alaraby Salem M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094680>
 53. **Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection.** J Biomol Struct Dyn 2020:1-17 Maurya VK, Kumar S, Bhatt MLB, Saxena SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073699>
 54. **Nitric oxide's physiologic effects and potential as a therapeutic agent against Covid-19.** J Breath Res 2020; Ricciardolo FLM, Bertolini F, Carriero V, Högman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080582>
 55. **Nitric Oxide Ventilation Improves Recirculation and Right Ventricular Function During Venovenous Extracorporeal Membrane Oxygenation in a COVID-19 Patient.** J Cardiothorac Vasc Anesth 2020; Heuts S, Ubben JF, Banks-Gonzales V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077329>
 56. **Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.** J. Clin. Pharm. Ther. 2020; Chilimuri S, Sun H, Alemam A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098139>
 57. **The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis.** J Med Virol 2020; Wang Y, Chen B, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33095513>
 58. **Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect.** J. Mol. Struct. 2020:129459 Altalhi TA, Alswat K, Alsanie WF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33082599>
 59. **Fenoterol and dobutamine as COVID-19 main protease inhibitors: A virtual screening study.** J. Mol. Struct. 2020:129449 Bolelli K, Ertan-Bolelli T, Unsalan O,

- Altunayar-Unsalan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071354>
60. **Targeting Proteases for Treating COVID-19.** *J. Proteome Res.* 2020; Luan B, Huynh T, Cheng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090793>
 61. **Impact of lockdown during COVID-19 pandemic on annual effective dose equivalent values of natural gamma radiation.** *J Radioanal Nucl Chem* 2020:1-13Jindal MK, Sar SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071418>
 62. **Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial.** *J Transl Med* 2020; 18:405Perrone F, Piccirillo MC, Ascierto PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087150>
 63. **Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.** *JCI Insight* 2020; Rosenke K, Jarvis MA, Feldmann F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090972>
 64. **Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes.** *Mar. Drugs* 2020; 18Mazzotta S, Carullo G, Schiano Moriello A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081023>
 65. **Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.** *Microorganisms* 2020; 8Sada M, Saraya T, Ishii H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092045>
 66. **Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors.** *Mol. Divers.* 2020:1-14Pundir H, Joshi T, Joshi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079314>
 67. **Critical reappraisal of remdesivir investigational trials in COVID-19.** *New Microbes New Infect* 2020; 38:100745Brouqui P, Giraud-Gatineau A, Raoult D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088576>
 68. **Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.** *Open Forum Infect Dis* 2020; 7:ofaa421Salton F, Confalonieri P, Meduri GU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072814>
 69. **Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.** *Pathog Immun* 2020; 5:327-341Fomina DS, Lysenko MA, Beloglazova IP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089038>
 70. **Sepsis, Phages, and COVID-19.** *Pathogens* 2020; 9Górski A, Borysowski J, Międzybrodzki R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076482>
 71. **Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.** *Pharmaceuticals (Basel)* 2020; 13Rossi B, Nguyen LS, Zimmermann P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080877>
 72. **An efficient planning technique for low dose whole lung radiation therapy for covid-19 pandemic patients.** *Phys Imaging Radiat Oncol* 2020; 16:85-88Yuan L, Kim S, Palta J, Hagan MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072896>
 73. **Anti-inflammatory effects of cordycepin: A review.** *Phytother. Res.* 2020; Tan L, Song X, Ren Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090621>
 74. **Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.** *Rev Cardiovasc Med* 2020; 21:365-384Goyal RK, Majeed J, Tonk R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070542>
 75. **Cardiovascular system and COVID-19: manifestations and therapeutics.** *Rev Cardiovasc Med* 2020; 21:399-409Mahenthiran AK, Mahenthiran AK, Mahenthiran J.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33070544>

76. **Can Traditional Chinese Medicine provide insights into controlling the COVID-19 pandemic: Serpentinization-induced lithospheric long-wavelength magnetic anomalies in Proterozoic bedrocks in a weakened geomagnetic field mediate the aberrant transformation of biogenic molecules in COVID-19 via magnetic catalysis.** *Sci Total Environ* 2020;142830Bility MT, Agarwal Y, Ho S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071142>
77. **Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?** *Sex Med Rev* 2020; Mostafa T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077403>
78. **Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.** *Transl Med Commun* 2020; 5:17Hartman WR, Hess AS, Connor JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072871>
79. **The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:876Hassaniazad M, Inchehsablagh BR, Kamali H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092653>
80. **Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:866Panda PK, Bandyopadhyay A, Singh BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081849>
81. **"Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".** *Trials* 2020; 21:875Teofili L, Landolfi R, Cingolani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092632>
82. **A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.** *Turk J Med Sci* 2020; Gemici A, Bilgen H, ErdoĖan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078604>
83. **Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.** *Viol J* 2020; 17:162Gao W, Chen S, Wang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097047>
84. **Nitric oxide (NO) and nanoparticles - potential small tools for the war against COVID-19 and other human coronavirus infections.** *Virus Res.* 2020:198202Pieretti JC, Rubilar O, Weller RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33086123>
85. **Viral Related Tools against SARS-CoV-2.** *Viruses* 2020; 12Fernandez-Garcia L, Pacios O, González-Bardanca M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081350>
86. **Are Viral Vectors Any Good for RNAi Antiviral Therapy?** *Viruses* 2020; 12Lundstrom K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092124>
87. **Enhancing innate immunity against virus in times of COVID-19: trying to untangle facts from fictions.** *World Allergy Organ J* 2020:100476Larenas-Linnemann D, Rodríguez-Pérez N, Arias-Cruz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072240>
88. **Clinical application of combined detection of SARS-CoV-2-specific antibody and nucleic acid.** *World J Clin Cases* 2020; 8:4360-4369Meng QB, Peng JJ, Wei X

Trials (11 articles)

1. **Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study.** Clin Transl Immunology 2020; 9:e1192Shao Z, Feng Y, Zhong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082954>
 2. **BRACE-CORONA trial - COVID-19: No severe course in patients undergoing RAS inhibition.** Deutsches Arzteblatt International 2020; 117:A1816Eckert N.
 3. **Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.** Int Immunopharmacol 2020; 89:107102Malekzadeh R, Abedini A, Mohsenpour B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075713>
 4. **Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia.** Int J Infect Dis 2020; Mohana A, Sulaiman T, Mahmoud N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075525>
 5. **Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.** J. Clin. Pharm. Ther. 2020; Chilimuri S, Sun H, Alemam A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098139>
 6. **Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial.** J Transl Med 2020; 18:405Perrone F, Piccirillo MC, Ascierto PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087150>
 7. **Critical reappraisal of remdesivir investigational trials in COVID-19.** New Microbes New Infect 2020; 38:100745Brouqui P, Giraud-Gatineau A, Raoult D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088576>
 8. **Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.** Pharmaceuticals (Basel) 2020; 13Rossi B, Nguyen LS, Zimmermann P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33080877>
 9. **Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:866Panda PK, Bandyopadhyay A, Singh BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33081849>
 10. **"Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".** Trials 2020; 21:875Teofili L, Landolfi R, Cingolani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092632>
 11. **A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.** Turk J Med Sci 2020; Gemicli A, Bilgen H, ErdoĖan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078604>
-
1. **Vaccines for adults: An update.** Deutsche Medizinische Wochenschrift 2020; 145:1464-1468Seybold U.
 2. **COVID-19 vaccine development: Millions for German companies.** Deutsches Arzteblatt International 2020; 117:A1808Eckert N.
 3. **COVID-19 vaccine development: Faster, but safe.** Deutsches Arzteblatt International 2020; 117:A1810-A1813Wagner R, Hildt E, Grabski E *et al.*

4. **Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering Aging and Frailty.** Front Med (Lausanne) 2020; 7:558835Palermo S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33072783>
5. **Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context.** Front. Psychol. 2020; 11:565128Bertin P, Nera K, Delouvée S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071892>
6. **The Missing Link in the Covid-19 Vaccine Race.** Hum Vaccin Immunother 2020:1-3Zizzo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33079612>
7. **Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19.** Inform Med Unlocked 2020; 21:100438Oladipo EK, Ajayi AF, Ariyo OE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33043110>
8. **Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.** J. Chem. Neuroanat. 2020:101874Singh N, Rai S, Singh V, Singh MP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33091590>
9. **BCG as an adjunct or alternative vaccine to prevent COVID-19?** J Travel Med 2020; Weng CH, Chan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073845>
10. **The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic.** mBio 2020; 11Good MF, Hawkes MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33097654>
11. **Development of a novel platform of virus-like particle (VLP) based vaccine against coronavirus 2019 (SARS-CoV-2) by exposing of epitopes: an immunoinformatics approach.** New Microbes New Infect 2020:100786Ghorbani A, Zare F, Sazegari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072338>
12. **A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.** Risk Anal. 2020; Thompson KM, Kalkowska DA, Badizadegan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33084153>
13. **Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey.** Vaccine 2020; Goldman RD, Yan TD, Seiler M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071002>
14. **Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.** Vaccine 2020; Gurwith M, Condit RC, Excler JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070999>
15. **COVID-19 vaccine and boosted immunity: Nothing ad interim to do?** Vaccine 2020; Roncati L, Vadalà M, Corazzari V, Palmieri B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33071005>
16. **Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.** Vaccine 2020; Safavi A, Kefayat A, Mahdevar E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082015>
17. **Bacillus Calmette-Guérin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally.** Vaccine 2020; Vergkizi S, Nikolakakis I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071000>
18. **The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.** Vaccines (Basel) 2020; 8Gopalaswamy R, Ganesan N, Velmurugan K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33081331>

19. **Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers.** Vaccines (Basel) 2020; 8Martínez-Baz I, Trobajo-Sanmartín C, Arregui I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33076405>

Women – pregnancy (19 articles)

1. **Establishing Better Evidence on Remote Monitoring for Postpartum Hypertension: A Silver Lining of the Coronavirus Pandemic.** AJP Rep 2020; 10:e315-e318Sawyer MR, Jaffe EF, Naqvi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094021>
2. **New-Onset myocardial injury in COVID-19 Pregnant Patients: A Case Series of 15 Patients.** Am J Obstet Gynecol 2020; Mercedes BR, Serwat A, Naffaa L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098814>
3. **Immunity and Coagulation/Fibrinolytic Processes may Reduce the Risk of Severe Illness in Pregnant Women with COVID-19.** Am J Obstet Gynecol 2020; Zhong Y, Cao Y, Zhong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098813>
4. **Decreased incidence of preterm birth during COVID-19 pandemic.** Am J Obstet Gynecol MFM 2020;100258Berghella V, Burd J, Anderson K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083779>
5. **The effect of COVID-19 on general anaesthesia rates for caesarean section. A cross sectional analysis of six hospitals in the north-west of England.** Anaesthesia 2020; Bhatia K, Columb M, Bewlay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073371>
6. **Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China.** BMC Med 2020; 18:330Yang R, Mei H, Zheng T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33070775>
7. **SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.** Euro Surveill 2020; 25Lumley SF, Eyre DW, McNaughton AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094717>
8. **Care of pregnant patients with COVID-19 and protection of newborns.** Geburtshilfe Frauenheilkd. 2020; 80:966-967.
9. **Why I Can't Breastfeed My New-born Baby? Psychosocial Dilemma of a COVID-Positive Post-LSCS Mother.** Indian J. Palliat. Care 2020; 26:S150-s152Kumar S, Rathore P, Shweta *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088107>
10. **Challenging Concerns of Transgender Community Amidst COVID-19.** Indian J. Palliat. Care 2020; 26:S166-s167Thankachan A, Rathore P, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33088112>
11. **COVID-19 Mediated by Basigin Can Affect Male and Female Fertility.** Int J Fertil Steril 2020; 14:262-263Mahdian S, Shahhoseini M, Moini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098397>
12. **An Overview on Guidelines on COVID-19 Virus and Natural and Assisted Reproductive Techniques Pregnancies.** Int J Fertil Steril 2020; 14:264-271Pirjani R, Rabiei M, Abiri A, Moini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098398>
13. **Utilization cost of maternity services for childbirth among pregnant women with COVID-19 in Nigeria's epicenter.** Int J Gynaecol Obstet 2020; Banke-Thomas

- A, Chigozie Makwe C, Balogun M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098673>
14. **Management of gestational diabetes in women with a concurrent Sars-Cov-2 infection, experience of a single center in Northern Italy.** Int J Gynaecol Obstet 2020; D'Ambrosi F, Rossi G, Soldavini CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099770>
 15. **Assessing risk factors for severe forms of COVID-19 in a pregnant population: A clinical series from Lombardy, Italy.** Int J Gynaecol Obstet 2020; Di Martino D, Chiaffarino F, Patanè L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098568>
 16. **Co-infection of malaria and dengue in pregnant women with SARS-CoV-2.** Int J Gynaecol Obstet 2020; Mahajan NN, Kesarwani SN, Shinde SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090458>
 17. **Clinical characteristics of COVID-19 in pregnant women: A retrospective descriptive single-center study from a tertiary hospital in Muscat, Oman.** Int J Gynaecol Obstet 2020; Santhosh J, Al Salmani M, Khamis F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33075146>
 18. **Reply to Jakovac: Sex differences in COVID-19 course and outcome: progesterone should not be neglected.** J Appl Physiol (1985) 2020; 129:1009-1010 Gargaglioni LH, Marques DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096967>
 19. **Sex differences in COVID-19 course and outcome: progesterone should not be neglected.** J Appl Physiol (1985) 2020; 129:1007-1008 Jakovac H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33096966>
 20. **Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19.** J. Cardiovasc. Pharmacol. Ther. 2020;1074248420967792 Salah HM, Mehta JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078623>
 21. **Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.** J Crohns Colitis 2020; 14:S807-s814 De Lima-Karagiannis A, Juillerat P, Sebastian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085970>
 22. **Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19.** J Eur Acad Dermatol Venereol 2020; Cadegiani FA, Lim RK, Goren A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089570>
 23. **Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups.** J Gynecol Oncol 2020; 31:e92 Bogani G, Apolone G, Ditto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33078597>
 24. **Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: A living systematic review.** J Med Virol 2020; Bwire GM, Njiro BJ, Mwakawanga DL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090535>
 25. **In Utero SARS-CoV-2 Infection.** J Pediatric Infect Dis Soc 2020; Von Kohorn I, Stein SR, Shikani BT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33089311>
 26. **Systematic screening for SARS-CoV-2 in pregnant women admitted for delivery in a Portuguese maternity.** J. Perinat. Med. 2020; Figueiredo R, Tavares S, Moucho M, Ramalho C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33085639>
 27. **Report of four pregnant women getting COVID-19 in Ilam, Iran: Case Series.** New Microbes New Infect 2020;100783 Gheysarzadeh A, Sadeghifard N, Safari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072336>

28. **Challenges for the female health-care workers during the COVID-19 pandemic: the need for protection beyond the mask.** Pulmonology 2020; Crimi C, Carlucci A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33087308>
29. **A call to action: Documenting and sharing solutions and adaptations in sexual, reproductive, maternal and newborn health care provision during the COVID-19 pandemic.** Sex Reprod Health Matters 2020;1-5 Benova L, Sarkar ND, Fasehun LO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33073726>
30. **Spiritual Health and Stress in Pregnant Women During the Covid-19 Pandemic.** SN Compr Clin Med 2020;1-7 Nodoushan RJ, Alimoradi H, Nazari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33083694>
31. **Sex-biased Immune Responses Following SARS-CoV-2 Infection.** Trends Microbiol. 2020; Ursin RL, Shapiro JR, Klein SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33077340>
32. **Pregnancy worsens the morbidity of COVID-19 and this effect becomes more prominent as pregnancy advances.** Turk J Obstet Gynecol 2020; 17:149-154 Tug N, Yassa M, Köle E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072417>
33. **How to perform and interpret the lung ultrasound by the obstetricians in pregnant women during the SARS-CoV-2 pandemic.** Turk J Obstet Gynecol 2020; 17:225-232 Yassa M, Mutlu MA, Kalafat E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072428>
34. **Anxiety levels and obsessive compulsion symptoms of pregnant women during the COVID-19 pandemic.** Turk J Obstet Gynecol 2020; 17:155-160 Yassa M, Yassa A, Yirmibeş C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33072418>
35. **Coronavirus testing in women attending antenatal care.** Women Birth 2020; Rolnik DL, Korman TM, Rindt A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092997>

to subscribe click [here](#)
